
Safety Assessment of *Melaleuca alternifolia* (Tea Tree)-Derived Ingredients as Used in Cosmetics

Status: Tentative Report for Public Comment
Release Date: April 5, 2021
Panel Meeting Date: September 13-14, 2021

All interested persons are provided 60 days from the above release date (i.e., June 5, 2021) to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth.

The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; David E. Cohen, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Lisa A. Peterson, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Monice M. Fiume, Senior Director, CIR.

ABBREVIATIONS

ACC	allergic contact cheilitis	MPO	myeloperoxidase
ACD	atopic contact dermatitis	mRNA	messenger RNA
ADR	adriamycin-resistant	MS	mass spectrometry
aq	aqueous	MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
AR	androgen receptor	<i>MYC</i>	a proto-oncogene
BCOP	bovine corneal opacity and permeability	NACDG	North American Contact Dermatitis Group
<i>C1orf116</i>	chromosome 1 open reading frame 116	NLT	not less than
CAP	compound auditory nerve action potential	NMT	not more than
CGC	capillary gas chromatography	NOAEL	no-observable-adverse-effect-level
CIR	Cosmetic Ingredient Review	NR	not reported/none reported
COLIPA	European Cosmetic Toiletry and Perfumery Association	NR	nuclear receptor (Table 15)
Council	Personal Care Products Council	NS	not specified
<i>CTSD</i>	cathepsin D	NSWPIC	New South Wales Poisons Information Centre
<i>CYP4F8</i>	cytochrome P450 family 4 subfamily F member 8	NZW	New Zealand white
DHT	dihydrotestosterone	OECD	Organisation for Economic Co-operation and Development
<i>Dictionary</i>	<i>International Cosmetic Ingredient Dictionary and Handbook</i>	OTC	over-the-counter
DKG	German Contact Dermatitis Research Group	P_{app}	apparent permeability constant
DMSO	dimethyl sulfoxide	Panel	Expert Panel for Cosmetic Ingredient Safety
E2	17 β -estradiol	PBMC	peripheral blood mononuclear cells
EC	European Commission	PBS	phosphate-buffered saline
EC3	estimated concentration of a substance expected to produce a stimulation index of 3	PCE	polychromatic erythrocytes
ECHA	European Chemicals Agency	PCR	polymerase chain reaction
EMA	European Medicines Agency	PEG	polyethylene glycol
ER α	estrogen receptor- α	pet	petrolatum
ERE	estrogen response element	<i>PGR</i>	progesterone receptor
ESCD	European Society of Contact Dermatitis	RPE	relative proliferative effect
EU	European Union	RPMI	Roswell Park Memorial Institute
FCA	Freund's complete adjuvant	SCCNFP	Scientific Committee on Cosmetic Products and Non-Food Products
FDA	Food and Drug Administration	SCCP	Scientific Committee on Consumer Products
FEMA	Flavor and Extract Manufacturer's Association	SCE	stratum corneum and epidermis
FID	flame-ionization detection	<i>SEC14L2</i>	SEC14-like lipid binding 2
GC	gas chromatography	SED	systemic exposure dose
GRAS	generally recognized as safe	SGOT	serum glutamine-oxaloacetic transaminase
<i>GREB1</i>	growth regulation by estrogen in breast cancer 1	SGPT	serum glutamic-pyruvic transaminase
GSD	geometric standard deviation	SI	stimulation index
HaCaT	normal human keratinocytes	SIDAPA	Italian Society of Allergological, Occupational and Environmental Dermatology
HET-CAM	hen's egg test on the chorioallantoic membrane	SLS	sodium lauryl sulfate
HMPC	Committee on Herbal Medicinal Products	SPF	specific pathogen-free
HPLC	high-performance liquid chromatography	SPIN	Significance-Prevalence Index Number
HRIPT	human repeated insult patch test	SRC	steroid receptor coactivator
HSE	heat-separated epidermis	TG	test guideline
HS-SPME	headspace solid-phase microextraction	TNCB	2,4,6-trinitrochlorobenzene
IC ₅₀	concentration eliciting 50% inhibition	TNF	tumor necrosis factor
ICDRG	International Contact Dermatitis Research Group	<i>UGT2B28</i>	UDP glucuronosyltransferase family 2 member B28
Ig	immunoglobulin	UK	United Kingdom
<i>IGFBP3</i>	insulin like growth factor binding protein 3	US	United States
ISO	International Organization for Standardization	UV	ultraviolet
K _p	permeability coefficient	UVB	mid-wavelength irradiation
LBD	ligand-binding domain	V79 cells	Chinese hamster lung fibroblasts
LC	liquid chromatography	VCRP	Voluntary Cosmetic Registration Program
LLNA	local lymph node assay	Vis	visible
MMAD	mass median aerodynamic diameter	WHO	World Health Organization
MMTV	mouse mammary-tumor virus	WT	wild-type
MOS	margin of safety		

ABSTRACT

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 8 *Melaleuca alternifolia* (tea tree)-derived ingredients as used in cosmetic formulations; 5 of these ingredients are reported to function in cosmetics as skin-conditioning agents. Because final product formulations may contain multiple botanicals, each containing the same constituents of concern, formulators are advised to be aware of these constituents and to avoid reaching levels that may be hazardous to consumers. Industry should use good manufacturing practices to minimize impurities that could be present in botanical ingredients. The Panel noted that oxidized tea tree oil could be a sensitizer, and stated that industry should employ methods to minimize oxidation of the oil in the final cosmetic product. The Panel considered all the data and concluded that these ingredients are safe in cosmetics in the present practices of use and concentration described in this safety assessment when formulated to be non-sensitizing.

INTRODUCTION

This assessment reviews the safety of the following 8 *Melaleuca alternifolia* (tea tree)-derived ingredients as used in cosmetic formulations:

Melaleuca Alternifolia (Tea Tree) Extract	Melaleuca Alternifolia (Tea Tree) Leaf Oil
Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Extract	Melaleuca Alternifolia (Tea Tree) Leaf Powder
Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Oil	Melaleuca Alternifolia (Tea Tree) Leaf Water
Melaleuca Alternifolia (Tea Tree) Leaf	
Melaleuca Alternifolia (Tea Tree) Leaf Extract	

According to the web-based *International Cosmetic Ingredient Dictionary and Handbook (Dictionary)*, 5 of these ingredients are reported to function in cosmetics as skin-conditioning agents (Table 1).¹ Other reported functions include abrasive, antioxidant, fragrance ingredient, flavoring ingredient, anti-acne agent, antifungal agent, and antimicrobial agent. It should be noted that use as an anti-acne agent is not considered a cosmetic function in the United States (US), and therefore, use as such does not fall under the purview of the Expert Panel for Cosmetic Ingredient Safety (Panel).

Melaleuca alternifolia contains over 100 constituents, some of which have the potential to cause adverse effects. For example, 1,8-cineole (also known as eucalyptol²) can be an allergen,³ and terpinolene, α -terpinene, α -phellandrene, limonene, ascaridole (a product of tea tree oil oxidation), and 1,2,4-trihydroxymenthane (a product that might be found in aged tea tree oil) are sensitizers.^{4,5} In this assessment, the Panel is evaluating the potential toxicity of each of the *Melaleuca alternifolia* (tea tree)-derived ingredients as a whole, complex substance; potential toxicity from exposures to mixtures of different chemical compounds may not replicate the biological activity of the individual components.

This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world's literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the endpoints that the Panel typically evaluates, is provided on the Cosmetic Ingredient Review (CIR) website (<https://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites>; <https://www.cir-safety.org/supplementaldoc/cir-report-format-outline>). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

Some of the data included in this safety assessment were obtained from reviews (such as those issued by the European Commission (EC) Scientific Committee on Consumer Products (SCCP),⁶ European Chemicals Agency (ECHA),⁷ and European Medicines Agency (EMA)^{3,8,9}). These data summaries are available on the respective websites, and when deemed appropriate, information from the summaries has been included in this report.

The cosmetic ingredient names, according to the *Dictionary*, are written as listed above, without italics and without abbreviations. When referring to the plant from which these ingredients are derived, the standard scientific practice of using italics will be followed (i.e., *Melaleuca alternifolia*). Often in the published literature, the general name "tea tree" is used, especially, tea tree oil. If it is not known whether the substance being discussed is equivalent to the cosmetic ingredient, the test substance will be identified by the name used in the publication that is being cited; it is possible that the oil may be obtained from more than one species of *Melaleuca*, or from parts other than the leaves. However, if it is known that the substance is a cosmetic ingredient, the *Dictionary* nomenclature (e.g., Melaleuca Alternifolia (Tea Tree) Leaf Oil) will be used.

CHEMISTRY

Definition and Plant Identification

According to the *Dictionary*, the most recent definition of Melaleuca Alternifolia (Tea Tree) Extract is the extract of the whole sapling, *Melaleuca alternifolia*; in the past, this ingredient was defined as the extract of the whole tree (Table 1).¹ Each of the other *Melaleuca alternifolia* (tea tree)-derived ingredients is named based on the plant part(s) from which they

are obtained. Several of these ingredients have the generic CAS No. 85085-48-9; however, *Melaleuca Alternifolia* (Tea Tree) Leaf Oil has CAS Nos. (68647-73-4; 8022-72-8) that are specific to that ingredient.

The *Melaleuca* genus belongs to the Myrtaceae family, within the Myrtales order.¹⁰ *Melaleuca alternifolia* occurs in riparian zones of freshwater and swamps. It is a commercially-grown plant that is indigenous to Australia,¹¹ and plants with the genetic make-up necessary to produce the oil are native to northern New South Wales.¹² However, *Melaleuca alternifolia* has been introduced and cultivated in China, Indonesia, Kenya, Madagascar, Malaysia, South Africa, Tanzania, Thailand, the US, and Zimbabwe.^{13,14}

Melaleuca alternifolia is a tall shrub or small tree that typically grows up to 7 m high, with a bushy crown and papery bark.¹⁵ The total biomass (above-ground growth) of the tea tree can be subdivided into three components: leaves, fine stems, and main stems.¹⁶ The fine stems are defined as stems of less than 2.5 mm in diameter, and they carry virtually all the leaves; the leaves and fine stems, together, are referred to as twigs. The main stems make up the remainder. The hairless leaves are scattered to whorled, and are 10 - 35 mm long by about 1 mm wide.¹⁵ The leaves, which have prominent oil glands and are rich in aromatic oil, are borne on a petiole (leaf stalk) that is approximately 1 mm long. Tea tree oil is only found in the leaves; it is stored in the subepidermal glands that are adjacent to the epidermis, and the glands are equally distributed on both sides of the leaf.¹⁶ The oil glands first appear in immature leaves, and the number per leaf increases as the leaf expands, reaching a maximum just prior to the leaf fully expanding.

The inflorescences are many-flowered spikes, 3 - 5 cm long, with axes bearing short hairs.¹⁵ The white flowers are solitary, each within a bract, and have petals 2 - 3 mm long. There are 30 - 60 stamens per bundle and the style is 3 - 4 mm long. The fruit is cup-shaped and 2 - 3 mm in diameter, with a hole 1.5 - 2.5 mm in diameter that enables release and dispersal of the seeds by wind. Fruits are usually sparsely spaced along the branches.

Chemical Properties

Tea tree oil is a volatile essential oil;¹⁷ *Melaleuca Alternifolia* (Tea Tree) Leaf Extract is described as non-volatile.¹⁸ The log P_{ow} of *Melaleuca Alternifolia* (Tea Tree) Leaf Oil is 3.4 - 5.5.¹⁹ Available properties data for *Melaleuca Alternifolia* (Tea Tree) Oil, tea tree oil, and *Melaleuca Alternifolia* (Tea Tree) Leaf Extract are provided in [Table 2](#).

Stability

Tea Tree Oil

Because of the possibility for degradation, a supplier of tea tree oil recommends that the use-by date for tea tree oil sold in commercially-available, small (up to 100 ml), dark, glass bottles stored at ambient temperature be set at 12 mo from when first opened, or 24 mo in unopened bottles.²⁰ They also recommend that, wherever possible, tea tree oil should be stored at or below 25°C. The supplier also stated that when stored correctly, tea tree oil can retain its quality for periods of up to 10 yr.

In a 3-mo trial examining stability in accelerated (40°C) and real-time shelf conditions, including exposure to fluorescent light, no discernible difference was demonstrated in the tea tree oil quality based on constituent values in either amber or clear glass bottles.²⁰ In a 12-mo study designed to replicate normal consumer use conditions, there was no appreciable oxidation or degradation of tea tree oil.^{12,21} No significant change in the level of terpinen-4-ol was reported. A downward trend in α -terpinene and γ -terpinene, and an upward trend in *p*-cymene, were observed, and peroxide levels increased. The amber glass bottles of tea tree oil were regularly opened, exposed to air and light for short periods of time, and a small amount of oil was removed; when not in use, the bottles were stored away from heat and light.

A supplier also provided some data on the stability of tea tree oil in formulated products, using solvent extraction and gas chromatography/flame ionization detection (GC/FID).²² The rates of degradation of the oil varied with the medium. Degradation in a cream was faster than seen in a gel or a solution. For the tea tree cream, solution, and gel, the constituents were extremely stable over a period of 1.5, 3, and 5 yr, respectively.

Method of Manufacture

The majority of the methods below are general to the processing of *Melaleuca alternifolia* (tea tree)-derived ingredients, and it is unknown if they apply to cosmetic ingredient manufacturing. In some cases, the definition of the ingredients, as given in the *Dictionary*, provides insight as to the method of manufacture.¹

Melaleuca Alternifolia (Tea Tree) Leaf Extract

A supplier submitted information describing production of a concentrate; details were not provided regarding raw material or solvents, however, the data were provided for *Melaleuca Alternifolia* (Tea Tree) Leaf Extract.²³ The supplier indicated that raw material is packed into the extraction system and sealed, liquid extractant is added to the vessel, which is then closed and sealed, and the raw material is extracted under pressure in the closed system. The resulting extract is reported to be a pure extract of the raw material used (e.g., plant, bark, fruit).

Melaleuca Alternifolia (Tea Tree) Leaf Water

Melaleuca Alternifolia (Tea Tree) Leaf Water is an aqueous solution of the steam distillates obtained from the leaves of *Melaleuca alternifolia*.¹

Tea Tree Oil

Tea tree oil is defined by International Organization for Standardization (ISO) standard 4730:2017 as the essential oil obtained by steam of the leaves and terminal branchlets of *Melaleuca alternifolia* (Maiden et Betche) Cheel or of *Melaleuca linariifolia* Sm.;²⁴ steam distillation is required to conform to ISO standards.²⁵ Tea tree oil also can be prepared by hydrodistillation in a laboratory, usually with a Clevenger-type apparatus.⁴

More than 80% of the world's tea tree oil is produced in Australia.¹² Minor quantities come from China, South Africa and Vietnam. Tea tree oil produced in, and exported from, Australia conforms to the ISO standard (personal communication; T. Larkman, Aug 31, 2020).

According to a supplier of Australian tea tree oil, *Melaleuca alternifolia* tea trees are harvested and mulched into biomass, from which the oil is extracted using low-temperature pressurized steam distillation.²⁶ Oil from glands in the leaves is vaporized with the steam, and the steam is then condensed with cold water. The oil is separated out, and cooled for 16 h. Following cooling, the oil is filtered to remove any organic debris, sampled for quality assurance, and then bottled.

A researcher extracted tea tree oil from the leaf, twig (< 0.3 cm in diameter), and branch (0.3 – 0.7 cm in diameter) of *Melaleuca alternifolia* using a Clevenger-type apparatus.²⁷ After 7 h, the yield of tea tree oil was 2.02% from the leaves, 0.59% from twigs, and 0.01% from branches.

Another possible method for obtaining tea tree oil is solvent extraction.²⁵ It was reported that solvent extraction methods, including ethanol extraction, have been found to avoid the loss of certain terpenes that occurs during steam distillation, use less leaf material, and are quicker than steam distillation. Total leaf oil content can range from 0.5 – 3%, but yield via “traditional design water distillation” is 1%.²⁸ A study compared recovery from tea tree leaves by ethanol extraction (3 d) and steam distillation (2 – 6 h) using both dry and fresh leaves from a low- and a high-oil concentration trees.²⁹ Ethanol extraction gave 48 and 77 mg of oil/g of leaf for the low- and high-oil concentration trees, respectively; with steam distillation, 42 and 63 mg of oil/g of leaf were obtained after 2 h, and 42 and 66 mg of oil/g of leaf were obtained after 6 h for the same low- and high-oil concentration trees, respectively. Absolute amounts of monoterpenoids and sesquiterpenoids extracted with ethanol were higher than those recovered from the 2-h, and most of the 6-h, steam distillations. As a percent of total oil, the oil obtained by steam distillation for 2 h had a higher percentage of total monoterpenoids. Oil yield is considered to be more affected by environmental conditions than oil composition, and has been shown to fluctuate diurnally, seasonally and in response to environmental conditions, particularly moisture levels.²⁵ However, in the study described above, no significant difference in the quantity or quality of oil extracted from fresh (approximately 50% dry matter) and air-dried leaves (approximately 90% dry matter) sampled from either low- or high-oil concentration trees was found.²⁹

Composition/Impurities

Melaleuca Alternifolia (Tea Tree) Leaf Extract

According to one supplier, *Melaleuca Alternifolia* (Tea Tree) Leaf Extract is a cellular extraction of the *Melaleuca alternifolia* leaf and is composed of 20 – 50% *Melaleuca alternifolia* leaf, 34 – 55% glycerin, and 14 – 24% water, and it is preserved with $\leq 0.5\%$ sodium benzoate, $\leq 0.4\%$ citric acid, and $\leq 0.3\%$ potassium sorbate.¹⁸ SCCNFP allergens listed in Annex III of the European Union (EU) Cosmetics Directive (2003/15/EC) were not detected in the extract (limit of detection, 0.001%). Additionally, according to certificates of analysis provided by another source, specifications for *Melaleuca Alternifolia* (Tea Tree) Leaf Extract ($\geq 0.001\%$ leave-on and $\geq 0.01\%$ w/w rinse-off) indicate that none of the 26 potential fragrance allergens, which according to the EC Directive are required to be listed on the label, were detected (limit of detection of 0.001%).³⁰ High-performance liquid chromatography (HPLC) - mass spectrometry (MS) of a test sample of *Melaleuca Alternifolia* (Tea Tree) Leaf Extract identified a range of phenolic and flavonoid derivatives, based on available ultraviolet (UV)-visible (Vis) and MS spectra.³¹

Information was also provided for a cellular extraction composed of < 98% *Vitis vinifera* (grape) seed oil, < 1.0 – 5.0% *Melaleuca Alternifolia* (Tea Tree) Leaf Extract, and < 0.5% mixed tocopherols (low α -type).³² According to this submission, as well as certificates of analysis provided by another source,³³ specifications for the mixture (≥ 0.001 leave-on and $\geq 0.01\%$ w/w rinse-off) indicate that none of the 26 potential fragrance allergens, which according to the EC Directive are required to be listed on the label, were detected (limit of detection of 0.001%). Fatty acid analysis via GC/FID indicated fatty acid content of the mixture ranged from 0.003% magaric acid to 68.11% linoleic acid.³⁴

Melaleuca Alternifolia (Tea Tree) Leaf Oil

Methyleugenol is reported as a minor constituent of *Melaleuca Alternifolia* (Tea Tree) Leaf Oil.⁶ Analysis of 128 samples, using GC/MS methods with selected ion monitoring, reported that levels of methyleugenol ranged from 0.01 - 0.06% (mean, 0.02%) for commercial distillations.³⁵ Longer distillation times can result in slightly higher amounts; however, amounts did not exceed 0.07% for exhaustive laboratory distillations. According to the European Commission, based on the Scientific Committee on Cosmetic Products and Non-Food Products (SCCNFP) opinion on methyleugenol in fragrances, the highest concentration in the finished products must not exceed 0.01% in fine fragrance, 0.004% in eau de toilette, 0.002% in a fragrance cream, 0.0002% in other leave-on products and in oral hygiene products, and 0.001% in rinse-off products.³⁶ In

Norway, purity requirements for tea tree oil state that levels of methyleugenol should not exceed 200 ppm (0.02%) as a minor constituent of tea tree oil, and the content should be indicated in the ingredient list.³⁰

Tea Tree Oil

There are several varieties, or chemotypes, of *Melaleuca alternifolia*, and each produces oil with a distinct chemical composition.³⁷ (Chemotypes often occur where a geographical or geological difference influences diversification of biosynthetic pathways, and may result from diverging evolutionary pathways, or from environmental cues, such as soil type or altitude.³⁸) Six chemotypes have been described for *Melaleuca alternifolia*, and include a terpinen-4-ol chemotype, a terpinolene chemotype, and four 1,8-cineole chemotypes (Table 3).²⁵ The terpinen-4-ol chemotype is typically used in commercial tea tree oil production.

Tea tree oil typically contains approximately 100 constituents;³⁹ however, one publication reported that over 220 constituents have been identified in tea tree oil samples, and the concentration of these constituents present in the oil can vary widely depending on the sample.⁴ Eight constituents (i.e., terpinen-4-ol, α -terpinene, γ -terpinene, 1,8-cineole, terpinolene, *p*-cymene, α -pinene, and α -terpineol) typically comprise up to 90% of the oil,³⁹ and the 3 constituents reported to be present in the greatest amounts are terpinen-4-ol (up to 48%), γ -terpinene, (up to 28%), and 1,8-cineole (up to 15%).²⁴ Another notable constituent is limonene (up to 4%). The main constituents of tea tree oil have molecular weights ranging from 134 g/mol (*p*-cymene) to 222 g/mol (globulol and viridiflorol).^{6,40,41} The log P of the main constituents ranges from 2.73 (α -terpineol) to 6.64 (δ -cadinene).

Tea tree oil is reported to be composed mainly of monoterpene and sesquiterpene hydrocarbons and their associated alcohols.³⁷ For one sample, GC/MS analysis determined that oxygenated monoterpenes constituted 51% of the oil, monoterpene hydrocarbons constituted 47%, and the remaining 2% of the oil was composed of sesquiterpene hydrocarbons.⁴² Another study reported that GC/MS analysis of ethanolic extracts of mature leaf material of *Melaleuca alternifolia* revealed the presence of 47 compounds, comprising 20 monoterpenes and 27 sesquiterpenes.⁴³

According to the ISO standard for tea tree oil, high quality tea tree oil should have an enantiomeric distribution for terpinen-4-ol that is (*R*)(+) 67% - 71% and (*S*)(-) 29% - 33%.⁴⁴ The commercial standard for the composition of tea tree oil that conforms to ISO 4730:2017 is identified in Table 4.²⁴ World Health Organization (WHO) specifications and *European Pharmacopoeia* specifications also are provided in Table 4.³ Many of the specifications listed in the *European Pharmacopoeia* are similar to those specified in ISO standard; two notable differences are that the *European Pharmacopoeia* allows a higher maximum of limonene (4% vs. 1.5%) and *p*-cymene (12% vs. 8%) in tea tree oil. (However, for cosmetics, according to EC Regulation No. 344/2013, the presence of limonene in a cosmetic product must be indicated in the list of ingredients when its concentration exceeds 0.001% in leave-on products and 0.01% in rinse-off products; also, the peroxide value must be less than 20 mmol, with this limit applied to the substance and not to the finished cosmetic product.⁴⁵) Also, the ISO standard allows only two species, *Melaleuca alternifolia* and *Melaleuca linariifolia*, to be used for the production of tea tree oil, while the *European Pharmacopoeia* monograph also includes *Melaleuca dissitiflora* and other species of *Melaleuca* as sources of tea tree oil.^{8,14}

Constituent profiles of tea tree oil from several sources are presented in Table 5.^{11,27,39,46-48} Table 6 includes the percentage of constituents, identified using GC/MS, in 97 commercial tea tree oil samples from Australia, Vietnam, and China that were analyzed between 1998 and 2013.⁴

The composition of tea tree oil varies due to environmental factors, method of manufacture, the age of the oil, and whether oxidation occurred. For example, the climate, the time of year, the leaf maceration, the biomass used (i.e., wild or cultivated trees, leaves only, or leaves and branchlets), the age of the leaves, the mode of production (e.g., commercial steam distillation or laboratory hydrodistillation), and the duration of distillation can greatly affect the natural content of the individual constituents of tea tree oil.^{4,6,16,39,49} Incomplete distillation results in enhanced terpinen-4-ol levels and lower levels of sesquiterpenoids. The composition of tea tree oil collected at different times during distillation is provided in Table 7. Levels of α - and γ -terpinene, terpinolene, and α -pinene are almost doubled, and the amount of terpinen-4-ol halved, with distillation for 30 - 90 min as compared to that for 0 - 30 min.

The age of the oil can also affect the composition. Using GC/MS to analyze new and aged tea tree oil, one study found the concentrations of α -terpinene were 10 - 11% in newly purchased oil, 5% in a 10-yr-old oil, and 8% in an oil that was more than 10-yr old.⁵⁰ Using liquid chromatography(LC)/UV and LC/MC/MC spectrometry methods, several oxidation products of α -terpinene were identified in the samples (i.e., *p*-cymene, 1,2-epoxide, diol, and (*E*)-3-isopropyl-6-oxohept-2-enal); the amounts present were not determined, and the possibility that these products originated from another compound present in tea tree oil could not be excluded. A comparison of the monoterpene concentrations of *Melaleuca alternifolia* present in aged oils, with various rates of deterioration, is provided in Table 8.³⁹

The composition of tea tree oil changes in the presence of atmospheric oxygen, exposure to light, and at higher temperatures, and the relative rate of deterioration plays a role in the changes in concentrations of the components.^{6,39} The levels of α -terpinene, γ -terpinene and terpinolene decrease with oxidation, particularly with rapid deterioration, and these substances oxidize, leading to an increased level of *p*-cymene. Ascaridole and 1,2,4-trihydroxymethane have been identified as oxidation products; *p*-cymene concentrations are reported to increase proportionally with 1,2,4-trihydroxymethane.²²

However, one researcher examined 26 samples of tea tree oil and found that the presence of 1,2,4-trihydroxymenthane was rare; when 1,2,4-trihydroxymenthane was found, the oil was extremely old and degraded, and the concentration present was < 5%.^{3, 6,39} The composition of tea tree oil at various stages of oxidation is presented in [Table 9](#).⁵¹

Oxidation processes also lead to the formation of peroxides, endoperoxides, and epoxides.^{6,39} As tea tree oil undergoes oxidation, peroxide values increase from zero to “unacceptable” levels in the early stages of oxidative degradation.²² Once the rate of degradation of the peroxides exceeds the rate of their formation, the peroxide values return to zero in highly degraded aged oil. In a study using GC/MS, it was reported that unoxidized, partially oxidized, and oxidized tea tree oil had *p*-cymene concentrations of 2.5, 10.5, and 19.4%, respectively, and peroxide values of 1.1, 11.7, and 30.5 µeq O₂, respectively.⁶

According to one supplier, product specifications for tea tree oil stipulate heavy metal limits of ≤ 3 ppm arsenic, ≤ 1 ppm cadmium, ≤ 1 ppm mercury, and ≤ 10 ppm lead.⁵² A certificate of analysis states that the presence of these heavy metals was < 1.0 ppm.⁵³ Heavy metal impurities are expected to be low because steam distillation does not concentrate these impurities.⁵⁴

The recommended maximum pesticides residue limits for aldrin and dieldrin in tea tree oil, according to the WHO, are not more than (NMT) 0.05 mg/kg.¹¹ Possible adulterants of tea tree oil include camphor, eucalyptus, cajuput, broadleaf paperbark, Masson pine, maritime pine, and Chir pine.¹³ The adulterating materials may not be the essential oil of these species, but materials enriched in terpenes obtained from the waste stream after rectification of camphor, eucalyptus, and pine essential oils.

Melaleuca Alternifolia (Tea Tree) Leaf Powder

Melaleuca Alternifolia (Tea Tree) Powder is reported to contain 3% tea tree oil.⁵⁵

USE

Cosmetic

The safety of the cosmetic ingredients addressed in this assessment is evaluated based on data received from the US Food and Drug Administration (FDA) and the cosmetics industry on the expected use of this ingredient in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in the Voluntary Cosmetic Registration Program (VCRP) database. Use concentration data are submitted by the cosmetic industry in response to a survey, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category.

Collectively, the frequency and concentration of use data indicate that 6 of the 8 ingredients included in this safety assessment are used in cosmetic formulations; however, although all 6 in-use ingredients are listed by the VCRP in 2021,⁵⁶ concentration of use data collected in 2019 only reported use for 3 ingredients.⁵⁷ According to 2021 VCRP data and 2019 Council survey data, Melaleuca Alternifolia (Tea Tree) Leaf Oil has the greatest frequency and concentration of use; it is reported to be used in 536 cosmetic formulations at a maximum leave-on concentration of 0.63% in cuticle softeners ([Table 10](#)). The highest concentration reported for use in a leave-on product that result in dermal contact is 0.5% Melaleuca Alternifolia (Tea Tree) Leaf Oil in aerosol deodorants. Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Oil and Melaleuca Alternifolia (Tea Tree) Leaf Powder are not reported to be in use.

Melaleuca Alternifolia (Tea Tree) Leaf and Melaleuca Alternifolia (Tea Tree) Leaf Oil are reported to be used in products applied near the eye (concentration of use not reported), and Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Extract and Melaleuca Alternifolia (Tea Tree) Leaf Oil in products that can result in incidental ingestion (e.g., at up to 0.02% of the oil in lipstick). Several of the *Melaleuca alternifolia* (tea tree)-derived ingredients are used in formulations that come into contact with mucous membranes (e.g., 0.3% Melaleuca Alternifolia (Tea Tree) Leaf Oil in bath soaps and detergents). Additionally, Melaleuca Alternifolia (Tea Tree) Leaf Oil is reported to be used in baby products; concentration of use data were not reported for this category.

Additionally, some of the *Melaleuca alternifolia* (tea tree)-derived ingredients are used in cosmetic sprays and powders and could possibly be inhaled; for example, Melaleuca Alternifolia (Tea Tree) Leaf Oil is reported to be used at up to 0.5% in aerosol deodorant formulations,⁵⁷ and according to VCRP data, Melaleuca Alternifolia (Tea Tree) Leaf Oil and Melaleuca Alternifolia (Tea Tree) Leaf Water are reported to be used in face powders.⁵⁶ In practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters > 10 µm, with propellant sprays yielding a greater fraction of droplets/particles < 10 µm compared with pump sprays.^{58,59} Therefore, most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and thoracic regions of the respiratory tract and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount.^{60,61} There is some evidence indicating that deodorant spray products can release substantially larger fractions of particulates having aerodynamic equivalent diameters in the range considered to be respirable.⁶⁰ However, the information is not sufficient to determine whether significantly greater lung exposures result from the use of deodorant sprays, compared to other cosmetic sprays. Conservative estimates of inhalation exposures to respirable particles during the use of loose powder cosmetic products are

400-fold to 1000-fold less than protective regulatory and guidance limits for inert airborne respirable particles in the workplace.⁶²⁻⁶⁴

In 2002, the European Cosmetic Toiletry and Perfumery Association (COLIPA) stated “COLIPA recommends that Tea Tree Oil should not be used in cosmetic products in a way that results in a concentration greater than 1% oil being applied to the body.⁶ When formulating Tea Tree Oil in a cosmetic product, companies should consider that the sensitisation potential increases if certain constituents of the oil become oxidised. To reduce the formation of these oxidation products, manufacturers should consider the use of antioxidants and/or specific packaging to minimise exposure to light.”

In Germany, the Federal Institute for Risk Assessment recommends limiting the concentration of tea tree oil in cosmetics to a maximum of 1%; cosmetic products containing tea tree oil should be protected against light and admixed with antioxidants to avoid oxidation of terpenes.⁶⁵ Norway allows *Melaleuca Alternifolia* (Tea Tree) Leaf Oil to be used at a maximum of 0.5% in mouth care products and 2% in all other cosmetics; it must not be used in products meant for children under 12 years of age.⁴⁰ In Australia, typical use concentrations of up to 2% are reported in leave-on (including deodorants and foot sprays) and rinse-off products (including soaps).¹² Use in mouthwash at a typical concentration of 0.2% is also indicated.

Non-Cosmetic

Tea tree oil is listed as a generally recognized as safe (GRAS) flavoring substance by Flavor and Extract Manufacturer’s Association (FEMA).^{66,67}

Tea tree oil is reported to have use as an herbal medicine; it has been used for centuries as a traditional medicine to treat cuts and wounds by the aboriginal people of Australia.^{28,68} The EMA EU herbal monograph on *Melaleuca alternifolia* (Maiden and Betch) Cheel, *Melaleuca linariifolia* Smith, *Melaleuca dissitiflora* F. Mueller and/or other species of *Melaleuca aetheroleum* describes traditional cutaneous use (liquid or semi-solid form, up to 100%) in treatment of small superficial wounds and insect bites, small boils, and itching and irritation due to tinea pedis (athlete’s foot), as well as oromucosal use (liquid form, diluted in water) for symptomatic treatment of minor inflammation of the oral mucosa;⁸ the Committee on Herbal Medicinal Products (HMPC) concluded that, on the basis of its long-standing use, tea tree oil preparations can be used for these uses.^{3,9}

According to the WHO, clinical data supports use of tea tree oil in topical applications for symptomatic treatment of common skin disorders (such as acne, tinea pedis, bromidrosis, furunculosis, and onychomycosis), and of vaginitis due to *Trichomonas vaginalis* or *Candida albicans*, cystitis, or cervicitis.¹¹ Tea tree oil is reported to have antimicrobial activity. In traditional medicine, it is used as an antiseptic and disinfectant in the treatment of wounds. Additionally, tea tree oil is reported to have antibacterial, anti-viral, anti-inflammatory activity, analgesic, anti-tumoral, insecticidal, and acaricidal activities.^{4,12}

The US FDA issued a final action in April 2019 (effective April 13, 2020) for tea tree oil, establishing that its use in non-prescription over-the-counter (OTC) consumer antiseptic products intended for use without water (i.e., antiseptic rubs or consumer rubs) is not eligible for evaluation under the OTC Drug Review for use in consumer antiseptic rubs.⁶⁹ Drug products containing these ineligible active ingredients will require approval under a new drug application or abbreviated new drug application prior to marketing.

Additionally, in a 2016 review, the FDA Pharmacy Compounding Advisory Committee did not recommend *Melaleuca Alternifolia* (Tea Tree) Leaf Oil for inclusion on the list of bulk drug substances that can be used in pharmacy compounding for topical use in the treatment of nail fungus under Section 503A of the Federal Food, Drug, and Cosmetic Act.⁵⁴ The final compounded topical formulations being considered were at strengths of 5 - 10%. The Committee considered that although products containing the oil have been commercially available since at least 1982 for use as topical formulations for a wide variety of skin, ocular, oral, and vaginal conditions, the oil may cause local reactions, and a lack of evidence of efficacy in the treatment of onychomycosis and a lack of information on the past use of tea tree oil in pharmacy compounding was cited.

Tea tree oil is reportedly active as an antioxidant.⁷⁰ Depending on the testing used, tea tree oil was reported to be a stronger antioxidant than α -lipoic acid, vitamin C, and vitamin E.

TOXICOKINETICS

Dermal Penetration/Absorption

The EMA monograph on *Melaleuca* species stated that because tea tree oil is a semi-volatile substance, the majority of an applied dose would be expected to evaporate from the skin surface before it could be absorbed into the skin.³ In a study in which tea tree oil was applied to filter paper, stored in an oven at 30°C, and then weighed, application of 1.4 mg/cm² evaporated within 1 h, and 84, 98, and 100% of a 7.4 mg/cm² application evaporated within 2, 4, and 8 h, respectively.²²

In Vitro

The dermal penetration potential of tea tree oil was estimated in numerous in vitro studies (using both pig ear skin^{71,72} and human skin^{41,73-76}), and the activities of the components were generally used as markers (Table 11). Because the components are present at different concentrations in the oil, and based on chemical characteristics, these would not be

expected to have equal absorption rates.⁷⁷ Specifically, the oxygenated terpenes penetrated the skin in much greater amounts than did the hydrocarbons. For example, using a finite dosing regimen for 27 h without occlusion, application of a 5% tea tree oil in an oil/water emulsion to pig ear skin mounted in a static Franz cell resulted in permeation rates (and percent permeation) of 49.1 $\mu\text{g}/\text{cm}^2$ (49.7%) for terpinen-4-ol (aka 4-terpineol); 8.90 $\mu\text{g}/\text{cm}^2$ (53.5%) for α -terpineol, and 3.85 $\mu\text{g}/\text{cm}^2$ (12.4%) for 1,8-cineole; meanwhile, permeation rates could not be measured for α - and β -pinene and α - and γ -terpinene, because very little of these components penetrated.⁷¹ All markers were retained to some extent by the whole skin.

It was also demonstrated that the formulation vehicle affects absorption.⁷² Again using pig ear skin, mounted in vertical Franz cell that were sealed to prevent evaporation, and varying amounts of tea tree oil formulated using a cream (2.5 – 10%), an ointment (5 – 30%), and a hydrophilic gel (5%), the fastest permeation rate was with the 5% tea tree oil gel, followed by the 30% ointment. Additionally, the effect of excipients used as penetration enhancers on the penetration of pure tea tree oil was investigated.⁷⁶ Oleic acid enhanced the penetration of tea tree oil (as determined by using terpinen-4-ol as a marker); the amount permeated increased from 0.56 mg/cm^2 pure tea tree oil to 6.06 mg/cm^2 with oleic acid used as an excipient, and lag time decreased from 59 min to 12 min, respectively. Other excipients also had an effect, but to a lesser extent.

Volatility of tea tree oil upon application was also investigated. In the study using pig ear skin in which the donor chamber was not covered, substantial amounts of markers were released into the atmosphere; the highest percentage of oxygenated compounds (i.e., 1,8-cineole, 4-terpineol, α -terpineol) was released into the headspace within the first hour, with approximately 90% of 1,8-cineole and 40 - 45% of 4-terpineol and α -terpineol released.⁷¹ For the hydrocarbons (i.e., α - and β -pinene and α - and γ -terpinene), release into the headspace was constant over the 27-h test period. The vehicle also affected the amount of each component released; for example, in a study using sealed diffusion cells, 52% of the α -terpineol was released from a 5% gel, but only 0.8% was released from a 5% ointment.⁷² In a finite dosing study with human skin samples under open test conditions in horizontal Franz cells, the potential total absorption of undiluted tea tree oil (using terpinen-4-ol, 1,8-cineole, and α -terpineol as markers) was determined to be 2.0 – 4.1%; at 20% in ethanol, potential total absorption was determined to be 1.1 – 1.9%.⁴¹ When the donor chamber was partially occluded, potential total absorption of undiluted tea tree oil was 7.1%.

As demonstrated, a difference in bioavailability of the components exists. Therefore, when using in vitro data related to topical use of tea tree oil, the bioavailability, and more specifically, the absorption profile of the individual constituents of the oil, should be considered for in vitro-to-in vivo extrapolation.⁷⁸

Effect on Skin Integrity

Tea Tree Oil

The effect of tea tree oil on skin integrity was determined using full-thickness human breast skin or abdominal skin samples (0.5 – 1.1 mm; 3 - 4 donors) mounted in static diffusion cells.⁷⁹ The skin samples were exposed for 24 h to solutions of 0, 0.1, 1.0, or 5.0% tea tree oil (50 $\mu\text{l}/\text{cm}^2$) in an aqueous solution containing 1% Tween, 0.9% saline, and tritiated water, and to tritiated water, using infinite dosing conditions. The median diffusion area was 2.12 cm^2/cell , and donor and receptor cells were covered with wax film to avoid evaporation. Prior to the study, the epidermal site was exposed to ambient laboratory conditions and the dermis exposed to an aqueous solution of 0.9% saline and 1% Tween for 18 h. The maximal flux of tritiated water was significantly reduced with 1.0% tea tree oil, but not at the other two concentrations. At 5%, there was some evidence of damage to the barrier integrity, in that the maximal flux the water increased to was 121% of the controls; however, the increase was not statistically significant.

Comparable results were found in a similar study with concentrations of 1 and 5% tea tree oil (48-h exposure) using full-thickness human breast skin or abdominal skin samples (avg thickness, 0.87 mm) mounted in static diffusion cells.⁸⁰ Again, 1% tea tree oil (same vehicle as above) did not affect barrier conditions, but there was an increase in the K_p value for tritiated water with 5% tea tree oil. The researchers stated that this demonstrated that the barrier integrity is affected at this concentration of tea tree oil. However, although the effect on the barrier integrity was statistically significant with 5% tea tree oil in the donor phase, the mean permeability coefficient (K_p) value was still considerably below the cut-off level (35 $\mu\text{m}/\text{h}$) used for assessment of barrier function in percutaneous penetration studies.

Penetration Enhancement

Tea Tree Oil

The effect of tea tree oil on permeation of ketoprofen was examined using excised porcine skin mounted in Franz diffusion cells; degassed phosphate-buffered saline (PBS) was placed in the receptor chamber.⁸¹ The skin samples were pre-treated with 500 μl of tea tree oil or deionized water (negative control) for 1 h. After removal of the pre-treatment solution, 500 μl of ketoprofen in polyethylene glycol (PEG)-400 was added to the cell, and the donor chamber was occluded with wax film; the receptor phase was sampled at various intervals for 48 h. The flux of ketoprofen was ~ 7.5 times greater with tea tree oil, as compared to the negative control (38.4 vs 5.19 $\mu\text{g}/\text{cm}^2/\text{h}$, respectively), the K_p of ketoprofen increased from 2.1 x 10⁻⁴ cm/h with deionized water to 15.5 x 10⁻⁴ cm/h with tea tree oil, and the percentage of ketoprofen that was delivered across the skin in 24 h increased from 0.50% to 3.11% with tea tree oil.

Full-thickness samples from human breast or abdominal skin were used to examine the effect of up to 5% tea tree oil on the dermal absorption of methiocarb and benzoic acid (solubilities of 0.03 and 3.0 g/l, respectively).⁸⁰ Using static diffusion

cells, with a median diffusion area of 2.12 cm²/cell, 50 µl/cm² of the test substance was applied for 48 h using an infinite dosing regimen. Donor and receptor cells were covered with wax film to limit evaporation. Tea tree oil reduced the maximal flux, thereby reducing the overall amount of benzoic acid and methiocarb entering the receptor chamber.

Absorption, Distribution, Metabolism, and Excretion

Tea Tree Oil

In a study using rats, the pharmacokinetics of tea tree oil was examined.⁷ Oral, dermal, and inhalation absorption was reported as 70%, 3%, and 100%, respectively. Details were not provided.

TOXICOLOGICAL STUDIES

Acute Toxicity Studies

The acute toxicity studies summarized below are presented in [Table 12](#).

In rabbits, following a single 24-h occlusive patch of tea tree oil that was applied to clipped intact or abraded abdominal skin, the LD₅₀ was > 5 g/kg; 2 of 10 animals dosed with 5 g/kg died, and mottled livers and stomach and intestinal abnormalities were reported in 3 other animals.⁸² In another study, tea tree oil had a dermal LD₅₀ > 2 g/kg in rabbits.^{6,7} Dermal applications of “very high concentrations” of tea tree oil have been reported to cause tea tree oil toxicosis in dogs and cats.^{83,84}

In studies in which Swiss mice were given a single dose of up to 2 g/kg *Melaleuca Alternifolia* (Tea Tree) Leaf Oil by gavage, animals dosed with 2 g/kg had a wobbly gait, prostration, and labored breathing.⁶ In male Wistar rats given a single dose of 1.2 - 5 g/kg *Melaleuca Alternifolia* (Tea Tree) Leaf Oil by gavage, the LD₅₀ was calculated to be 1.9 g/kg bw.⁸² For tea tree oil, the LD₅₀ was > 2 g/kg (in PEG 400) in female mice⁷ and calculated as 2.3 g/kg bw and ~1.7 g/kg bw (in peanut oil) in specific pathogen-free (SPF) and non-SPF Sprague-Dawley rats, respectively.⁷

In an acute inhalation study in which groups of 5 male and 5 female Wistar rats were exposed nose-only to tea tree oil for 4 h, the LC₅₀ was calculated as 4.78 mg/l for males and females combined, as 5.23 mg/l for males only, and as 4.29 mg/l for females only.⁷ No abnormal behavior or signs of toxicity were observed during or after dosing when groups of 10 Sprague-Dawley rats were exposed for 1 h to 50 or 100 mg/l of a test substance that contained 0.3% w/w tea tree oil and 1.8% ethanol in carbon dioxide.⁶

Short-Term Toxicity Studies

Dermal

Tea Tree Oil

Tea tree oil (2%; 50 µl) was applied to the shaved backs of 3 Wistar rats daily for 28 d.²⁷ (Additional details, including whether or not collars were used or if the test site was covered, were not provided.) Serum glutamine-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) levels were measured on days 0, 14, and 28 using blood samples taken from the tail vein. Repeated dermal applications of tea tree oil did not result in any significant changes in SGOT or SGPT levels.

Oral

Tea Tree Oil

Groups of 5 male and 5 female Sprague-Dawley rats were dosed for 28 d with tea tree oil in corn oil by gavage at doses of 0, 5, 15, and 45 mg/kg/d, in accordance with Organisation for Economic Co-operation and Development (OECD) test guideline (TG) 407.⁷ No mortality was observed, and no test-article related clinical signs of toxicity were reported. Additionally, there were not changes in functional observation battery, motor activity body weight, body weight gain, food consumption, or food efficiency during the study. There were no test-article related gross or microscopic findings reported, and absolute and relative organ weights were similar to controls. The no-observable-adverse-effect-level (NOAEL) was determined to be 45 mg/kg/d for both male and female rats.

Subchronic and Chronic Toxicity

Subchronic and chronic toxicity studies on the *Melaleuca alternifolia* (tea tree)-derived ingredients were not found in the published literature, and unpublished data were not submitted.

DEVELOPMENTAL AND REPRODUCTIVE TOXICITY

Tea Tree Oil

Groups of 27 mated female Hannover Wistar rats were dosed by gavage with 0, 20, 100, and 250 mg/kg bw/d tea tree oil in PEG 400 on days 5 to 19 of gestation, in a developmental toxicity study performed in accordance with OECD TG 414.⁷ The dams were killed on day 20 of gestation. Severe maternal toxicity was observed in dams of the 100 and 250 mg/kg bw/d groups, as evidenced by clinical signs, reduced food consumption, and weight gain reductions of 20% and 45%, respectively, over the gestation period. Seven of the high dose dams died between days 8 and 11 of gestation; there was no mortality in the other test groups. Bilateral enlarged adrenals were observed in all high-dose dams that died during the study and in 6/20

that survived until necropsy; this observation was made in one dam of the mid-dose group. A dose-related decrease in mean fetal weights, related to intrauterine growth retardation, was noted in the mid- and high-dose groups. An increase in the number of late embryonic deaths and post-implantation loss, leading to an overall higher total intrauterine mortality, was observed in the high-dose (but not mid- or low-dose) group; the increase in post-implantation mortality was considered to be secondary to maternal toxicity. There was no statistically significant difference, compared to controls, in the number of visceral malformations in the fetuses of test animals, but there were statistically significant higher numbers of visceral variations reported in the 250 mg/kg bw/d dose group. A statistically significant higher incidence of skeletal malformations unrelated to intrauterine growth retardation was noted in the 250 mg/kg bw/d group, and a statistically significant increase in the number of skeletal variations, secondary to maternal toxicity, was noted in the 100 and 250 mg/kg bw/d groups. The NOAELs for maternal toxicity and for developmental toxicity (secondary to severe maternal toxicity) were 20 mg/kg bw/d tea tree oil.

Effects on Spermatozoa

Animal

The effects of tea tree oil (containing 41.49% terpinen-4-ol, 20.55% γ -terpinene, 9.59% α -terpinene, and 4.42% α -terpineol) on the morpho-functional parameters of porcine spermatozoa were evaluated.⁸⁵ Spermatozoa samples (15 x 10⁷ spermatozoa in 5 ml of medium) were exposed to 0.2 – 2 mg/ml tea tree oil for 3 h. A concentration-dependent decrease in motility was observed with concentrations of 0.4 mg/ml and greater; the decrease was statistically significant at concentrations \geq 0.8 mg/ml. Viability of spermatozoa was statistically significant decreased with \geq 1 mg/ml tea tree oil, and sperm acrosome reaction was statistically significantly increased at concentrations of \geq 1.4 mg/ml. The effects of terpinen-4-ol alone were also evaluated; a greater concentration of terpinen-4-ol only (relative to the amount in tea tree oil) was needed to have an effect on the morpho-functional parameters.

GENOTOXICITY STUDIES

In vitro, tea tree oil was not mutagenic in an Ames test using *Salmonella typhimurium* and *Escherichia coli* WP2 uvr A, with or without metabolic activation,^{7,86,87} in chromosomal assays using Chinese hamster lung fibroblasts (V79) cells (\leq 58.6 μ g/ml)⁷ or human lymphocytes (\leq 365 μ g/ml),⁸⁸ in an in vitro mammalian cell micronucleus assay using human lymphocytes (\leq 365 μ g/ml), in a mammalian cell transformation assay (120 and 275 μ g/ml, without and with metabolic activation, respectively),⁷ or in a Comet assay using normal human keratinocytes (HaCaT) cells (\leq 0.064%).⁸⁹ In vivo, Melaleuca Alternifolia (Tea Tree) Leaf Oil was not clastogenic in a mammalian erythrocyte micronucleus test in which mice were dosed orally with up to 1750 mg/kg bw in corn oil.⁶ These studies are described in detail in [Table 13](#).

CARCINOGENICITY STUDIES

Carcinogenicity data on the *Melaleuca alternifolia* (tea tree)-derived ingredients were not found in the published literature, and unpublished data were not submitted.

ANTI-CARCINOGENICITY STUDIES

Tea tree oil exhibited antiproliferative activity against murine AE17 mesothelioma cells and B16 melanoma cells,⁹⁰ it impaired the growth of human M14 melanoma cells,⁹¹ and it induced apoptosis in human malignant melanoma (A-375) and squamous cell carcinoma (Hep-2) cells.⁹² In human MCF-7 and murine 4T1 breast cancer cells, tea tree oil exhibited an antitumor effect by decreasing cell viability and modulating apoptotic pathways.⁹³ Tea tree oil also inhibited glioblastoma cell growth in vitro (in human U87MG glioblastoma cells) and in vivo (in a subcutaneous model using nude CD1 mice) at a dose- and time-dependent manner, and the mechanisms were associated with cell cycle arrest, triggering DNA damage and inducing apoptosis and necrosis.⁹⁴ The concentration of tea tree oil that elicited 50% inhibition (IC₅₀) in human MDA MB breast cancer cells was 25 μ g/ml (48 h).⁹⁵ The IC₅₀ in several other cancer cell lines ranged from 12.5 μ g/ml (24 h) in human HT29 colon cancer cells,⁹⁶ to 2800 μ g/ml (4 h) in epithelioid carcinomic (HeLa), hepatocellular carcinomic (Hep G2), and human chronic myelogenous leukemia (K-562) cells.⁹⁷ In immunocompetent C57BL/6 mice, tea tree oil inhibited the growth of subcutaneous tumors; effectiveness was carrier-dependent.⁹⁸ The details of these studies are provided in [Table 14](#).

OTHER RELEVANT STUDIES

Effect on Endocrine Activity

Tea Tree Oil

Studies evaluating the effects of tea tree oil on endocrine activity, summarized below, are described in [Table 15](#).

The effect of tea tree oil on estrogen receptor- α (ER α)-regulated gene expression was determined in the human MCF-7 breast cancer cell line; ER α target genes showed significant induction when treated with tea tree oil, and the estrogen response element (ERE)-dependent luciferase activity was stimulated in a dose-dependent manner (maximum activity observed at 0.025%).^{99,100} Fulvestrant inhibited transactivation of the 3X-ERE-TATA-luciferase reporter, indicating that the activity observed is ER-dependent. In an E-screen assay using MCF-7 BUS cells, tea tree oil (without 17 β -estradiol (E2))

induced a weak, but significant, dose-dependent estrogenic response at concentrations ranging from 0.00075% - 0.025%, with a maximal response (corresponding to 34% of the maximal E2 response) induced by a concentration of 0.0125% tea tree oil; when tested in the presence of E2, concentrations of < 0.025% tea tree oil reduced the relative proliferative effect (RPE) by 10%.⁷⁸ Terpinen-4-ol, α -terpineol, and 1,8-cineole, as well as an 8:1:1 mixture of these constituents, did not induce a significant estrogenic response at concentrations of \leq 0.1%. A robotic version of the E-screen cell proliferation assay was performed with MCF-7:WS8 cells to evaluate the estrogenic activity (with \leq 5×10^{-6} g/ml) and the anti-estrogenic activity (with \leq 6.85×10^{-7} g/ml) of an ethanol extract of a hair conditioner product that contained tea tree oil.¹⁰¹ The formulation did not exhibit estrogenic activity, but it did exhibit anti-estrogenic activity; the normalized anti-estrogenic activity (as relative maximum % of the positive control) was 79%. The effects of tea tree oil were also evaluated with human HepG2 hepatocellular cancer cells (ER α -negative).⁹⁹ In a luciferase reporter assay using transfected cells, tea tree oil (\leq 0.025%) produced a maximum of an ~20-fold increase in ER α ERE-mediated promoter activity. In a mammalian two-hybrid binding assay to determine binding activity to the ER α ligand-binding domain (LBD), there was a significant induction of ER α ERE-mediated activity with 0.01% tea tree oil, and tea tree oil demonstrated binding to the LBD of ER α .

The effect of tea tree oil (in the presence and absence of dihydrotestosterone (DHT) on androgenic activity was evaluated in MDA-kb2 breast cancer cells transfected with an androgen- and glucocorticoid-inducible mouse mammary-tumor virus (MMTV)-luciferase reporter plasmid.¹⁰⁰ Tea tree oil did not transactivate the reporter plasmid at any concentration tested (\leq 0.01%), and it inhibited plasmid transactivation by DHT in a concentration-dependent manner; maximum inhibition occurred with 0.005% tea tree oil. Additional experiments in MDA-kb2 cells indicated that the anti-androgenic properties of tea tree oil extended to inhibition of DHT-stimulated expression of androgen-inducible endogenous genes. In another luciferase reporter assay with androgen receptor (AR) MMTV, increasing concentrations of tea tree oil, co-treated with testosterone, significantly inhibited MMTV-mediated activity at concentrations \geq 0.0005% (v/v); change in activity, as compared to testosterone, was 36%.⁹⁹ The effect of tea tree oil on AR-regulated gene expression was determined in MDA-kb2 cells; tea tree oil, co-treated with testosterone, significantly inhibited the target genes.

In an opinion paper, the SCCP commented that an estrogenic potential of tea tree oil was shown in vitro, but in vivo studies were not available to elucidate the relevance of this finding.⁶ The potentially endocrine-active constituents of tea tree oil have not been shown to penetrate the skin; therefore, the (hypothesized) correlation of gynecomastia due to the topical use of tea tree oil, in conjunction with lavender oil, in a 10-yr old male,¹⁰⁰ was considered implausible by the SCCP.

Mucosal Toxicity

Tea Tree Oil

The potential for tea tree oil (0.5 – 500 mg/ml) to induce mucosal damage was examined in porcine uterine mucosa (n = 8) using an Evans Blue permeability assay; the highest concentration of tea tree oil was used as a positive control.¹⁰² Emulsifiers only served as the negative control. Tea tree oil induced a dose-dependent increase in the amount of dye absorbed, and the increase was statistically significant at concentrations of 40 and 500 mg/ml. No damage was observed with 0.2, 0.4, or 20 mg/ml tea tree oil; at 40 mg/ml, moderate damage was induced to the uterine mucosa, with a multifocal detachment of the epithelium.

The same researchers also performed an ex vivo study, filling the uterine horns from 8 female sows with 0.2 or 0.4 mg/ml tea tree oil, and incubating the horns for 1 h. After incubation, each uterine horn was emptied, washed with Dulbecco's PBS, and 3 cm x 3 cm section was examined. At these test concentrations, tea tree oil did not alter the structure of swine uterine mucosa.

Ototoxicity

Tea Tree Oil

The ototoxicity of tea tree oil was examined in guinea pigs by measuring the thresholds of the compound auditory nerve action potential (CAP) to tone bursts before and after instillation of the oil into the middle ear.¹⁰³ After 30 min, undiluted tea tree oil (n = 5) caused a partial CAP threshold elevation at 20 kHz. With 2% tea tree oil in saline (n = 4), no significant lasting threshold change was observed after the same amount of time. Normal saline (n = 4) was used as a negative control.

Immunologic Effects

Tea Tree Oil

In Vitro

The effect of tea tree oil on neutrophil activation was investigated by measuring the tumor necrosis factor- α -induced adherence reaction of human peripheral neutrophils.¹⁰⁴ Tea tree oil was diluted to concentrations of 0.025 – 0.2% using dimethyl sulfoxide (DMSO) and Roswell Park Memorial Institute (RPMI) medium (containing 10% fetal calf serum; complete medium). The suppressing activity of tea tree oil was weak; the concentration of tea tree oil providing 50% inhibition (IC₅₀) of neutrophil adherence was 0.033%. Additionally, tea tree oil did not suppress lipopolysaccharide-induced neutrophil-induced adherence.

Animal

Dermal

Five experiments were performed in which BALB/c mice (3/group) were sensitized on shaved abdominal skin with 100 μ l of 5% 2,4,6-trinitrochlorobenzene (TNCB) in acetone; after 7 d, a contact hypersensitivity response was elicited (challenge phase) by application of 50 μ l of 1% TNCB in acetone to shaved dorsal skin.¹⁰⁵ Undiluted tea tree oil (20 μ l) was applied topically to the shaved area 30 min before or 2, 4, or 7 h after challenge, and the change in double skinfold thickness was determined at various time points for up to 120 h. Controls included mice that were treated with tea tree oil alone (sensitized 7 d prior, but not challenged with TNCB) and mice that were not sensitized 7 d previously, but were challenged with TNCB.

For the first 7 h post-challenge, swelling was detected in the skin of both sensitized and non-sensitized mice. The change in double skinfold thickness in the non-sensitized mice (irritant response) subsided significantly in the following 17 h, but remained high in the sensitized mice. Undiluted tea tree oil applied 30 min before TNCB application to the non-sensitized mice did not reduce the increase in double skinfold thickness observed in the first 7 h after TNCB exposure. However, a significant reduction in swelling was observed in sensitized mice that received a single topical application of undiluted tea tree oil before or after challenge.

The researchers then investigated the effect of a single topical application (30 μ l) of 5% tea tree oil ointment, 10% gel, or control gel at 7 h after challenge. The 5% tea tree oil ointment and the 10% tea tree oil gel significantly suppressed TNCB-induced swelling by 39 and 35%, respectively. The control gel had little effect, and did not cause a significant suppression when compared with the TNCB control.

The researchers also examined whether tea tree oil alleviated swelling induced by mid-wavelength (UVB) irradiation. Shaved skin of BALB/c mice (3/group) was exposed to 2 kJ/m² (1 trial) or 8 kJ/m² (3 trials) UVB (corresponding to a minimal erythema dose of 1 or 4, respectively) using a bank of FS40 sunlamps (250 – 360 nm; wavelengths < 290 nm were screened out). Undiluted tea tree oil (20 μ l) was applied topically to the shaved area at either 30 min before or up to 7 h after UVB exposure, and the change in double skinfold thickness was measured at 24, 48, and 120 h. Control mice were treated with tea tree oil, but not exposed to UVB. A single topical application of undiluted tea tree oil after irradiation did not suppress UVB-induced swelling. Furthermore, swelling was significantly increased when tea tree oil was applied before UVB irradiation (8 kJ/m²).

The effect of the cutaneous application of tea tree oil on myeloperoxidase (MPO) activity was examined using groups of 3 - 4 ICR mice.¹⁰⁶ The mice were injected intradermally with a curdlan suspension (10 mg/ml), followed by application of 0.01 ml tea tree oil to the shaved dorsal skin (immediately, and after 3 h). The animals were killed 6 h after curdlan injection, and skin preparations were obtained. Control mice received applications of 0.1 ml DMSO. Dermal application of tea tree oil decreased MPO activity significantly, from 100% in controls to approximately 55% in the test group.

Inhalation

In mice exposed to tea tree oil via multiple inhalation sessions, there was an increase in the level of circulating blood immunoglobulins and the blood granulocyte number, plus stimulation of the local graft-versus-host reaction of spleen cells.¹⁰⁷ (Details were not available.)

Male C₅₇BI₁₀ x CBA/H (F1) mice (number per group not provided) were exposed to tea tree oil via inhalation, 3x/d (15 min each) for 7 d; the animals were subjected to the vapors by applying 5 drops of the oil to cotton wool, and placing the wool near the cage.¹⁰⁷ A negative control group (no inhalation treatment) and a sham control group (water placed on cotton wool) were used. One day before the termination of dosing, subgroups of mice from each group were injected intraperitoneally with zymosan (to induce peritonitis), PBS, or left untreated. Spleens and peritoneal exudates were collected 24 h after injection. The activity of peritoneal leukocytes in the test group was equivalent to that seen in the negative and sham control groups without inflammation, indicating that tea tree oil had anti-inflammatory action. Additionally, tea tree oil stopped the proliferation of splenocytes in response to T- and B-cell mitogens. The effect of tea tree oil in inflammation was reversed by an opioid receptor antagonist (administered in drinking water). An additional inhalation study reported that the hypothalamic-pituitary-adrenal axis mediated the anti-inflammatory effect of tea tree oil administered to the same strain of mice.¹⁰⁸

Human

Dermal

The effect of tea tree oil on a histamine-induced wheal and flare reaction was examined.¹⁰⁹ Subjects were injected intradermally in each forearm with histamine (50 μ l of a 100 μ g/ml solution), and after 20 min, undiluted tea tree oil (25 μ l) was applied topically at the injection site of one arm (test arm) of 21 subjects. In an additional 6 subjects, paraffin oil (25 μ l; oil control) was applied to one arm. The arm not treated with any oil served as a negative control. The flare and wheal responses were measured every 10 min for 1 h; wheal scores were normalized as a percentage of the wheal volume at 20 min due to inter- and intraindividual variability. There was no difference in the mean flare area between the control and test arms in the tea tree oil group. However, the mean wheal volume was statistically significantly decreased as of 10 min after tea tree oil application; at 10 min after application, the mean wheal volume was 92% of that measured prior to application, as

opposed to 163% at the same time on the control arm. At 20, 30, and 40 min after oil application, the wheal volume decreased to 83, 62, and 43% of that prior to oil application, respectively, on the test arm; on the control arm, the wheal volumes were 175, 130, and 113%, respectively, at the same times. Liquid paraffin had no effect on wheal or flare response. There was no significant difference in itch (subjective scoring), with or without either oil.

A similar study was conducted in 18 subjects, in which undiluted tea tree oil was applied to the injection site at both 10 and 20 min after histamine injection.¹¹⁰ In this study, tea tree oil significantly reduced both the flare and the wheal response.

Cytotoxicity

Tea Tree Oil

Emulsions of tea tree oil in culture medium containing 10% fetal calf serum were cytotoxic to adherent peripheral blood mononuclear cells (PBMC); toxicity ranged from 9% (not significant), with 0.004% tea tree oil, to 69% (significant), with 0.016% tea tree oil.¹¹¹ In an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay evaluating the cytotoxic effects of tea tree oil on HaCaT cells following a 24-h exposure to 0.00 – 0.25% w/v, the IC₅₀ was determined to be 0.066%.

IRRITATION AND SENSITIZATION

Dermal irritation and sensitization studies summarized below are described in [Table 16](#).

Irritant effects were reported in rabbits after a single 4-h semi-occlusive application,¹¹² and after a single 24-h occlusive application^{82,113} of undiluted *Melaleuca Alternifolia* (Tea Tree) Leaf Oil. Tea tree oil was reported to cause irritation in animals in a concentration-dependent manner; in rats, application of 5% tea tree oil produced very slight erythema, and 10% produced well-defined erythema.²⁷ In rabbits, concentrations of up to 75% were, at most, slightly irritating;⁶ with undiluted tea tree oil, a 4-h semi-occlusive application¹¹⁴ and application for 72 h to intact and abraded skin produced severe irritation.^{6,7} In 22 human subjects, a 48-h occlusive patch with 1% *Melaleuca Alternifolia* (Tea Tree) Leaf Oil in petrolatum (pet) produced no irritation.^{113,115} In a clinical 3-wk occlusive patch test, slight irritation was reported with concentrations of up to 10% tea tree oil in sorbolene cream (5 patches/wk, duration not stated; 28 subjects).¹⁶ Two dermal irritation studies were performed with 25% tea tree oil; in one study, no irritation was reported (details were not provided).¹⁶ In the other study, which was a 3-wk occlusive patch test in 28 subjects, no irritation was reported with 25% tea tree oil in soft white paraffin; however, an allergic response (erythema with marked edema and itching) was observed in 3 subjects.¹¹⁶⁻¹¹⁸ In a 48-h patch test with undiluted tea tree oil in 219 subjects, the prevalence of marked irritancy was 2.4 - 4.3%, and the prevalence of any irritancy (mild to marked) was 7.2 - 10.1%.^{6,12}

In the local lymph node assay (LLNA), tea tree oil was predicted to be a weak or moderate sensitizer at a concentration up to 50%,^{3,6,7} and a moderate sensitizer when tested undiluted.^{6,7} In guinea pig studies, tea tree oil was not sensitizing (30% at challenge)^{3,7} or had a low sensitizing capacity (tested “pure”);¹¹⁹ however, one study indicated that tea tree oil was possibly a weak sensitizer, with 30% tea tree oil producing positive reactions in 3/10 animals at challenge.^{3,120} In guinea pig studies in which “pure” tea tree oil was used at induction and oxidized tea tree oil was used at challenge, an increase in mean response was observed when compared to challenge with “pure” oil.¹¹⁹ In clinical studies, a formulation containing 0.001% *Melaleuca Alternifolia* (Tea Tree) Flower/Leaf/Stem Extract (25 subjects; maximization test),¹²¹ a formulation containing 0.0078% *Melaleuca Alternifolia* (Tea Tree) Leaf Extract (105 subjects; modified Draize human repeated insult patch test (HRIPT)),¹²² and *Melaleuca Alternifolia* (Tea Tree) Leaf Oil at 1% in pet (22 subjects; maximization test)^{113,115} and at 10% in caprylic/capric triglycerides (102 subjects; modified HRIPT),¹²³ were not sensitizers. In a Draize sensitization study with 5%, 25%, or 100% tea tree oil in various excipients, 3 of 309 subjects (0.97%) developed skin reactions suggestive of active sensitization during the induction period; only 1 of the 3 subjects returned for challenge, and the reaction was confirmed in that subject.¹²⁴ Because different samples of tea tree oil were tested simultaneously, it was not possible to determine which specific concentration was responsible for inducing sensitization in this subject at challenge; no other subjects had reactions at challenge. The three subjects (out of an initial 28 subjects) that developed reactions in the irritation study with 25% tea tree oil in soft white paraffin, described previously, had positive reactions when challenged 2 wk after the initial study; testing was also performed using components of tea tree oil, and all 3 sensitized subjects reacted positively to the sesquiterpenoid fractions and sesquiterpene hydrocarbons.¹¹⁶⁻¹¹⁸

Phototoxicity

Animal

Tea Tree Oil

A single application of undiluted tea tree oil was applied to the backs (20 μ l/5 cm²) of 12 Skh hairless mice.^{113,125} Thirty min after application, the skin was treated with a combination of psoralen and long-wave ultraviolet irradiation or broad light spectrum (UV to infrared), Xenon lamps. The test sites were examined at 4, 24, 48, 72, and 96 h, and tea tree oil was not phototoxic in hairless mice; however, some irritation was observed. (Additional details were not provided.)

Cross Allergenicity

Melaleuca alternifolia is contraindicated in cases of known allergy to plants of the *Myrtaceae* family.¹¹ Tea tree oil can cross react with colophony.⁴⁰

OCULAR IRRITATION

In Vitro

Tea Tree Oil

In a hen's egg test on the chorioallantoic membrane (HET-CAM) assay, undiluted tea tree oil and water-soluble tea tree oil had mean irritation indices of 16.1 and 14.7, respectively, and both were classified as a severe irritant.⁶ In a surfactant, the control (10% surfactant, 0% tea tree oil), 10% tea tree oil in 10% surfactant, and 25% tea tree oil in 5% surfactant were classified as severe irritants, with mean irritation indices of 10.3, 12.1, and 9.8, respectively. However, 5% tea tree oil in 8% surfactant was classified as a slight irritant, with a mean irritation index of 4.5.

A bovine corneal opacity and permeability (BCOP) test was performed in accordance with OECD TG 437 to evaluate the irritation potential of undiluted tea tree oil.⁷ Tea tree oil had an in vitro irritancy score of 2.2, and was considered not to be an ocular corrosive or severe irritant. (The negative and positive controls had in vitro irritancy scores of 2.3 and 44.5, respectively.)

Tea Tree Powder

Tea tree powder and tea tree ground leaf were classified as non-irritants in the HET-CAM assay.⁶ Both test substances had a mean irritation index of 0.0.

Animal

Tea Tree Oil

One-tenth ml of 1% or 5% tea tree oil in liquid paraffin was instilled into the conjunctival sac of Japanese white rabbits (3/group).⁶ Conjunctival discharge was observed for up to 6 h following instillation of 1% tea tree oil, and conjunctival redness and discharge were observed for up to 24 h following instillation of 5% tea tree oil. Both test concentrations were classified as minimally irritating to rabbit eyes.

Undiluted tea tree oil (0.1 ml) was instilled into the conjunctival sac of the right eye of two New Zealand white (NZW) rabbits.⁷ The eyes, which were not rinsed, were examined at 1, 24, 48, and 72 h after instillation. The contralateral eye served as the untreated control. In both animals, conjunctival irritation was moderate at 1 h, minimal at 24 and 48 h, and resolved at 72 h. Tea tree oil produced a maximum group mean score of 9.0, and was classified as a mild ocular irritant.

CLINICAL STUDIES

Retrospective and Multicenter Studies

Oxidized tea tree oil (5% in pet) has been part of the North American Contract Dermatitis Group (NACDG) screening series since 2003.¹²⁶ Tea tree oil (5% pet, oxidized) was added to the British Society for Cutaneous Allergy facial allergy series in 2019; allergens that had a positive patch test rate > 0.3% were included.¹²⁷ Retrospective and multicenter studies are summarized below and described in [Table 17](#).

From 2000 to 2007, the Mayo Clinic tested 869 patients with 5% tea tree oil (oxidized); a positive response was found in 18 patients (2.1%).¹²⁸ In screening by the NACDG, when tested at 5% (oxidized, in pet) in dermatology patients over 2-yr time frames, frequencies of positive reactions ranged from 0.9% (2003 - 2004; 2011 - 2012) to 1.4% (2005 - 2006; 2007 - 2008).^{126,129-133} The NACDG measured the positivity ratio (percentage of weak reactions among the sum of all positive reactions) and reaction index (number of positive reactions minus questionable and irritant reactions/sum of all 3) for test results obtained between 2003 - 2006; testing with oxidized tea tree oil had a positivity ratio of 54.5% and a reaction index of 0.73, indicating that 5% tea tree oil (oxidized, in pet) was an "acceptable" patch test preparation.¹³⁴ The NACDG also examined the frequency of positive patch test reactions with oxidized tea tree oil as compared to fragrance markers; in 2003, only 1 of the 5/1603 patients that reacted to oxidized tea tree oil also reacted to the fragrance markers fragrance mix and *Myroxilon pereirae*.¹³⁵ During the 2009 - 2014 time frame, 63 of the 123/13,398 patients that reacted to oxidized tea tree oil did not react to any of the fragrance mixes that were tested.¹³⁶ Testing at the Northwestern Medicine patch-testing clinic found no difference in positive results between patients with or without atopic dermatitis.¹³⁷

Cross-sectional studies were performed by the NACDG. In a subgroup of 835 patients with moisturizer-associated positive reactions (from a parent group of 2193 patients; 2001 - 2004), 1.2% had positive reactions to oxidized tea tree oil.¹³⁸ In subgroups of patients (2003 - 2004) with hand-only reaction, the percent of positive reactions to oxidized tea tree oil was slightly greater in patients with a final diagnosis code of allergic contact dermatitis only (0.4%), as opposed to those whose diagnosis included allergic contact dermatitis (0.2%).¹³⁹ Three of 60 patients (5%) with lip allergic contact cheilitis (ACC) (2001 - 2004) had positive reactions to oxidized tea tree oil.¹⁴⁰ Cross-sectional NACDG studies also evaluated the sensitization rates in pediatric and older patients. In 2003 - 2007, 0.4% of pediatric patients (4/1007) that were ≤ 18 yr old

had positive reactions to oxidized tea tree oil; during the same time frame, 0.3% of adults (35/11,649) aged 19 – 64 yr old and 0.3% of older patients (8/2409) aged \geq 65 yr old reacted positively.¹⁴¹ It was reported that from 2001 - 2004, 14.3% of children aged 0 – 5 yr, and 1.1% of children aged 0 - 18 yr, had a positive reaction to oxidized tea tree oil (total number of patients tested not stated).¹⁴² However, from 2005 - 2012, no pediatric patients (0/40) aged 0 - 5 yr, and 0.3% of patients (n = 876) aged 0 – 18 yr, reacted to the oxidized oil.¹⁴³

Testing was also performed in Europe. In Denmark, 44/217 subjects (September 2001 - January 2002) had weak irritant reactions to a commercial lotion that contained 5% tea tree oil, and 1 subject had a ++ reaction to the lotion and 10% tea tree oil in pet;¹⁴⁴ in June – August 2003, 5/160 subjects had irritant reactions to lotions containing 5% tea tree oil.¹⁴⁴ In Sweden (prior to 2004), 2.7% of 1075 patients tested had a positive reaction to 5% tea tree oil in alcohol.¹⁴⁵ In Germany, testing with 5% tea tree oil (standardized) in diethyl phthalate produced positive results in 1.1% of the 3375 patients tested (1999 - 2000),^{4,6,146} and testing at 5% (oxidized) in pet (1998 - 2003) produced positive results in 0.9%-1.0% of the patients tested.¹⁴⁷ Testing performed in the Netherlands (2012 - 2013) reported positive results in 0.9% (2/221) of patients patch-tested with 5% tea tree oil (oxidized) in pet.¹⁴⁸ However, when this group and an additional 29 patients from a different study were patch-tested with the 5% oxidized tea tree oil and up to 5% ascaridole (a possible contaminant in aged tea tree oil), 6 of 30 patients that had positive reactions to any concentration of ascaridole also tested positive with tea tree oil; in the 220 patients that did not react to any concentration of ascaridole, none reacted to tea tree oil. In Belgium, 11 of 105 patients (10.5%) had positive reactions to 1 and 5% oxidized tea tree oil in pet; these patients were a sub-group of 15,980 patients that were tested (1990 - 2016) and identified as being allergic to herbal medicines and/or botanical ingredients.¹⁴⁹ Additional studies performed in Belgium (2000 - 2010) with fragrance and non-fragrance allergens reported positive reactions in skin care products containing tea tree oil, but not in the other cosmetic product categories.^{150,151} In testing in Italy with 19 patients that had positive reactions to a botanical integrative series, 2 reacted to 5% tea tree oil in pet.¹⁵² In a Swiss clinic (1997), positive reactions were reported in 0.6% of 1216 patients tested with 5 – 100% tea tree oil in arachis oil,^{6,153} and in Spain (prior to 2015), 0.4% of patients had positive reactions to testing with 5% tea tree oil in pet.¹⁵⁴ In the United Kingdom (UK) (1996 - 1997), 7 of 29 patients thought to have a cosmetic dermatitis had positive patch test reactions to tea tree oil, applied neat,¹⁵⁵ and in 2001, 2.4% of 550 patients tested with neat, oxidized tea tree oil had positive reactions.⁴ Between 2008 and 2016, positive reactions from testing with 5% tea tree oil in pet ranged from 0.1 – 0.29% in the UK,^{156,157} and in 2016 - 2017, 0.45% of 4224 patients in the UK and Ireland that were patch-tested with 5% tea tree oil (oxidized) in pet had positive reactions.¹²⁷

In Australia, positive reaction rates generally appear to be higher than those reported in the US or Europe. The Skin and Cancer Foundation reported a positive reaction rate of 1.8% (41/2320 patients) with 5 and 10% tea tree oil (oxidized);¹⁵⁸ however, the same group reported that from 2001 - 2010, the positive reaction rates with 5% (oxidized) and 10% tea tree oil were 3.5% (794 subjects) and 2.5% (5087 subjects), respectively.¹⁵⁹ Additionally, positive reaction rates of up to 4.8% have been reported with 10% tea tree oil.¹⁵⁸

Provocative Testing

Tea Tree Oil

Eight subjects confirmed to previously be sensitized to tea tree oil were tested using occlusive patches to determine their allergic reaction threshold.^{3,12} Reaction threshold concentrations varied among the subjects, from 0.5% in one subject to a doubtful reaction at 10% in another subject. For the remaining subjects, a 1-3 response was produced in one subject with 1%, in 3 subjects with 2%, and in 2 subjects with 5% tea tree oil. Eleven individual components of tea tree oil were also tested; *p*-cymene, terpinolene, α -terpinene, and γ -terpinene produced reactions in the sensitized subjects. The study authors commented that they were concerned that the oil samples may have become oxidized during the study.

Forty-three patients with the primary complaint of vulvar pruritus were patch-tested with a battery of allergens, including tea tree oil (undiluted) and common OTC topical vulvar treatments.¹⁶⁰ Of 21 patients that reported using 4 or more topical treatments, 5 of these patients had a positive reaction to tea tree oil. However, tea tree oil was not considered clinically relevant because it was not reported by the patients as being used directly on the vulva to alleviate pruritus.

Cross-Reactivity

Studies noting cross-reactivity with tea tree oil, summarized below, are described in [Table 18](#).

Cross-reactivity with tea tree oil was indicated in some retrospective and multi-center studies. With testing of up to 100% tea tree oil in arachis oil, 2 of the 7 patients that had positive reactions to tea tree oil also exhibited a type IV hypersensitivity towards fragrance mix or colophony; the researchers stated there was a possibility of an allergic group reaction caused by contamination of the colophony with the volatile fractions of turpentine.^{6,153} In one study in which 36/3375 patients reacted to 5% tea tree oil in diethyl phthalate, 14 of those 36 also had positive patch test reactions to turpentine.¹⁴⁶ However, in another study, no correlation was reported between positive reactions to tea tree oil and to colophony.¹⁴⁵ In 45 patients that had positive patch tests to compound tincture of benzoin, 9 of the 45 also had positive reactions to tea tree oil.¹⁶¹ In several case reports of reactions to tea tree oil (described later in this report), reactions were also noted with eucalyptol,⁴⁹ colophony,^{162,163} and ascaridole.¹⁶⁴

Case Reports

Tea Tree Oil

Numerous case reports of reaction to tea tree oil are available in the published literature; in 2005, tea tree oil was the most common botanical reported to cause allergic contact dermatitis.⁴ A sampling of dermal case reports describing reactions from use of treatment of dermatitis and/or psoriasis,^{49,119,120,154,164-166} other direct skin applications,^{119,162-164,167-175} and from use of hand wash or shampoos^{119,176,177} is presented in [Table 19](#). Patients with sensitivity to tea tree oil (dermal and/or oral) were also reported to have reactions to constituents or degradation products of tea tree oil.¹⁷⁸ Positive reactions were also reported in a patient with hand eczema following inhalation of tea tree oil vapors.¹⁷⁹

Oral ingestion can be poisonous; serious symptoms, such as confusion and ataxia, can occur.⁶⁸ In 2011, the National Capital Poison Center received nearly twice as many calls about tea tree oil than any other named essential oil, including cinnamon oil, clove oil, and eucalyptus oil.¹⁸⁰ In Australia, a retrospective study of essential oil exposure was conducted by analyzing calls to the New South Wales Poisons Information Centre (NSWPIC) during July 2014 – June 2018; NSWPIC takes about half of all calls to poisons information centers in Australia.¹⁸¹ Tea tree oil was involved in 17% of the reported poisonings.

RISK ASSESSMENT

In a 2008 opinion on tea tree oil, the SCCP concluded that a margin of safety (MOS) had not been calculated, and the safety of tea tree oil could not be assessed.⁶ The following factors led to this conclusion: tea tree oil is a sensitizer, and sensitization may be enhanced by irritancy; neat tea tree oil and some formulations of 5% or more can induce skin and eye irritation; tea tree oil is prone to oxidation when exposed to air and heat, yielding epoxides and further oxidation products which are considered to contribute to the skin sensitizing potential; and, percutaneous absorption of some constituents of tea tree oil may occur following topical application of the oil and oil-containing products leading to a considerable systemic exposure, but the magnitude of systemic exposure to tea tree oil was uncertain due to a lack of adequate dermal absorption studies.

Daily exposure of tea tree oil was calculated for the various product types, using a rate of percutaneous absorption of 3%, and was adjusted for the skin retention factor according to SCCP Notes of Guidance (version not specified).⁶ Where retention factors were not stipulated by the SCCP, a value of 0.01 was used for rinse-off products and a value of 1 was used for leave-on products. Systemic exposure dose (SED) estimates between 0.0017 mg/kg/d (2% tea tree oil in a hand soap) and 3.33 mg/kg/d (undiluted tea tree oil) were obtained. The SEDs that were calculated for various formulations containing tea tree oil are presented in [Table 20](#).

Another source reported SEDs for several product types using an assumption of 100% dermal absorption.⁴⁰ MOS were then calculated; an NOAEL of 117 mg/kg bw/d (for renal effects, derived based on repeated dose systemic toxicity of tea tree oil constituents; species not specified) was chosen for illustrative purposes. Assuming complete absorption as % of applied dose, SED values for different product types ranged from 0.030 mg/kg bw/d (2.0% tea tree oil in a shampoo) to 1.54 mg/kg/d (1.25% tea tree oil in a body lotion), and MOS values ranged from 76 (body lotion) to 3900 (shampoo). Based on an aggregate exposure (shampoo + deodorant stick + foot powder + body lotion + hand wash soap + neat tea tree oil (nails)), the SED was calculated as 2.22 mg/kg bw/d, and the overall MOS was 53. The SED and MOS values for several types of cosmetic formulations are presented in [Table 21](#).

SUMMARY

Five of the 8 *Melaleuca alternifolia* (tea tree)-derived ingredient included in this assessment are reported to function in cosmetics as skin-conditioning agents. Other reported cosmetic functions include abrasive, antioxidant, fragrance ingredient, flavoring ingredient, antifungal agent, and antimicrobial agent.

Often, in the published literature, the general name “tea tree” is used, especially, tea tree oil; however, it is not known whether the substance being discussed is equivalent to the cosmetic ingredient. Some constituents of *Melaleuca alternifolia* have the potential to cause adverse effects. For example, 1,8-cineole (also known as eucalyptol) can be an allergen, and terpinolene, α -terpinene, α -phellandrene, and limonene, ascaridole (a product of tea tree oil oxidation), and 1,2,4-trihydroxymethane (a product that might be found in aged tea tree oil) are sensitizers. However, the Panel evaluates each ingredient as a whole, complex substance, and not the safety of the individual components.

Melaleuca Alternifolia (Tea Tree) Leaf Water is an aqueous solution of the steam distillates obtained from the leaves of *Melaleuca alternifolia*. Tea tree oil is the essential oil obtained by steam distillation of the leaves and terminal branchlets of *Melaleuca alternifolia* (or of *Melaleuca linariifolia*); it also can be prepared by hydrodistillation, or by solvent extraction.

Six chemotypes have been described for *Melaleuca alternifolia*; the terpinen-4-ol chemotype is typically used in commercial tea tree oil production. Tea tree oil is reported to contain approximately 100 constituents, with 8 constituents (i.e., terpinen-4-ol, α -terpinene, γ -terpinene, 1,8-cineole, terpinolene, *p*-cymene, α -pinene, and α -terpineol) typically comprising up to 90% of the oil. Commercial standards for tea tree oil that conform to an ISO specification are indicated. The natural content of the individual constituents of tea tree oil varies considerably depending on the climate, the time of

year, the leaf maceration, the biomass used, the age of the leaves, the mode of production, and the duration of distillation. The composition can change as the oil ages, especially when exposed to air, light, and/or high temperatures. Methyl Eugenol is reported as a minor constituent of *Melaleuca Alternifolia* (Tea Tree) Leaf Oil.

According to 2021 US FDA VCRP data and Council survey results, 6 of the 8 ingredients included in this safety assessment are currently used in cosmetic formulations. *Melaleuca Alternifolia* (Tea Tree) Leaf Oil has the greatest frequency and concentration of use; it is reported to be used in 536 cosmetic formulations at a maximum leave-on concentration of 0.63% in cuticle softeners. The highest concentration reported for use in a leave-on product that result in dermal contact is 0.5% *Melaleuca Alternifolia* (Tea Tree) Leaf Oil, in aerosol deodorants. Collectively, the *Melaleuca alternifolia* (tea tree)-derived ingredients are reported to be used in products applied near the eye, in products that can result in incidental ingestion, in formulations that come into contact with mucous membranes, and in baby products. Additionally, some of these ingredients are used in spray and powder formulations.

Tea tree oil is listed as a GRAS flavoring substance by FEMA. It is reported to have antimicrobial and antioxidant activity, and has been used as a traditional herbal medicine for centuries. The EMA HMPC concluded that, on the basis of its long-standing use, tea tree oil preparations are approved for a variety of traditional uses. However, the US FDA issued a final action for tea tree oil, establishing that its use in non-prescription OTC consumer antiseptic products intended for use without water is not eligible for evaluation under the OTC Drug Review for use in consumer antiseptic rubs. Additionally, the FDA Pharmacy Compounding Advisory Committee did not recommend *Melaleuca Alternifolia* (Tea Tree) Leaf Oil for inclusion on the list of bulk drug substances that can be used in pharmacy compounding for topical use in the treatment of nail fungus.

In rats, the oral, dermal, and inhalation absorption of tea tree oil was reported to be 70, 3, and 100%, respectively. Because tea tree oil is a semi-volatile substance, the majority of an applied dose would be expected to evaporate from the skin surface before it could be absorbed into the skin. In *in vitro* studies that used the individual components as markers for penetration, it was demonstrated that the components have distinctly different absorption rates. Additionally, formulation vehicle affects absorption, as does excipients that are used as penetration enhancers.

Tea tree oil increased the percentage of ketoprofen that was delivered across excised porcine skin. However, using human skin samples, it reduced the overall amount of benzoic acid and methiocarb entering the receptor chamber of a static diffusion cell.

In an acute dermal toxicity tests in rabbits, the LD₅₀ of tea tree oil was > 5 g/kg. Dermal applications of “very high concentrations” of tea tree oil have been reported to cause tea tree oil toxicosis in dogs and cats. In an acute oral study, Swiss mice that were given a single dose of 2 g/kg *Melaleuca Alternifolia* (Tea Tree) Leaf Oil by gavage exhibited a wobbly gait, prostration, and labored breathing. In male Wistar rats dosed once with ≤ 5 g/kg *Melaleuca Alternifolia* (Tea Tree) Leaf Oil by gavage, the LD₅₀ was calculated to be 1.9 g/kg bw. For tea tree oil, the LD₅₀ was > 2 g/kg (in PEG 400) in female mice, and calculated as 22.3 g/kg bw and ~1.7 g/kg bw (in peanut oil) in SPF and non-SPF Sprague-Dawley rats, respectively.

In an acute inhalation study in which groups of 5 male and 5 female Wistar rats were exposed nose-only to tea tree oil for 4 h, the LC₅₀ was calculated as 4.78 mg/l for males and females combined, as 5.23 mg/l for males only, and as 4.29 mg/l for females only. No abnormal behavior or signs of toxicity were observed during or after dosing when groups of 10 Sprague-Dawley rats were exposed for 1 h to 50 or 100 mg/l of a test substance that contained 0.3% w/w tea tree oil and 1.8% ethanol in carbon dioxide.

Repeated dermal applications of 2% tea tree oil to the shaved back of rats for 28 d did not result in any significant changes in SGOT or SGPT levels. In a 28-d gavage study (OECD TG 407) with doses of up to 45 mg/kg/d tea tree oil in corn oil, the NOAEL was determined to be 45 mg/kg/d for both male and female rats.

A developmental toxicity study was performed in accordance with OECD TG 414, in which gravid female rats were dosed by gavage with up to 250 mg/kg bw/d tea tree oil in PEG 400 on days 5 to 19 of gestation. The NOAELs for maternal toxicity and for developmental toxicity (secondary to severe maternal toxicity) were 20 mg/kg bw/d tea tree oil. An increase in the number of late embryonic deaths and post-implantation loss, leading to an overall higher total intrauterine mortality, was observed in the high-dose group; the increase in post-implantation mortality was considered to be secondary to maternal toxicity. A statistically significant higher incidence of skeletal malformations unrelated to intrauterine growth retardation was noted in the high-dose group, and a statistically significant increase in the number of skeletal variations secondary to maternal toxicity was noted in the 100 and 250 mg/kg bw/d groups.

The effects of tea tree oil on the morpho-functional parameters of porcine spermatozoa were evaluated by exposing spermatozoa samples to ≤ 2 mg/ml tea tree oil for 3 h. Viability of spermatozoa was statistically significant decreased with ≥ 1 mg/ml tea tree oil, and a concentration-dependent decrease in motility was observed with concentrations of 0.4 mg/ml and greater.

Tea tree oil did not demonstrate genotoxic activity. *In vitro*, tea tree oil was not mutagenic in an Ames test using *S. typhimurium* and *E. coli* WP2 *uvr* A, with or without metabolic activation, in chromosomal assays using V79 cells (≤ 58.6 μg/ml) or human lymphocytes (≤ 365 μg/ml), in an *in vitro* mammalian cell micronucleus assay using human lymphocytes (≤ 365 μg/ml), in a mammalian cell transformation assay (120 and 275 μg/ml, without and with metabolic activation,

respectively), or in a Comet assay using HaCaT cells ($\leq 0.064\%$). In vivo, Melaleuca Alternifolia (Tea Tree) Leaf Oil was not clastogenic in a mammalian erythrocyte micronucleus test in which mice were dosed orally with up to 1750 mg/kg bw in corn oil.

Carcinogenicity studies were not identified in the published literature. However, numerous studies investigating anti-carcinogenic potential of tea tree oil were found. Tea tree oil exhibited antiproliferative activity against murine AE17 mesothelioma cells and B16 melanoma cells, it impaired the growth of human M14 melanoma cells, and it induced apoptosis in human malignant melanoma (A-375) and squamous cell carcinoma (Hep-2) cells. In human MCF-7 and murine 4T1 breast cancer cells, tea tree oil exhibited an anti-tumor effect by decreasing cell viability and modulating apoptotic pathways. Tea tree oil also inhibited glioblastoma cell growth in vitro (in human U87MG glioblastoma cells) and in vivo (in a subcutaneous model using nude CD1 mice) in a dose- and time-dependent manner, and the mechanisms were associated with cell cycle arrest, triggering DNA damage and inducing apoptosis and necrosis. The IC_{50} of tea tree oil in human MDA MB breast cancer cells was 25 $\mu\text{g/ml}$ (48 h). The IC_{50} in several other cancer cell lines ranged from 12.5 $\mu\text{g/ml}$ (24 h) in human HT29 colon cancer cells, to 2800 $\mu\text{g/ml}$ (4 h) in epithelioid carcinomic (HeLa), hepatocellular carcinomic (Hep G2), and human chronic myelogenous leukemia (K-562) cells. In immunocompetent C57BL/6 mice, tea tree oil inhibited the growth of subcutaneous tumors; effectiveness was carrier-dependent.

Human MCF-7 breast cancer cells were used to examine the effect of tea tree oil on $ER\alpha$ -regulated gene expression; $ER\alpha$ target genes showed significant induction when treated with tea tree oil, and the ERE-dependent luciferase activity was stimulated in a dose-dependent manner (maximum activity observed at 0.025%). Fulvestrant inhibited transactivation of the 3X-ERE-TATA-luciferase reporter, indicating that the activity observed is ER-dependent. In an E-screen assay using MCF-7 BUS cells, tea tree oil ($\leq 0.1\%$; without E2) induced a weak, but significant, dose-dependent estrogenic response at concentrations ranging from 0.00075% - 0.025%, with a maximal response (corresponding to 34% of the maximal E2 response) induced by a concentration of 0.0125% tea tree oil; when tested in the presence of E2, concentrations of $< 0.025\%$ tea tree oil reduced the RPE effect by 10%. A robotic version of the E-screen cell proliferation assay was performed with MCF-7:WS8 cells to evaluate the estrogenic activity (with $\leq 5 \times 10^{-6}$ g/ml) and the anti-estrogenic activity (with $\leq 6.85 \times 10^{-7}$ g/ml) of an ethanol extract of a hair conditioner product that contained tea tree oil. The formulation did not exhibit estrogenic activity, but it did exhibit anti-estrogenic activity; the normalized anti-estrogenic activity (as relative maximum % of the positive control) was 79%. Human HepG2 hepatocellular cancer cells were also used to examine estrogenic effects. In a luciferase reporter assay using transfected cells, tea tree oil ($\leq 0.025\%$) produced a maximum of an ~ 20 -fold increase in $ER\alpha$ ERE-mediated promoter activity, and in a mammalian two-hybrid binding assay to determine binding activity to the $ER\alpha$ LBD, there was a significant induction of $ER\alpha$ ERE-mediated activity with 0.01% tea tree oil, and tea tree oil demonstrated binding to the LBD of $ER\alpha$.

The androgenic activity of tea tree oil was evaluated in MDA-kb2 breast cancer cells (in the presence and absence of DHT). In cells transfected with an MMTV-luciferase reporter plasmid, tea tree oil did not transactivate the reporter plasmid at any concentration tested ($\leq 0.01\%$), and it inhibited plasmid transactivation by DHT in a concentration-dependent manner; maximum inhibition occurred with 0.005% tea tree oil. Additional experiments indicated that the anti-androgenic properties of tea tree oil extended to inhibition of DHT-stimulated expression of androgen-inducible endogenous genes. In another luciferase reporter assay AR MMTV, increasing concentrations of tea tree oil, co-treated with testosterone, significantly inhibited MMTV-mediated activity at concentrations $\geq 0.0005\%$ (v/v); change in activity, as compared to testosterone, was 36%. In a study examining the effect of tea tree oil on AR-regulated gene expression, tea tree oil, co-treated with testosterone, significantly inhibited the target genes.

The potential for tea tree oil to induce mucosal damage was examined in porcine uterine mucosa; no damage was observed with up to 20 mg/ml tea tree oil, but at 40 mg/ml, moderate damage was induced to the uterine mucosa, with a multifocal detachment of the epithelium. In an ex vivo study using uterine horns from female sows, tea tree oil (≤ 0.4 mg/ml) did not alter the structure of the uterine mucosa.

Immunological effects of tea tree oil were examined in vitro, in mice (via dermal route and inhalation), and in humans (dermal application). In vitro, tea tree oil had a weak effect on suppression of neutrophil activation; the IC_{50} of neutrophil adherence was 0.033%.

In dermal studies using mice, undiluted tea tree oil (applied before or after challenge) reduced swelling induced by TNCB in sensitized, but not in non-sensitized, mice. In examining whether the oil had an effect on swelling associated with UVB irradiation, a single topical application of undiluted tea tree oil after irradiation did not suppress swelling in mice; additionally, swelling was significantly increased when tea tree oil was applied before UVB irradiation. Cutaneous application of tea tree oil to mice decreased MPO activity, from 100% in controls to approximately 55% in the treated group. In mice exposed to tea tree oil via inhalation, there was an increase in the level of circulating blood immunoglobulins and the blood granulocyte number. Additionally, in mice exposed to tea tree oil vapors, and then induced with peritonitis, peritoneal leukocyte activity in the test group was equivalent to that seen in control groups without inflammation, indicating that tea tree oil had anti-inflammatory action.

In one study using human subjects, undiluted tea tree oil did not have an effect on the mean flare area induced by histamine when the oil was applied 20 min after histamine injection; however, the mean wheal volume was statistically

significantly decreased. In another study, in which undiluted tea tree oil was applied to the injection site at both 10 and 20 min after histamine injection, a significant reduction in both the flare and the wheal response was observed.

Emulsions of tea tree oil in in culture medium containing 10% fetal calf serum were cytotoxic to adherent PBMCs. Significant toxicity was reported at a concentration of 0.016%.

Irritant effects were reported in rabbits after a single 4-h semi-occlusive application and after a single 24-h occlusive application of undiluted *Melaleuca Alternifolia* (Tea Tree) Leaf Oil. Tea tree oil was reported to cause irritation in animals, in a concentration-dependent manner; in rats, application of 5% tea tree oil produced very slight erythema, and 10% produced well-define erythema. In rabbits, concentrations of up to 75% were, at most, slightly irritating; with undiluted tea tree oil, a 4-h semi-occlusive application and application for 72 h to intact and abraded skin produced severe irritation. In 22 human subjects, a 48-h occlusive patch with 1% *Melaleuca Alternifolia* (Tea Tree) Leaf Oil in pet produced no irritation. In a clinical 3-wk occlusive patch test, slight irritation was reported with concentrations of up to 10% tea tree oil in sorbolene cream (5 patches/wk, duration not stated; 28 subjects). Two dermal irritation studies were performed with 25% tea tree oil; in one study, no irritation was reported. In the other study, which was a 3-wk occlusive patch test in 28 subjects, no irritation was reported with 25% tea tree oil in soft white paraffin; however, an allergic response (erythema with marked edema and itching) was observed in 3 subjects. In a 48-h patch test with undiluted tea tree oil in 219 subjects, the prevalence of marked irritancy was 2.4 - 4.3%, and the prevalence of any irritancy (mild to marked) was 7.2 - 10.1%.

In the LLNA, tea tree oil was predicted to be a weak or moderate sensitizer at a concentration up to 50%, and a moderate sensitizer when tested undiluted. In guinea pig studies, tea tree oil was not sensitizing (30% at challenge) or had a low sensitizing capacity (tested “pure”); however, one study indicated that tea tree oil was possibly a weak sensitizer, with 30% tea tree oil producing positive reactions in 3/10 animals at challenge. In guinea pig studies in which “pure” tea tree oil was used at induction and oxidized tea tree oil was used at challenge, an increase in mean response was observed when compared to challenge with “pure” oil. In clinical studies, a formulation containing 0.001% *Melaleuca Alternifolia* (Tea Tree) Flower/Leaf/Stem Extract (25 subjects; maximization test), a formulation containing 0.0078% *Melaleuca Alternifolia* (Tea Tree) Leaf Extract (105 subjects; modified Draize HRIPT), and *Melaleuca Alternifolia* (Tea Tree) Leaf Oil at 1% in pet (22 subjects; maximization test) and at 10% in caprylic/capric triglycerides (102 subjects; modified HRIPT), were not sensitizers. In a Draize sensitization study with 5, 25, or 100% tea tree oil in various excipients, 3 of 309 subjects (0.97%) developed skin reactions suggestive of active sensitization during the induction period; only 1 of the 3 subjects returned for challenge, and the reaction was confirmed in that subject. Because different samples of tea tree oil were tested simultaneously, it was not possible to determine which specific concentration was responsible for inducing sensitization in this subject at challenge; no other subjects had reactions at challenge. Three of an initial 28 subjects that developed reactions in the irritation study with 25% tea tree oil in soft white paraffin, had positive reactions when challenged 2 wk after the initial study; testing was also performed using components of tea tree oil, and all 3 sensitized subjects reacted positively to the sesquiterpenoid fractions and sesquiterpene hydrocarbons. *Melaleuca alternifolia* is contraindicated in cases of known allergy to plants of the *Myrtaceae* family. Tea tree oil can cross react with colophony.

A single application of undiluted tea tree oil was not phototoxic in hairless mice. However, some irritation was observed.

Tea tree powder and tea tree ground leaf were classified as non-irritants in the HET-CAM assay. Undiluted tea tree oil and water-soluble tea tree oil were both classified as a severe irritant in the HET-CAM assay; however, tea tree oil was classified as not to be an ocular corrosive or severe irritant in a BCOP test. Additionally, using rabbits, tea tree oil was classified as minimally irritating to rabbit eyes when tested at a concentration of up to 5%, and undiluted tea tree oil was considered a mild ocular irritant.

Oxidized tea tree oil (5% in pet) has been part of the NACDG screening series since 2003, and it was added to the British Society for Cutaneous Allergy facial allergy series in 2019. From 2000 to 2007, the Mayo Clinic tested 869 patients with 5% tea tree oil (oxidized); the positive response rate was 2.1%. In screening by the NACDG, when tested at 5% (oxidized) in pet in dermatology patients over 2-yr time frames, frequencies of positive reactions ranged from 0.9% to 1.4%. The NACDG also examined the frequency of positive patch test reactions with tea tree oil as compared to fragrance markers; in 2003, only 1 of the 5/1603 patients that reacted to oxidized tea tree oil also reacted to the fragrance makers fragrance mix and *Myroxilon pereirae*. During the 2009 - 2014 timeframe, 63 of the 123/13,398 patients (51%) that reacted to oxidized tea tree oil did not react to any of the fragrance mixes that were tested. Testing at the Northwestern Medicine patch-testing clinic found no difference in positive results between patients with or without atopic dermatitis.

Cross-sectional studies were also performed by the NACDG examining the effects of oxidized tea tree oil, based on symptoms or age. In patients with moisturizer-associated positive reactions (2001 - 2004), 1.2% had positive reactions to oxidized tea tree oil. In subgroups of patients (2003 - 2004) with hand-only reactions, the percent of positive reactions to oxidized tea tree oil was slightly greater in patients with a final diagnosis code of allergic contact dermatitis only (0.4%), as opposed to those whose diagnosis included allergic contact dermatitis (0.2%) among the diagnoses. In 60 patients with lip ACC (2001 - 2004), 3 (5%) had positive reactions to oxidized tea tree oil. In 2003 - 2007, 0.4% of pediatric patients that were \leq 18 yr had positive reactions to oxidized tea tree oil; during the same time frame, 0.3% of adults aged 19 – 64 yr and 0.3% of older patients aged \geq 65 yr reacted positively. It was reported that from 2001 - 2004, 14.3% of children aged 0 – 5

yr, and 1.1% of children aged 0 – 18 yr, had a positive reaction to oxidized tea tree oil; however, from 2005 - 2012, no pediatric patients (0/40) aged 0 – 5 yr, and 0.3% of patients aged 0 – 18 yr, reacted to the oxidized oil.

Testing was also performed in Europe. Frequencies of positive reactions varied greatly, especially when examining reactions in subgroups of patients. In Denmark, 20% of subjects (September 2001 - January 2002) had weak irritant reactions to a commercial lotion that contained 5% tea tree oil, and 1 subject had a ++ reaction to the lotion and 10% tea tree oil in pet; in June – August 2003, 3.1% of subjects had irritant reactions to lotions containing 5% tea tree oil. In Sweden (prior to 2004), 2.7% of patients tested had a positive reaction to 5% tea tree oil in alcohol.¹⁴⁵ In Germany, testing with 5% tea tree oil (standardized) in diethyl phthalate produced positive results in 1.1% of the patients tested (1999 - 2000), and testing at 5% (oxidized) in pet (1998 - 2003) produced positive results in 0.9% - 1.0% of the patients tested. Testing performed in the Netherlands (2012 - 2013) reported positive results in 0.9% of patients patch-tested with 5% tea tree oil (oxidized, in pet). However, when this group and an additional 29 patients from a different study were patch-tested with the 5% oxidized tea tree oil and up to 5% ascaridole (a possible contaminant in aged tea tree oil), 6 of 30 patients (20%) that had positive reactions to any concentration of ascaridole also tested positive with tea tree oil; in the 220 patients that did not react to any concentration of ascaridole, none reacted to tea tree oil. In Belgium, 10.5% of patients had positive reactions to 1 and 5% oxidized tea tree oil in pet; these patients were a sub-group of 15,980 patients that were tested (1990 - 2016) and identified as being allergic to herbal medicines and/or botanical ingredients. Additional studies performed in Belgium (2000 - 2010) with fragrance and non-fragrance allergens reported positive reactions in skin care products containing tea tree oil, but not in the other cosmetic product categories. In testing in Italy with 19 patients that had positive reactions to a botanical integrative series, 2 (10.5%) reacted to 5% tea tree oil in pet. In a Swiss clinic (1997), positive reactions were reported in 0.6% of patients tested with 5 – 100% tea tree oil in arachis oil, and in Spain (prior to 2015), 0.4% of patients had positive reactions to testing with 5% tea tree oil in pet. In the UK (1996 - 1997), 7 of 29 patients (24%) thought to have a cosmetic dermatitis had positive patch test reactions to tea tree oil, applied neat, and in 2001, 2.4% of 550 patients tested with neat, oxidized tea tree oil had positive reactions. Between 2008 and 2016, positive reactions from testing with 5% tea tree oil in pet ranged from 0.1 – 0.29% in the UK, and in 2016 - 2017, 0.45% of 4224 patients in the UK and Ireland that were patch-tested with 5% tea tree oil (oxidized) in pet had positive reactions.

In Australia, positive reaction rates generally appear to be higher than those reported in the US or Europe when patch-testing general populations of patients. The Skin and Cancer Foundation reported a positive reaction rate of 1.8% with 5 and 10% tea tree oil (oxidized); however, the same group reported that from 2001 - 2010, the positive reaction rates with 5% and 10% tea tree oil were 3.5% and 2.5%, respectively. Additionally, positive reaction rates of up to 4.8% have been reported with 10% tea tree oil.

Cross-reactivity with tea tree oil was indicated in some retrospective and multi-center studies. With testing of up to 100% tea tree oil in arachis oil, 2 of the 7 patients that had positive reactions to tea tree oil also exhibited a type IV hypersensitivity towards fragrance mix or colophony; the researchers stated study there was a possibility of an allergic group reaction caused by contamination of the colophony with the volatile fractions of turpentine. In one study in which 36/3375 patients reacted to 5% tea tree oil in diethyl phthalate, 14 of those 36 also had positive patch test reactions to turpentine. However, in another study, no correlation was reported between positive reactions to tea tree oil and to colophony. In 45 patients that had positive patch tests to compound tincture of benzoin, 9 of the 45 also had positive reactions to tea tree oil. In several case reports of reactions to tea tree oil, reactions were also noted with eucalyptol, colophony, and ascaridole.

Numerous cases of reaction to tea tree oil have been reported. Adverse reactions were reported with use for treatment of dermatitis and/or psoriasis, other direct skin applications, and from use of hand wash or shampoos. Patients with sensitivity to tea tree oil (dermal and/or oral) were also reported to have reactions to constituents or degradation products of tea tree oil, and positive reactions were reported in a patient with hand eczema following inhalation of tea tree oil vapors. Oral ingestion can be poisonous; serious symptoms, such as confusion and ataxia, can occur.

Daily exposure to tea tree oil was calculated for various product types. Using a rate of percutaneous absorption of 3%, SED estimates between 0.0017 mg/kg/d (2% tea tree oil in a hand soap) and 3.33 mg/kg/d (undiluted tea tree oil) were obtained. When assuming complete absorption as % of applied dose, SED values for different product types ranged from 0.030 mg/kg bw/d (2.0% tea tree oil in a shampoo) to 1.54 mg/kg/d (1.25% tea tree oil in a body lotion). Using 100% absorption and an NOAEL of 117 mg/kg bw/d (for renal effects, derived based on repeated dose systemic toxicity of tea tree oil constituents), and MOS values ranged from 76 (body lotion) to 3900 (shampoo). Based on an aggregate exposure, the SED was calculated as 2.22 mg/kg bw/d, and the overall MOS was 53.

DISCUSSION

This assessment reviews the safety of 8 *Melaleuca alternifolia* (tea tree)-derived ingredients as used in cosmetic formulations. The majority of the data included in the report is on tea tree oil. Although this name is not an International Nomenclature Cosmetic Ingredient (INCI) name, the Panel considered these data relevant for evaluating the safety all of the cosmetic ingredients named in this report because most constituents of concern are present at the highest levels in oil-derived ingredients, and no signals for additional constituents of concern were noted in the extracts.

The Panel noted that oxidized tea tree oil has the potential to be a sensitizer, and stated that methods should be employed to minimize oxidation of the oil in the final cosmetic formulation. For example, to reduce the formation of oxidation products, manufacturers should consider the use of antioxidants, as well as specific packaging to minimize exposure to light.

Also, because final product formulations may contain multiple botanicals, each possibly containing the same constituents of concern, formulators are advised to be aware of these constituents and to avoid reaching levels that may be hazardous to consumers. For *Melaleuca alternifolia* (tea tree)-derived ingredients, examples of the constituents the Panel was concerned about include 1,8-cineole (also known as eucalyptol), a possible allergen, and terpinolene, α -terpinene, α -phellandrene, and limonene, possible sensitizers. Additionally, the Panel was aware that variances in the composition of tea tree oil based on a geographical or geological difference in growth have been reported, which could also affect the potential for sensitization. Therefore, when formulating products, manufacturers should avoid reaching levels of plant constituents that may cause sensitization or other adverse health effects.

The Panel expressed concern about pesticide residues, heavy metals, and other plant species that may be present in botanical ingredients. Additionally, the Panel was made aware that some of the *Melaleuca alternifolia* (tea tree)-derived ingredients could be supplied as adulterated products; the Panel acknowledged this could always be a concern. For these reasons, it was stressed that the cosmetics industry should continue to use current good manufacturing practices (cGMPs) to limit impurities.

Adverse effects that were reported in developmental and reproductive toxicity studies, as well as in studies examining effects on endocrine activity, were noted by the Panel. Because the adverse results were observed at concentrations that were much higher than those used in cosmetic formulations concern, concern for these effects with use in cosmetics was mitigated.

The Panel recognized that tea tree oil can enhance the penetration of other ingredients through the skin. The Panel cautioned that care should be taken in formulating cosmetic products that may contain these ingredients in combination with any ingredients whose safety was based on their lack of dermal absorption data, or when dermal absorption was a concern.

Finally, some of the *Melaleuca alternifolia* (tea tree)-derived ingredients are used in cosmetic sprays or powders, and could possibly be incidentally inhaled during customary use; for example, *Melaleuca Alternifolia* (Tea Tree) Leaf Oil is reported to be used at up to 0.5% in aerosol deodorant formulations, and *Melaleuca Alternifolia* (Tea Tree) Leaf Oil and *Melaleuca Alternifolia* (Tea Tree) Leaf Water are reported to be used in face powders. Therefore, the Panel discussed the issue of potential inhalation toxicity. Little inhalation toxicity data (i.e., acute studies in rats) were available. However, the Panel noted that in aerosol products, 95% – 99% of droplets/particles would not be respirable to any appreciable amount. Furthermore, droplets/ particles deposited in the nasopharyngeal or bronchial regions of the respiratory tract present no toxicological concerns based on the chemical and biological properties of these ingredients. Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredient is used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects. A detailed discussion and summary of the Panel's approach to evaluating incidental inhalation exposures to ingredients in cosmetic products is available at <https://www.cir-safety.org/cir-findings>.

CONCLUSION

The Expert Panel for Cosmetic Ingredient Safety concluded that the following 8 *Melaleuca alternifolia* (tea tree)-derived ingredients are safe in cosmetics in the present practices of use and concentration described in this safety assessment when formulated to be non-sensitizing.

Melaleuca Alternifolia (Tea Tree) Extract	Melaleuca Alternifolia (Tea Tree) Leaf Extract
Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Extract	Melaleuca Alternifolia (Tea Tree) Leaf Oil
Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Oil*	Melaleuca Alternifolia (Tea Tree) Leaf Powder*
Melaleuca Alternifolia (Tea Tree) Leaf	Melaleuca Alternifolia (Tea Tree) Leaf Water

* Not reported to be in current use. Were ingredients in this group not in current use to be used in the future, the expectation is that they would be used in product categories and at concentrations comparable to others in this group.

TABLES

Table 1. Definitions and reported cosmetic functions¹

Ingredient (CAS No.)	Definition	Cosmetic Function(s)
Melaleuca Alternifolia (Tea Tree) Extract (85085-48-9 [generic])	the extract of the whole sapling, <i>Melaleuca alternifolia</i>	skin-conditioning agent -emollient
<i>Melaleuca Alternifolia (Tea Tree) Extract was previously defined as the extract of the whole tree, Melaleuca alternifolia</i>		
Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Extract (84238-27-7; 85085-48-9 [generic])	the extract of the leaves, flowers, and stems of <i>Melaleuca alternifolia</i>	skin-conditioning agent - miscellaneous
Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Oil (85085-48-9 [generic])	the volatile oil obtained from the flowers, leaves, and stems of <i>Melaleuca alternifolia</i>	flavoring agent; fragrance ingredient; skin-conditioning agent - miscellaneous
Melaleuca Alternifolia (Tea Tree) Leaf	the leaves of <i>Melaleuca alternifolia</i>	abrasive; skin-conditioning agent - miscellaneous
Melaleuca Alternifolia (Tea Tree) Leaf Extract (85085-48-9 [generic])	the extract of the leaves of the tea tree, <i>Melaleuca alternifolia</i>	skin-conditioning agent - miscellaneous
Melaleuca Alternifolia (Tea Tree) Leaf Oil (68647-73-4; 8022-72-8)	the oil distilled from the leaves of the <i>Melaleuca alternifolia</i>	antioxidant; fragrance ingredient
Melaleuca Alternifolia (Tea Tree) Leaf Powder (85085-48-9 [generic])	the powder obtained from the dried, ground leaves of <i>Melaleuca alternifolia</i>	abrasive
Melaleuca Alternifolia (Tea Tree) Leaf Water (85085-48-9 [generic])	an aqueous solution of the steam distillates obtained from the leaves of <i>Melaleuca alternifolia</i>	antiacne agent; antifungal agent; antimicrobial agent

Table 2. Chemical properties

Property	Description	Reference
Melaleuca Alternifolia (Tea Tree) Leaf Oil		
physical characteristics	pale yellow to yellow clear mobile liquid with a myristic, characteristic odor	19
solubility		
in water (mg/l at 25°)	insoluble in water 332.1 (estimated)	19 182
other	1 part miscible with 2 parts ethanol (85% v/v) at 20°C soluble in alcohol, fixed oil, paraffin oil; insoluble in glycerin miscible in non-polar solvents	19 182 37
freezing point (°C)	-22	19
boiling point (°C)	97 - 220	19
relative density	0.885 – 0.906	19
refractive index (at 20°)	1.475 – 1.482	182
optical rotation	+7° to +12° +5° to +15°	19 182
log P _{ow}	3.4 – 5.5	19
peroxide value (µeq O ₂)	< 10 (good quality, fresh oil)	3
Tea Tree Oil		
physical characteristics	colorless to pale yellow clear, mobile liquid with a “characteristic” odor colorless to pale yellow liquid, with a myristic odor colorless to pale yellow, clear mobile liquid that has a “terpeny,” coniferous and “minty–camphoraceous” odor clear colorless liquid with a green/yellow tinge and “antiseptic” odor	24 11 4 7
solubility	insoluble in water; soluble in 2 volumes of 85% ethanol (20°C) sparingly soluble in water; miscible with non-polar solvents	6
freezing point (°C)	-22	7
boiling point (°C)	97 - 220	7
relative density (at 20°C)	0.885-0.906 0.89	24 7
refractive index	1.475 - 1.482 1.465 - 1.495	6 53
vapor pressure (Pa at 25°C)	2100	6
optical rotation	+ 7° to + 12°	24
log P _{ow} of constituents	2.82 – 6.64	6
log ₁₀ P _{ow} of constituents	3.4 - 5.5	7
α-terpineol	3.4	
terpinen-4-ol	3.5	
α-terpinene	5.2	
γ-terpinene	5.3	
Melaleuca Alternifolia (Tea Tree) Leaf Extract		
physical characteristics	translucent yellow to brown mobile liquid with a characteristic odor	18
solubility	soluble in water	18
specific gravity (at 20°)	1.130 – 1.280	18
refractive index (at 20°)	1.370 – 1.550	18

Table 3. Composition of the 6 *Melaleuca alternifolia* chemotypes measured by headspace GC²⁵

	1,8-cineole	terpinen-4-ol	terpinolene
Type 1 (terpinen-4-ol)	0-17%	22-40%	2-6%
Type 2 (terpinolene)	22-44%	< 3%	41-60%
Type 3 (1,8-cineole)	34-46%	10-14%	16-24%
Type 4 (1,8-cineole)	41-63%	6-14%	0-3%
Type 5 (1,8-cineole)	72-86%	<1%	<1%
Type 6 (1,8-cineole)	65-80%	<1%	6-14%

Table 4. Standards and specifications for tea tree oil

Constituent	ISO 4730:2017 standard (GC) ²⁴	European Pharmacopoeia ³	WHO Specifications ¹¹ (<i>Melaleuca Alternifolia</i> (Tea Tree) Leaf Oil)
α -pinene	1-4%	1-6%	not specified (NS)
sabinene	trace – 3.5%	NMT 3.5%	not less than (NLT) 3.5%
α -terpinene	6-12%	5-13%	1-6%
limonene	0.5-1.5%	0.5-4%	NS
<i>p</i> -cymene	0.5-8%	0.2-12%	0.5-12%
1,8-cineole	trace (i.e., < 0.01%) – 10%	NMT 15%	NMT 15%
γ -terpinene	14-28%	10-28%	10-28%
terpinolene	1.5-5%	1.5-5%	NS
terpinen-4-ol	35-48%	NLT 30%	NLT 30%
α -terpineol	2-5%	1.5-8%	1.5-8%
aromadendrene	0.2 – 3%	NMT 7%	NS
ledene (aka viridiflorene)	0.1 – 3%	NS	NS
δ -cadinene	0.2 – 3%	NS	NS
globulol	trace – 1%	NS	NS
viridiflorol	trace – 1%	NS	NS

Table 5. Constituent profiles of tea tree oil

Constituent	WHO (steam distillation) ¹¹	Supplier Information (GC) ⁴⁶ (<i>Melaleuca Alternifolia</i> (Tea Tree) Leaf Oil)	Test Samples (steam-distilled; (GC or GC/MS) ³⁹		Test Sample (steam-distilled from leaves; GC/MS) ²⁷		Essential Oil (from leaves) ⁴⁸
			Test Sample (GC/MS) ⁴⁷	Test Sample (GC/MS) ⁴⁷	Test Sample (GC/MS) ⁴⁷	Test Sample (GC/MS) ⁴⁷	
α -pinene	1-5%	1-6%	2.6%	2.52%	2.0%	2.4%	
sabinene	none reported (NR)	trace – 3.5%	0.2%	0.4%	1.6%	NR	
α -terpinene	2.7-13%	5-13%	10.4%	10.2%	9.6%	9.6%	
limonene	1-5%	0.5-1.5%	1.0%	0.9%	0.5%	1.1%	
<i>p</i> -cymene	1-5%	0.5-8%	2.9%	1.5%	1.5%	2.7%	
1,8-cineole	4.5-16.5%	trace-15%	5.1%	2.1%	1.7%	3.1%	
γ -terpinene	10-28%	10-28%	23%	21.2%	20.6%	20.1%	
terpinolene	1-5%	1.5-5%	3.1%	3.5%	3.0%	3.5%	
terpinen-4-ol	29-45%	30-48%	40%	41.5%	47.3%	39.8%	
α -terpineol	NR	1.5-8%	2.4%	2.9%	3.0%	2.8%	
aromadendrene	NR	trace – 3%	1.5%	1%	< 0.1%	2.1%	
ledene	NR	trace – 3%	NR	NR	NR	1.8%	
δ -cadinene	NR	trace – 3%	1.3%	1%	NR	1.6%	
globulol	NR	trace – 1%	0.2%	0.6%	0.3%	NR	
viridiflorol	NR	trace – 1%	0.1%	0.3%	NR	NR	

Table 6. Constituents identified by GC/MS in 97 commercial tea tree oil samples from Australia, Vietnam, and China^{a, 4}

Constituent	Concentration (%)	Constituent	Concentration (%)
1,8-cineole	0.5 – 18.3	α -eudesmol	0.03 – 0.5
terpinen-4-ol	6.2 – 44.9	α -gurjunene	0.2 – 1.0
terpinolene	0.04 – 45.7 ^b	<i>cis</i> -3-hexen-1-ol	0.01 – 0.07
α -terpinene	2.3 – 11.7	<i>cis</i> -3-hexenyl acetate	0 – 0.02
γ -terpinene	3.1 – 23.0	α -humulene	trace – 0.2
α -terpineol	1.9 – 4.2	ledol	0.02 – 0.3
limonene	0.5 – 3.0	linalool	0.06 – 0.8
sabinene	0.03 – 1.3	<i>p</i> -menth-2-en-1-ol	0.04 – 0.7
aromadendrene	0.1 – 0.2	methyl Eugenol	0.01 – 0.4
δ -cadinene	0.1 – 1.9	γ -murolene	0 – 0.3
globulol	0.02 – 0.6	myrcene	0.2 – 4.1
viridiflorol	0.08 – 0.8	α -phellandrene	0.2 – 0.6
α -pinene	1.8 – 9.2	β -phellandrene	trace – 5.2
<i>p</i> -cymene	0.3 – 19.4	β -pinene	0.3 – 1.7
ledene	0.3 – 2.1	piperitol	0.05 – 0.3
bicyclogermacrene	0 – 1.2	<i>cis</i> -sabinene hydrate	trace – 19.4
calamenene	trace – 0.2	<i>trans</i> -sabinene hydrate	0.01 – 0.3
camphene	trace – 0.07	spathulenol	trace – 1.1
β -caryophyllene	0.2 – 1.5	α -thujene	0.05 – 1.4
<i>p</i> -cymenene	0.04 – 3.1		

^a 1 sample from China^b the concentration of 45.7% was found in one sample from China only; the median value for all oils was 3.1%**Table 7. Composition of tea tree oil at different collection times during distillation³⁹**

Constituent	0-30 min	30-90 min
α -pinene	1.4%	3.5%
sabinene	0.2%	0.1%
α -terpinene	7.8%	14%
<i>p</i> -cymene	1.3%	1.4%
γ -terpinene	15.6%	29.1%
α -terpineol	3.8%	2.1%
terpinolene	2.6%	4.8%
terpinen-4-ol	55.9% ^b	25.1%
aromadendrene	0.3%	1.2%
ledene	0.5%	1.5%
δ -cadinene	0.3%	1.2%
limonene/ β -phellandrene/1,8-cineole ^a	5.7%	4.1%
α -thujene ^a	0.6%	1.1%
β -pinene ^a	0.5%	0.9%
myrcene ^a	0.7%	1.3%
α -phellandrene ^a	0.2%	0.4%

^a not included in the ISO 4730 standard^b the values in red text fail to meet the ISO 4730: 2017 standard

Table 8. Monoterpenoid composition comparison of aged oils of *Melaleuca alternifolia*³⁹

age of sample relative deterioration rate	unaged sample	1 yr moderate	2 yr rapid	5 yr rapid	10 yr rapid	10 yr slow
α -pinene	2.6%	2.5%	2%	trace	3.2%	2.2%
sabinene	0.2%	trace	trace	NR	0.1%	NR
α -terpinene	10.4%	6.6%	0.1%	NR	0.2%	5.8%
limonene	1.0%	NR	NR	NR	NR	NR
<i>p</i> -cymene	2.9%	8.0%	35.3%	21.7%	32%	4.3%
1,8-cineole	5.1%	NR	NR	NR	NR	NR
γ -terpinene	23%	17.6%	trace	trace	trace	15.9%
terpinolene	3.1%	3.1%	trace	trace	trace	2.7%
terpinen-4-ol	40%	37.3%	23.8%	45.9%	31.5%	41.6%
α -terpineol	2.4%	2.9%	8.2%	9.6%	6.4%	3.7%
limonene/ β -phellandrene/1,8-cineole ^a	NR	8%	35.3%	21.7%	32%	4.3%
α -thujene ^a	0.9%	0.8%	0.2%	NR	NR	0.6%
β -pinene ^a	0.3%	0.7%	0.4%	trace	0.3%	0.6%
myrcene ^a	0.5%	0.7%	0.1%	trace	0.2%	0.5%
α -phellandrene ^a	0.3%	0.4%	trace	NR	trace	0.2%
1,2,4-trihydroxymenthane ^a	trace	trace	3.6%	2.5%	4.6%	trace

^anot included in the ISO 4730 standard

NR – not reported

Table 9. Composition of tea tree oil at various stages of oxidation⁵¹

Component	Un-oxidized Oil	Intermediate Oxidation	Oxidized Oil
α -pinene	2.4%	2.5%	2.6%
sabinene	0.3%	0.2%	NR
α -terpinene	9.1%	5.3%	1.1%
limonene	1.2%	1.2%	1.2%
<i>p</i> -cymene	2.4%	10.2%	19.2%
1,8-cineole	4.5%	4.8%	5.0%
γ -terpinene	19.5%	13.6%	6.9%
terpinolene	3.5%	2.6%	1.5%
terpinen-4-ol	37.7%	36.1%	34.3%
α -terpineol	3.0%	3.1%	3.1%
aromadendrene	1.4%	1.6%	1.9%
ledene	1.0%	1.0%	0.9%
δ -cadinene	1.3%	1.2%	1.2%
globulol	0.4%	0.4%	0.4%
viridiflorol	0.3%	0.3%	0.4%

the values in red text fail to meet the ISO 4730:2017 standard

Table 10. Frequency (2021)⁵⁶ and concentration of use (2019)⁵⁷ according to duration and type of exposure

	<i># of Uses</i>	<i>Max Conc of Use (%)</i>	<i># of Uses</i>	<i>Max Conc of Use (%)</i>	<i># of Uses</i>	<i>Max Conc of Use (%)</i>
	Melaleuca Alternifolia (Tea Tree) Extract		Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Extract		Melaleuca Alternifolia (Tea Tree) Leaf	
Totals*	43	NR	17	0.001-0.01	13	NR
Duration of Use						
<i>Leave-On</i>	29	NR	13	0.01	10	NR
<i>Rinse-Off</i>	13	NR	4	0.001	3	NR
<i>Diluted for (Bath) Use</i>	1	NR	NR	NR	NR	NR
Exposure Type						
Eye Area	NR	NR	NR	NR	1	NR
Incidental Ingestion	NR	NR	1	NR	NR	NR
Incidental Inhalation-Spray	10 ^a ; 14 ^b	NR	3 ^a ; 8 ^b	NR	2; 3 ^b	NR
Incidental Inhalation-Powder	4 ^b	NR	8 ^b	NR	3 ^b	NR
Dermal Contact	43	NR	14	0.001-0.01	12	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	2	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	1	NR
Mucous Membrane	9	NR	1	NR	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR
	Melaleuca Alternifolia (Tea Tree) Leaf Extract		Melaleuca Alternifolia (Tea Tree) Leaf Oil		Melaleuca Alternifolia (Tea Tree) Leaf Water	
Totals*	23	0.0001-0.001	536	0.003-0.63	10	NR
Duration of Use						
<i>Leave-On</i>	18	0.0001	300	0.003-0.63	9	NR
<i>Rinse-Off</i>	5	0.001	221	0.0003-0.3	1	NR
<i>Diluted for (Bath) Use</i>	NR	NR	15	NR	NR	NR
Exposure Type						
Eye Area	NR	NR	8	NR	NR	NR
Incidental Ingestion	NR	NR	13	0.0003-0.02	NR	NR
Incidental Inhalation-Spray	3 ^a ; 14 ^b	NR	18; 89 ^a ; 84 ^b	0.01-0.3 ^a ; 0.03 ^b	4 ^a ; 3 ^b	NR
Incidental Inhalation-Powder	14 ^b	NR	4; 84 ^b ; 3 ^c	0.03 ^b	2; 3 ^b	NR
Dermal Contact	22	0.0001-0.001	409	0.0003-0.5	9	NR
Deodorant (underarm)	NR	NR	20 ^a	not spray: 0.2; spray: 0.5	NR	NR
Hair - Non-Coloring	1	NR	106	0.0072-0.3	NR	NR
Hair-Coloring	NR	NR	NR	NR	1	NR
Nail	NR	NR	7	0.005-0.63	NR	NR
Mucous Membrane	2	NR	96	0.0003-0.3	NR	NR
Baby Products	NR	NR	6	NR	NR	NR

*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

^a Includes products that can be sprays, but it is not known whether the reported uses are sprays

^b Not specified whether this product is a spray or a powder or neither, but it is possible it may be a spray or a powder, so this information is captured for both categories of incidental inhalation

^c Includes products that can be powders, but it is not known whether the reported uses are powders

Table 11. In vitro dermal penetration studies of tea tree oil using skin samples

Test Article	Concentration	Diffusion Cell	Skin Sample	Receptor Fluid	Procedure	Penetration/Absorption/Other Parameters	Reference
Animal Skin Samples							
tea tree oil	5% o/w emulsion	conventional static Franz cell; modified static Franz cell to monitor volatiles	pig ear skin; 1 mm thickness	PBS, 0.05 M (pH 5.5), containing 0.1% sodium dodecyl sulfate	Distribution of 7 tea tree oil components was measured Finite dosing regimen using 12 mg of formulation; donor compartment was kept open; sampling was carried out up to 27 h; after withdrawal, the same volume of fresh buffer was added; tape-stripping was used to remove stratum corneum; 3 trials were performed Conventional static Franz evaluated both the components that permeated and distributed in ear pig skin layers (area surface, 2.54 cm ²), and the donor compartment was kept open. The static Franz cell was modified to measure the amounts of components vaporized during the tests; a hermetically sealed glass vessel (75ml) connected online to a donor compartment to collect the components released by the formulation. Amount of each marker in the receiving phase was determined by headspace solid-phase microextraction (HS-SPME)-GC/MS (20 ml vial); the amount of each marker retained by the total skin, and by epidermis and dermis (separated via the cryostat method), were quantified by HS-SPME-GC/MS using the multiple headspace extraction approach	The skin layers contained less than 1% of each tea tree oil marker in total; only oxygenated terpenes significantly permeated across the skin, while hydrocarbons were only absorbed at trace levels. Over 27 h, permeation rates (and percent permeation) were 49.1 µg/cm ² (49.7%) for 4-terpineol; 8.90 µg/cm ² (53.5%) for α-terpineol, and 3.85 µg/cm ² (12.4%) for 1,8-cineole; permeation rates could not be measured for α- and β-pinene and α- and γ-terpinene because very low amounts permeated at each time All markers were retained by the whole skin, and the amounts ranged from 0.031 µg (β-pinene) to 1.3 µg (4-terpineol). The amounts found in the epidermis ranged from 0.012 µg (α-terpineol) to 0.042 µg α-pinene; β-pinene and α-terpinene were below the limit of detection. The amounts found in the dermis ranged from 0.031 µg β-pinene to 1.26 µg 4-terpineol. Almost no components remained in the residual formulation after 27 h. Substantial amounts of markers were released into the atmosphere; the highest percentage of oxygenated compounds (i.e., 1,8-cineole, 4-terpineol, α-terpineol) was released into the headspace within the first hour, with approximately 90% of 1,8-cineole, and 40-45% of 4-terpineol and α-terpineol, released into the headspace. For the hydrocarbons (i.e., α- and β-pinene, α- and γ-terpinene), release into the headspace was constant over 27 h	71
tea tree oil	2.5, 5, and 10% in a cream 5, 15, and 30% in an ointment 5% in a hydrophilic gel	static glass vertical Franz diffusion cell	pig ear skin for permeation tests; 1 mm thickness synthetic cellulose membrane for release studies	PBS, 0.05 M (pH 5.5), containing 0.1% sodium dodecyl sulfate	Eight marker compounds were identified. Infinite dose regimen; donor compartment contained 1 g of the test article, and was sealed with wax film to prevent evaporation Skin surface has a diffusion area of 1.54 cm ² 18 sampling times, over a 50-h period; receptor phase was completely replaced at each sampling time. Receiving phases were analyzed by HS-SPME with GC/MS; experiments were repeated 3 times	The fastest permeation rate was with the 5% gel, followed by the 30% ointment. All markers (α-pinene, α-terpinene, p-cymene, 1,8-cineole, γ-terpinene, α-terpinolene, 4-terpineol, α-terpineol) permeated the skin; the oxygenated monoterpenes (i.e. 1,8-cineole, 4-terpineol, and α-terpineol) preferentially diffused through the skin; hydrocarbons were only present in the skin (as well as the receptor fluid) at trace levels. <i>1,8-cineole (33 mg/g (3.3%) of the oil)</i> <i>Amount Released (% of the total amount initially present in the formulations)</i> 5% gel: 236 µg/cm ² (16.7%) 2.5% cream: 72 µg/cm ² (8.8%) 5% cream: 137 µg/cm ² (8.4%) 10% cream: 318 µg/cm ² (7.2%) 5% ointment: 88 µg/cm ² (4.7%) 15% ointment: 482 µg/cm ² (7.3%) 30% ointment: 3642 µg/cm ² (32.2%)	72

Table 11. In vitro dermal penetration studies of tea tree oil using skin samples

Test Article	Concentration	Diffusion Cell	Skin Sample	Receptor Fluid	Procedure	Penetration/Absorption/Other Parameters	Reference
						<u>Amount Permeated</u> 5% gel: 235 µg/cm ² (14.5%) 2.5% cream: 74 µg/cm ² (9.1%) 5% cream: 31 µg/cm ² (1.9%) 10% cream: 93 µg/cm ² (2.1%) 5% ointment: 29 µg/cm ² (1.6%) 15% ointment: 142 µg/cm ² (2.1%) 30% ointment: 2.1 µg/cm ² (1.9%)	
						<i>4-terpineol (450 mg/g (45%) of the oil)</i> <u>Amount Released</u> 5% gel: 5437 µg/cm ² (43.6%) 2.5% cream: 354 µg/cm ² (5.0%) 5% cream: 874 µg/cm ² (6.1%) 10% cream: 1648 µg/cm ² (4.2%) 5% ointment: 277 µg/cm ² (1.7%) 15% ointment: 2496 µg/cm ² (4.3%) 30% ointment: 10,047 µg/cm ² (10.1%)	
						<u>Amount Permeated</u> 5% gel: 2103 µg/cm ² (14.7%) 2.5% cream: 182 µg/cm ² (2.5%) 5% cream: 84 µg/cm ² (0.6%) 10% cream: 248 µg/cm ² (0.6%) 5% ointment: 71 µg/cm ² (0.4%) 15% ointment: 550 µg/cm ² (0.9%) 30% ointment: 663 µg/cm ² (0.7%)	
						<i>α-terpineol (65 mg/g (6.5%) of the oil)</i> <u>Amount Released</u> 5% gel: 941 µg/cm ² (52.0%) 2.5% cream: 38 µg/cm ² (3.6%) 5% cream: 102 µg/cm ² (4.9%) 10% cream: 190 µg/cm ² (3.3%) 5% ointment: 20 µg/cm ² (0.8%) 15% ointment: 275 µg/cm ² (3.2%) 30% ointment: 1120 µg/cm ² (7.7%)	
						<u>Amount Permeated</u> 5% gel: 312 µg/cm ² (15.0%) 2.5% cream: 14 µg/cm ² (1.3%) 5% cream: 6.3 µg/cm ² (0.3%) 10% cream: 21 µg/cm ² (0.4%) 5% ointment: 5.2 µg/cm ² (0.2%) 15% ointment: 46 µg/cm ² (0.5%) 30% ointment: 2.58 µg/cm ² (0.4%)	
						Only 4-terpineol and α-terpineol are retained in the skin; the highest retention was observed with the 30% ointment (0.52 µg/cm ² 4-terpineol; 0.41 µg/cm ² α-terpineol), and the lowest was with the 5% gel (0.09 µg/cm ² 4-terpineol; 0.15 µg/cm ² α-terpineol)	

Table 11. In vitro dermal penetration studies of tea tree oil using skin samples

Test Article	Concentration	Diffusion Cell	Skin Sample	Receptor Fluid	Procedure	Penetration/Absorption/Other Parameters	Reference
Human Skin Samples							
monolayer patch formulations containing 10.10% (w/w) tea tree oil; terpinen-4-ol content, 42.7%	as prepared	vertical Franz cells	female (n = 1) abdominal skin; stratum corneum and epidermis (SCE)	degassed mixture of ethanol/water (50:50 v/v)	Penetration was estimated using terpinen-4-ol as a marker. Six patch formulations were made of a self-adhesive controlled-release matrix containing methacrylic copolymers or a silicone resin; 3 contained 3.2% oleic acid as a skin penetration enhancer. Terpinen-4-ol content/patch ranged from: 265 ± 52 µg/cm ² to 485 ± 45 µg/cm ² . Diffusion area of the cell was 0.636 cm ² . Upper and lower parts of the cell were sealed with wax film. Samples were taken at various intervals for up to 24 h, and assayed using capillary gas chromatography (CGC)/FID. Three replicates were used.	A linear profile was observed for all patches, both with and without oleic acid Formulations containing the silicone resin had the highest flux (6.8 ± 1.0 µg/cm ² /h without, and 8.6 ± 0.4 µg/cm ² /h with, oleic acid); greatest permeation of terpinen-4-ol occurred with this patch (184.6 ± 28.0 µg/cm ² without, and 217.1 ± 28.3 µg/cm ² with, oleic acid) Avg flux from the 2 methacrylic copolymer patches was 3.7 ± 0.5 and 4.1 ± 1.9 µg/cm ² /h without, and 3.7 ± 1.4 and 6.6 ± 0.4 µg/cm ² /h with, oleic acid, respectively; amts of terpinen-4-ol that penetrated from these patches were 85.8 ± 10.6 and 128.0 ± 2.3 µg/cm ² without, and 97.7 ± 31.0 and 161.9 ± 9.9 µg/cm ² with, oleic acid, respectively Total amount of terpinen-4-ol retained in the skin sample ranged from 2.4 to 16.1 µg/cm ²	73
tea tree oil	100%	static Franz diffusion cells	Caucasian female abdominal skin; heat-separated epidermis (HSE)	ethanol/water mixture	All experiments measured terpinen-4-ol. Liberation experiments were performed by placing the test material in the donor compartment, and using an Isopore [®] membrane; concentration of saturation of terpinen-4-ol was 10.5 µl/ml, and samples were withdrawn at various intervals for up to 18 h. Permeation were determined using an infinite dosing regimen. HSE, which was rehydrated for 1 h prior to use with PBS, was transferred onto a cellulose membrane for handling. Samples were withdrawn at various intervals up to 48 h. GC was used to assay the components in the receptor fluid.	<u>terpinen-4-ol data (447.4 µl/ml in oil)</u> flux through HSE: 0.262 ± 0.019 µl/cm ² /h apparent permeability constant (P _{app}): 1.62 ± 0.12 cm/s x 10 ⁷ permeation: ~ 4.5 µl/cm ² (24 h); ~ 11.7 µl/cm ² (48 h)	74
cream	3, 5, and 10%					<u>from 5% cream (contained 22.37 µl/ml terpinen-4-ol)</u> flux through HSE: 0.022 ± 0.001 µl/cm ² /h P _{app} : 2.74 ± 0.06 cm/s x 10 ⁷ permeation: ~ 0.5 µl/cm ² (24 h); ~ 1 µl/cm ² (48 h) overall, release rate ranged from 0.184 ± 0.007 (3% cream) to 0.663 ± 0.017 µl/cm ² /h (10% cream)	
ointment (in white pet)	3, 5, and 10%					<u>from 5% ointment (contained 22.37 µl/ml terpinen-4-ol)</u> flux through HSE: 0.051 ± 0.002 µl/cm ² /h P _{app} : 6.36 ± 0.21 cm/s x 10 ⁷ permeation: ~ 1 µl/cm ² (24 h); ~ 2 µl/cm ² (48 h) overall, release rate ranged from 0.416 ± 0.010 (3% ointment) to 1.581 ± 0.035 µl/cm ² /h (10% ointment)	
semisolid o/w emulsion	3 and 5% (phase separation occurred at 10%)					<u>from 5% emulsion (contained 22.37 µl/ml terpinen-4-ol)</u> flux through HSE: 0.067 ± 0.001 µl/cm ² /h P _{app} : 8.41 ± 0.15 cm/s x 10 ⁷ permeation: ~ 1.7 µl/cm ² (24 h); ~ 3 µl/cm ² (48 h) overall, release rates were 0.565 ± 0.012 (3% emulsion) and 0.659 ± 0.038 µl/cm ² /h (5% emulsion)	

Table 11. In vitro dermal penetration studies of tea tree oil using skin samples

Test Article	Concentration	Diffusion Cell	Skin Sample	Receptor Fluid	Procedure	Penetration/Absorption/Other Parameters	Reference
tea tree oil; contained 37.5% terpinin-4-ol; 4.5% 1,8-cineole; 3.0% α -terpineol	20% in ethanol and 100%	horizontal Franz cells	female abdominal skin; HSE (n = 3 donors; 6 samples/donor)	PBS (pH 7.4) containing 4% bovine serum albumin	Penetration and skin retention of components of tea tree oil were studied. Exposed skin area was ~ 1.3 cm ² ; membranes were hydrated overnight with PBS placed in the receptor chamber. A finite dose of 10 μ l/cm ² (8.9 mg/cm ²) was used to simulate normal "in use" conditions. Samples were taken at various intervals for up to 24 h, and assayed using GC/MS..	<p>Only terpinen-4-ol and α-terpineol were found in the receptor fluid, but some other sesquiterpenes (not specified) were retained in the skin sample. The amounts varied among the 3 donors.</p> <p>Undiluted oil <u>Penetration:</u> 138.2 – 302.5 μg/cm² terpinen-4-ol (3.6 – 8.0% of the applied dose) and 14.2 – 33.0 μg/cm² α-terpineol (3.6 – 8.4% of the applied dose) was found in the receptor fluid over the 24-h period; total penetration: 1.73 - 3.82% <u>Epidermal retention:</u> 4.1 – 6.6 μg/cm² terpinen-4-ol (0.1 – 0.2% of the applied dose) and 16.3 – 25.7 μg/cm² α-terpineol + other components; total found in the epidermis: 0.23 – 0.37% <u>Potential total absorption:</u> 2.0 – 4.1%</p> <p>20% formulation <u>Penetration:</u> 18.6 – 32.9 μg/cm² terpinen-4-ol (1.1 – 1.9% of the applied dose) was found in the receptor fluid after 24 h; α-terpineol was not found <u>Epidermal retention:</u> 0.25 – 0.38 μg/cm² terpinen-4-ol (< 0.02% of the applied dose) and 0.5 – 1.18 μg/cm² α-terpineol + other components; total found in the epidermis: 0.05 – 0.09% <u>Potential total absorption:</u> 1.1 -1.9%</p>	41
	100%		n = 1 donor		Effect of partial occlusion was also evaluated by placing a glass slipcover on top of the donor chamber.	<p><u>Penetration:</u> terpinen-4-ol (289.7 μg/cm²) and α-terpineol (22.8 μg/cm²) were found in the receptor fluid after 12 h, and terpinen-4-ol (531.4 μg/cm²), α-terpineol (44.7 μg/cm²), and 1,8-cineole (19.8 μg/cm²) were present at 24 h total penetration of all 3 components after 24 h was 6.8%. (No other components were detected.) <u>Epidermal retention (24 h):</u> 4.3 μg/cm² terpinen-4-ol and 23.3 μg/cm² α-terpineol + 14 other components (0.27% of total dose) were found in the epidermis; total retained in epidermis: 0.31% <u>Potential total absorption:</u> 7.1%</p>	
tea tree oil; terpinen-4-ol content, 30%	100%	flow-through Teflon [®] diffusion cells	female cadaver thorax skin	isotonic phosphate buffer	200 mg of oil was applied to the skin sample for 8 h; donor compartment was occluded with wax film. Cells had a diffusion area of 0.65 cm ² . Stratum corneum layers were separated by tape-stripping. Assayed for 4-terpinen-ol using CGC/FID. Four replicates were used.	amounts of terpinen-4-ol found in the skin layers: outer stratum corneum: 711.5 μ g/cm ² middle stratum corneum: 128.3 μ g/cm ² inner stratum corneum: 69.0 μ g/cm ² remaining epidermis: 1510.6 μ g/cm ²	75

Table 11. In vitro dermal penetration studies of tea tree oil using skin samples

Test Article	Concentration	Diffusion Cell	Skin Sample	Receptor Fluid	Procedure	Penetration/Absorption/Other Parameters	Reference
tea tree oil; terpinen-4-ol content, 42.7%	100%	vertical Franz cells	female (n = 1) abdominal skin; SCE	degassed mixture of ethanol/water (50:50 v/v)	The effect of excipients on the permeability of tea tree oil was determined using infinite dosing conditions. Terpinen-4-ol was used as a marker. 500 µl (~ 700 mg/cm ²) tea tree oil, alone or with a 1 ml mixture (1:1 v/v) with isopropyl myristate, oleic acid, PEG400, or diethylene glycol ethyl ether, was added to the donor compartment, which was covered with wax film to avoid evaporation. Samples were taken at various intervals for up to 24 h, and assayed for 4-terpinen-ol using CGC/FID. Three replicates were used.	<p>tea tree oil only lag time – 59 min flux – 0.02 ± 0.00 mg/cm²/h K_p – 5.6 ± 1.1 x 10⁻⁵ cm/h amount permeated – 0.56 ± 0.14 mg/cm² retained in skin sample – 0.14 ± 0.00 mg/cm²</p> <p>tea tree oil with isopropyl myristate lag time – 30 min flux – 0.05 ± 0.01 mg/cm²/h K_p – 23.5 ± 6.3 x 10⁻⁵ cm/h amount permeated – 1.18 ± 0.31 mg/cm² retained in skin sample – 0.04 ± 0.02 mg/cm²</p> <p>tea tree oil with oleic acid lag time – 12 min flux – 0.70 ± 0.25 mg/cm²/h K_p – 325.1 ± 119.3 x 10⁻⁵ cm/h amount permeated – 6.06 ± 2.15 mg/cm² retained in skin sample – 0.36 ± 0.05 mg/cm²</p> <p>tea tree oil with PEG400 lag time – 47 min flux – 0.04 ± 0.03 mg/cm²/h K_p – 20.7 ± 13.0 x 10⁻⁵ cm/h amount permeated – 1.03 ± 0.67 mg/cm² retained in skin sample – 0.07 ± 0.01 mg/cm²</p> <p>tea tree oil with diethylene glycol ethyl ether lag time – 0 min flux – 0.06 ± 0.00 mg/cm²/h K_p – 28.7 ± 3.0 x 10⁻⁵ cm/h amount permeated – 1.65 ± 0.24 mg/cm² retained in skin sample – 0.18 ± 0.17 mg/cm²</p>	76

Table 12. Acute toxicity studies

Ingredient	Animals	No./Group	Vehicle	Concentration/Dose	Protocol	LD ₅₀ or LC ₅₀ /Results	Reference
DERMAL							
tea tree oil	rabbits	10 (sex not specified)	none	5 g/kg	A single 24-h occlusive patch was applied to clipped intact or abraded abdominal skin	> 5 g/kg 2 animals died; mottled livers were reported at necropsy; stomach and intestinal abnormalities were reported in 3 animals; the other 5 animals were normal	82
tea tree oil	NZW rabbits	5/sex	none	2 g/kg	Applied in accordance with OECD TG 402	> 2 g/kg 2 animals died (details not reported)	6,7
tea tree oil	dogs and cats	not stated	NR	“very high concentrations”	None stated.	Cases of tea tree oil toxicosis have been reported following topical application; onset of symptoms typically occurred 2-8 h after application; typically, the animals recovered; in one case, the cat died 3 d after exposure, and the cause of death was not determined	83,84
ORAL							
Melaleuca Alternifolia (Tea Tree) Leaf Oil	Swiss mice	not stated	not stated	0.5 - 2 g/kg	Preliminary dose-range-finding study; single dose by gavage	all animals dose with 2 g/kg exhibited a wobbly gait, prostration, and labored breathing at 30 min – 5 h after dosing	6
Melaleuca Alternifolia (Tea Tree) Leaf Oil	Swiss mice	5/sex	corn oil	0, 1, 1.35, or 1.750 g/kg bw	Single dose by gavage, in accordance with OECD TG 474; animals were killed after 24 h; an additional vehicle control and high dose group, as well as a positive control group dosed with 40 mg/kg bw of 9,10-diemthyl-1,2-benzanthracene, was killed 48 h after dosing	A statistically significant decrease of polychromatic erythrocytes (PCE) and PCE + normochromatic erythrocytes that was observed in the high dose group at 48 h was considered an indicator of toxicity. Reduced weight gain was noted in all high dose animals killed at 24 h	6
Melaleuca Alternifolia (Tea Tree) Leaf Oil	Wistar rats	10 males	none	1.2, 3, or 5 g/kg	Animals were dosed orally	LD ₅₀ = 1.9 g/kg bw (calculated) One animal dosed with 1.2 g/kg, 9 animals dosed with 3 g/kg, and all animals dosed with 5 g/kg died Abnormalities (not described) in the lungs, heart, liver, stomach, urinary tract, and intestines were reported in the animals that died	82
tea tree oil	CRL:(NMRI)BR mice	3 females	PEG 400	2 g/kg bw	Single dose by gavage, in accordance with OECD TG 423	LD ₅₀ > 2 g/kg; no dose-related mortality Clinical effects, such as decreased activity, hunched back position, and piloerection in all animals, incoordination in 4 animals, and dyspnea in 3 animals	7
tea tree oil	Sprague-Dawley rats	5/sex	peanut oil	2.5 – 3.0 ml/kg (SPF rats) 1.7 – 2.4 ml/kg (non-SPF rats)	Single dose by gavage	LD ₅₀ (SPF rats - 2.6 ml/kg (calculated; equivalent to 2.3 g/kg bw); 30%, 90%, 70%, and 70% of rats dosed with 2.5, 2.6, 2.75, and 3.0 ml/kg, respectively, died within 14 d of dosing LD ₅₀ (non-SPF rats) - 1.9 ml/kg (calculated; equivalent to ~1.7 g/kg bw); 60%, 30%, 80%, 100%, and 100% of rats dosed with 1.7, 2.1, 2.15, 2.25, and 2.4 ml/kg, respectively, died within 14 d of dosing SPF and non-SPF animals exhibited lack of tonus in the forelimbs, weeping eyes, and bloodied noses	7

Table 12. Acute toxicity studies

Ingredient	Animals	No./Group	Vehicle	Concentration/Dose	Protocol	LD ₅₀ or LC ₅₀ /Results	Reference
INHALATION							
tea tree oil	Wistar rats	5/sex	none	1.94, 3.7, and 5.04 mg/l	4-h exposure, nose-only mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and inhalable fraction (< 4 µm) were: 1.94 mg/l: 2.31 µm; 2.09; 77.2% 3.7 mg/l: 3.40 µm; 2.42; 57.2% 5.04 mg/l: 3.51 µm; 2.0; 57.1%	LC ₅₀ (calculated) = 4.78 mg/l [males and females, combined]; 5.23 mg/l [males only]; 4.29 mg/l [females only] Mortality was 70% with 5.04 mg/l; no mortality reported in the other 2 groups	7
0.3% tea tree oil and 1.8% ethanol in carbon dioxide	Sprague-Dawley rats	5/sex	none	50 or 100 mg/l	1 h exposure under dynamic airflow conditions in a 100-l inhalation chamber that generated ~ 50 mg/l of air	No abnormal behavior or signs of toxicity observed during or after dosing	6

Table 13. Genotoxicity studies

Test Article	Concentration/Dose	Vehicle/Solvent	Test System	Procedure	Results	Reference
IN VITRO						
tea tree oil	10 – 150 µl/plate		<i>S. typhimurium</i> TA 98, TA 100, TA 102	Ames test, with and without metabolic activation; appropriate positive controls were used	not mutagenic cytotoxic at ≥ 50 µl/plate	7
tea tree oil	<i>S. typhimurium</i> : up to 280 µg/plate (TA98) and 880 µg/plate (TA100) with metabolic activation, up to 2780 µg/plate without metabolic activation <i>E. coli</i> : up to 2000 µg/plate (tested at non-cytotoxic concentrations)	DMSO	<i>S. typhimurium</i> TA98 and TA100; <i>E. coli</i> WP2 <i>uvr A</i>	Ames test, with and without metabolic activation	not mutagenic	86
tea tree oil (and the component terpinen-4-ol)	up to 5000 µg/ml (tea tree oil) up to 2000 µg/ml (terpinen-4-ol)	acetone	<i>S. typhimurium</i> TA102, TA100, and TA98	Ames test, with and without metabolic activation	not mutagenic (tea tree oil and terpinen-4-ol)	87
tea tree oil	9.76 – 58.59 µg/ml (3/20 h and 3/28 h treatment/sampling time, with activation; 3/20 h treatment/sampling time without activation) 4.88 – 39.06 µg/ml (20/28 h treatment/sampling time, without activation)	DMSO	V79 cells	chromosomal aberration assay, with and without metabolic activation in accordance with OECD TG 473; solvent and positive controls	not clastogenic	7
tea tree oil	95, 182, and 365µg/ml; higher concentrations were cytotoxic	none	human lymphocytes	chromosomal aberration assay; negative (untreated culture) and appropriate positive controls were used	not genotoxic	88
tea tree oil	95, 182, and 365µg/ml	none	human lymphocytes	mammalian cells micronucleus assay; negative (untreated culture) and appropriate positive controls were used	not genotoxic	88
tea tree oil	5 – 275 µg/ml, with activation 5 – 120 µg/ml, without activation	DMSO	mouse lymphoma L5178Y cells	mammalian cell transformation assay, with (two 3-h assays) and without (one 3-h and two 24-h assays) metabolic activation, in accordance with OECD TG 476; negative, solvent, and positive controls were used	not genotoxic cytotoxicity was observed at ≥ 150 µg/ml with, and at ≥ 120 µg/ml (3 h) and ≥ 60 µg/ml (24 h) without, metabolic activation	7
tea tree oil	0 – 0.064%	none indicated	HaCaT cells	Comet assay to determine effect on DNA strand breaks (a % of tail DNA); hydrogen peroxide served as the positive control; 3 independent trials	did not induce DNA damage	89
IN VIVO						
Melaleuca Alternifolia (Tea Tree) Leaf Oil	0, 1000, 1350, or 1750 mg/kg bw	corn oil	5 mice/sex/group	mammalian erythrocyte micronucleus test, performed in accordance with OECD TG 474 animals were given single dose by gavage, and killed 24 h after dosing; an additional vehicle control and high dose group, as well as a positive control group dosed with 40 mg/kg bw of 9,10-dimethyl-1,2-benz-anthracene, were killed 48 h after dosing	not clastogenic no significant increase in micronucleated erythrocytes at 24 or 48 h in any of the test groups when compared to the negative controls	6

Table 14. Anti-carcinogenicity studies

Test Article	Concentration/Dose	Test System	Procedure	Results	Reference
IN VITRO					
tea tree oil	0 – 0.08%	murine AE17 mesothelioma cells and B16 melanoma cells	MTT assay; cells were treated for 24 and 48 h, and then measured for viability. Morphological fluorescent analysis was used to determine the primary mode of cell death.	A dose-dependent effect against both cell lines was observed. After 24 h, there was a greater effect against the AE17 cells compared to B16 cells; IC ₅₀ values were 0.03% and 0.05%, respectively. At 48 h, IC ₅₀ values were significantly reduced; values were 0.02% and 0.03% for AE17 and B16 cells, respectively. (An increase in exposure time to 72 h did not have a significant effect on the anti-proliferative effect against either cell line.) The primary mode of cell death in AE17 cells appeared to be necrosis; after 24 and 48 h exposure to 0.04% tea tree oil, necrosis levels were 36.2% and 55%, respectively, and apoptosis levels were 13.3% and 12.7%, respectively. Low levels of apoptosis and necrosis were observed with 0.04% tea tree oil in B16 cells at both exposure times (4.3% and 12.9% necrosis and 5.5% and 5.1% apoptosis at 24 and 48 h, respectively); significant necrotic cell death in B16 cells was only evident at concentrations > 0.06% tea tree oil. Cell cycle of B16 cells were significantly altered (0.04% of the oil), with only modest changes in AE17 cells.	90
tea tree oil	0.005 – 0.03%	human melanoma M14 wild-type (WT) and adriamycin-resistant (ADR) cells	Effect on cell growth was determined. Annexin V binding method was used to evaluate apoptosis. Migratory and invasive potential was evaluated using the transwell chamber invasion assay	A slight, but statistically significant decrease in the cell pool size of the ADR cells, but not the WT cells, was observed with 0.01% tea tree oil, and concentrations of 0.02% and 0.03% were strongly inhibitory in both the M14 WT and M14 ADR cells, with the effect being greater in the ADR cell line Caspase-dependent apoptosis of the cells, especially in the M14 ADR cells, was induced There was a significant decrease in the percentage of area occupied by the ADR cells migrated in the presence of tea tree oil, but no effect on migration and invasion of the WT cells	91
tea tree oil	0.004 – 2.0% (v/v) in DMSO	human malignant melanoma (A-375) and squamous cell carcinoma (Hep-2) cells	The viability of A-375 and HEp-2 cell lines was assessed using the MTT assay (24 h). Annexin V/ propidium iodide staining was measured for apoptosis detection, cell cycle analysis was monitored using flow cytometry, and messenger RNA (mRNA) expression levels of the apoptosis-regulatory genes <i>P53</i> , <i>BAX</i> , and <i>BCL-2</i> were determined by real-time polymerase chain reaction (PCR) and western blot analysis	tea tree oil markedly reduced viability in a dose-dependent manner, and exhibited a strong cytotoxicity towards both cell lines; IC ₅₀ values were 0.038% (v/v) for A-375 cells and 0.024% (v/v) for Hep-2 cells; cytotoxicity resulted from apoptosis in both cell lines. Cell cycle analysis showed that tea tree oil caused cell cycle arrest mainly at G2/M phase. Expression of proapoptotic genes (<i>P53</i> and <i>BAX</i>) was upregulated, while the anti-apoptotic gene <i>BCL-2</i> was downregulated	92

Table 14. Anti-carcinogenicity studies

Test Article	Concentration/Dose	Test System	Procedure	Results	Reference
tea tree oil	1 – 1000 µg/ml in DMSO	human MCF-7 and murine 4T1 breast cancer cells; HFF-1 fibroblast cells	MTT assay; 72 h Apoptosis was evaluated using flow cytometry (MCF-7 cells) Cell cycle analysis and a colony formation assay (after 10 d of treatment) were performed in MCF-7 cells	IC ₅₀ (72 h) was estimated to be 603 µg/ml for MCF-7 cells and 626 µg/ml for 4T1 cells; there was a significant decrease in MCF-7 and 4T1 cell proliferation at concentrations > 300 and > 600 µg/ml, respectively. With HFF-1 cells, a significant decrease in cell proliferation was observed at 1000 µg/ml; however, with 300 µg/ml, cell proliferation of HFF-1 cells was induced at 72 h after treatment The increase in apoptosis in MCF-7 cells at 300 µg/ml was approximately 6x higher compared to untreated cells. 300 µg/ml significantly increased the number of cells in the S phase of the cell cycle In the colony formation assay, 300 and 600 µg/ml significantly decreased the number of cell colonies	93
tea tree oil	10 – 50 µg/ml (0.195 – 100%) in DMSO	human MDA MB breast cancer cells	MTT assay; 48 h incubation NIH3T3 mouse fibroblast cells were used as a control	IC ₅₀ = 25 µg/ml	95
tea tree oil	0.025 and 0.05 % in DMSO and Tween 80	human U87MG glioblastoma cells	MTT assay; cells were incubated for 24, 48 or 72 h Cell cycle and apoptosis assay were assessed by flow cytometry (0.025%, for up to 24 h or up to 72 h)	tea tree oil decreased cell viability in a dose- and time-dependent manner. Cell cycle arrest was triggered in the G0/G1 phase in a time- and dose-dependent manner; treatment (72 h) caused an increase of cells in the G0/G1 phase	94
tea tree oil	10 – 50 µg/ml (0.195 – 100%) in DMSO	human HT29 colon cancer cell line	MTT assay; 24 h incubation period Cisplatin served as the positive control	IC ₅₀ = 12.5 µg/ml	96
tea tree oil	0.0001% - 100%, in ethanol	human Hep G2 hepatocellular carcinomic human cell line	[(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay; 4 h and 24 h exposure times Controls included ethanol; ethanol and cells; and ethanol and media	IC ₅₀ = 2800 µg/ml (4 h) IC ₅₀ = 20 µg/ml (24 h)	97
tea tree oil	0.0001% - 100%, in ethanol	HeLa epithelioid carcinomic cell line	as above	IC ₅₀ = 2800 µg/ml (4 h) IC ₅₀ = 2700 µg/ml (24 h)	97
tea tree oil	0.0001% - 100%, in ethanol	human MOLT-4 lymphoblastic leukemic T-cell line	as above	IC ₅₀ = 600 µg/ml (4 h) IC ₅₀ = 300 µg/ml (24 h)	97
tea tree oil	0.0001% - 100%, in ethanol	human K-562 chronic myelogenous leukemia cell line	as above	IC ₅₀ = 2800 µg/ml (4 h) IC ₅₀ = 270 µg/ml (24 h)	97
tea tree oil	0.0001% - 100%, in ethanol	CTVR-1; early B-cell line from bone marrow cells of a patient with acute myeloid leukemia	as above	IC ₅₀ = 310 µg/ml (24 h)	97

Table 14. Anti-carcinogenicity studies

Test Article	Concentration/Dose	Test System	Procedure	Results	Reference
ANIMAL					
tea tree oil, or a solution of its components	10% in DMSO, acetone, or isopropanol (50 µl); neat (5 µl); 10% solution of components (40% terpinen-4-ol, 20% γ-terpinene, 10% α-terpinene, 5% 1,8-cineole, 5% p-cymene, in ethanol) in DMSO (50 µl)	C57BL/6J mice; 5 females/group	subcutaneous implantation with $5 \times 10^5/100 \mu\text{l}$ PBS B16-F10 murine melanoma cells or $1 \times 10^7/100 \mu\text{l}$ PBS AE17 murine mesothelioma cells; once tumors measured $\sim 9 \text{ mm}^2$, mice were treated topically 1x/d for 4 d; 4 independent trials were performed Vehicle control received 10% water/DMSO; all animals were compared to untreated controls	<u>10% tea tree oil in DMSO</u> : regressed AE17 mesotheliomas in mice; untreated control growth levels resumed approximately 4 d after cessation of treatment. Significantly slowed the growth of B16-F10 melanomas; growth resumed at untreated control levels 2-3 d following cessation of treatment, rapidly reaching 100 mm^2 in size. Local skin irritation and inflammation (with an increased number of neutrophils and other immune cells including macrophages, mast cells, and lymphocytes, but not eosinophils) was observed with application <u>undiluted tea tree oil; 10% in acetone or isopropanol; vehicle control</u> : no effect on tumor growth; no local effects with undiluted oil, or vehicle control; minimal local dermal irritation with 10% in acetone or isopropanol. <u>10% solution of components in DMSO</u> : significantly inhibited the growth of AE17 tumors for a period of 5 d, and induced significant tumor regression in half of the test animals; growth resumed at untreated control levels 2 d following cessation of treatment.	98
tea tree oil	3.5%	nude CD1 mice; 8 males/group	subcutaneous implantation with 5×10^6 human glioblastoma cells /0.2 ml (matrigel and Dulbecco's modified Eagle's medium); after 7 d, tea tree oil was administered intratumorally, 2x/wk for 3 wk	Test mice had an 80% reduction in the tumor mass compared with control mice. Tumors treated with tea tree oil showed the same cell morphology as those that were untreated, but a marked reduction in cell density with large areas of necrosis was observed. Using the TUNEL assay, an increase in apoptotic tumor cells (DNA fragmentation) was found after treatment with tea tree oil.	94

Table 15. Effect on endocrine activity

Test Article	Concentration/Dose	Test System	Procedure	Results	Reference
ESTROGENIC EFFECTS					
tea tree oil	0.025% (v/v) in DMSO	MCF-7 (ER α -positive) cells	Determined ER α -regulated gene expression, using quantitative PCR; cells were treated for 18 h, with or without 5 μ M fulvestrant; vehicle controls and E2 (1 nM) controls were also used mRNA levels of ER α target genes (growth regulation by estrogen in breast cancer 1 (<i>GREB1</i>), progesterone receptor (<i>PGR</i>), and cathepsin D (<i>CTSD</i>)) were measured	All 3 genes showed significant induction when treated with tea tree oil; induction was blocked by co-treatment with fulvestrant	99
tea tree oil	0 – 0.05% (v/v) in DMSO	human MCF-7 breast cancer cells	MCF-7 cells that were positive for ER and were transiently transfected with an estrogen-inducible luciferase reporter plasmid containing 3 copies of an ERE (3X-ERE-TATA-luciferase) were treated for 18 h, with or without fulvestrant (an ER antagonist); 4 experiments were performed in duplicate. E2 (1 nM) served as the positive control.	ERE-dependent luciferase activity was stimulated in a dose-dependent manner, with the maximum activity observed at 0.025%; however, maximum activity corresponded to approximately 50% of the activity elicited by 1 nM E2. (Higher doses of tea tree oil were cytotoxic.) Fulvestrant inhibited tea tree oil-induced transactivation of the 3X-ERE-TATA-luciferase reporter plasmid; the researchers stated that this indicated that the activity observed with tea tree oil is ER-dependent. Additional testing in MCF-7 cells indicated that tea tree oil modulated the expression of the estrogen-regulated endogenous genes a proto-oncogene (<i>MYC</i>), <i>CTSD</i> , and insulin like growth factor binding protein 3 (<i>IGFBP3</i>), that it increased the expression of mRNA for <i>MYC</i> and <i>CTSD</i> , and it decreased the expression of mRNA for <i>IGFBP3</i> , as compared with the DMSO controls; the researchers stated that these effects on mRNA were similar to the effect of 1 nM E2, in magnitude and timing.	100
tea tree oil; terpinen-4-ol; α -terpineol; 1,8-cineole	0.00075 – 0.1% (v/v)	MCF-7 BUS cells	E-screen assay; effect on cell proliferation was examined in the presence and absence of 0.00005 μ M E2; proliferation results were expressed as the number of cells after 6 d of incubation, and given as the RPE compared to the maximum E2 response	Without E2, tea tree oil induced a weak, but significant, dose-dependent estrogenic response at concentrations ranging from 0.00075% - 0.025%, with a maximal response (corresponding to 34% of the maximal E2 response) induced by 0.0125% tea tree oil Terpinen-4-ol, α -terpineol, and 1,8-cineole, as well as an 8:1:1 mixture of these constituents, did not induce a significant estrogenic response (i.e., >10% of the maximal response induced by E2) at concentrations of 0.00075% - 0.1%. When tested in the presence of E2, < 0.025% tea tree oil reduced the RPE by 10%. Terpinen-4-ol produced a slight (~6%), and α -terpineol produced a significant and dose-dependent, inhibition of MCF-7 cell proliferation induced by E2; 1,8-cineole and the 8:1:1 mixture of the constituents did not have a significant effect. With all trials, the highest concentrations of tea tree oil and the constituents were cytotoxic.	78
ethanol extract of a hair conditioner product that contained tea tree oil	estrogenic activity assay: 1/100 - 1/100,000 dilution of the test material (i.e., 0.005 – 5 x 10 ⁻⁶ g/ml) anti-estrogenic activity assay: 1/333 - 1/729,000 dilution of the test material (i.e., 0.0015 - 6.85 x 10 ⁻⁷ g/ml)	MCF-7:WS8 cells (> 90% of the receptors are ER- α , and < 10% are ER- β)	E-screen cell proliferation assay (robotic version) Cells were treated with E2 or the test extract (0.5 g product/ml ethanol) for 6 d, and solutions were changed every other day. The vehicle control was 1% ethanol in estrogen-free medium, and fulvestrant (an ER antagonist) served as the positive control. Estrogenic activity was considered detectable if it produced a cell proliferation > 15% of the relative maximum % of E2, and anti-estrogenic activity was considered detectable if it suppressed low (set at 4.0 x 10 ⁻¹² M) E2-stimulated cell proliferation by at least 3 standard deviations for at least one dilution of the extract.	The test material did not exhibit estrogenic activity, but it did exhibit anti-estrogenic activity. The normalized anti-estrogenic activity (as relative maximum % of the positive control) was 79%.	101

Table 15. Effect on endocrine activity

Test Article	Concentration/Dose	Test System	Procedure	Results	Reference
tea tree oil components (13.2% eucalyptol, 42.3% 4-terpineol, 1.3% dipentene/limonene, 7.1% α -terpineol, 11.4% α -terpinene, 24.7% γ -terpinene)	0.005 – 0.025% (v/v) in DMSO	human HepG2 hepatocellular cancer cells (ER α negative)	Luciferase reporter assay with ER α ; transfected cells were treated for 18 h; vehicle controls and E2 (1 nM) controls were also used	Activation observed at all concentrations of tea tree oil, with a maximum of an ~20-fold increase in ER α ERE-mediated promotor activity; E2 produced an ~50-fold increase Components produced up to a 10-fold increase in activation; 0.005% did not produce a significant effect	⁹⁹
tea tree oil	0.025% (v/v) in DMSO	HepG2 cells	Mammalian two-hybrid binding assay to determine binding activity to the ER α LBD by analyzing ligand dependency of hER α , LBD, and steroid receptor coactivator (SRC)-2- nuclear receptor (NR) element interactions; transfected cells were treated for 18 h; vehicle controls and E2 (1 nM) controls were also used	Significant induction of ER α ERE-mediated activity with 0.01% tea tree oil (and with E2) Tea tree oil recruited SRC-2-NR and demonstrated binding to the LBD of ER α .	⁹⁹
ANTI-ANDROGENIC ACTIVITY					
tea tree oil	0.001 – 0.01% (v/v) in DMSO	MDA-kb2 breast cancer cells (positive for the AR)	Evaluation of effect on androgenic activity. The cells were stably transfected with an androgen-inducible and glucocorticoid-inducible MMTV-luciferase reporter plasmid, and were treated for 24 h tea tree oil in the presence and absence of DHT; 3 experiments were performed, in quadruplicate. Flutamide served as a positive control for androgen-receptor antagonism.	Tea tree oil did not transactivate the MMTV-luciferase reporter plasmid at any concentration tested, while 0.1 nM DHT produced an ~4-fold increase in luciferase activity when compared to DMSO controls. Transactivation of the MMTV-luciferase reporter plasmid by 0.1 nM DHT was inhibited in a concentration-dependent manner by tea tree oil (as well as by flutamide); upon simultaneous treatment of the cells with DHT and tea tree oil, maximum inhibition occurred with 0.005% tea tree oil, corresponding to a decrease in luciferase activity of 4% in the presence of 0.1 nM DHT. Additional experiments indicated that the anti-androgenic properties of tea tree oil extended to inhibition of DHT-stimulated expression of the androgen-inducible endogenous genes cytochrome P450 family 4 subfamily F member 8 (<i>CYP4F8</i>), chromosome 1 open reading frame 116 (<i>C1orf116</i>), UDP glucuronosyltransferase family 2 member B28 (<i>UGT2B28</i>), and SEC14-like lipid binding 2 (<i>SEC14L2</i>). The researchers stated that because the amount of androgen-receptor mRNA or protein was not altered, the anti-androgenic effect of the oil is not caused by down-regulation of the expression of the AR.	¹⁰⁰
tea tree oil	0.01% (v/v) in DMSO	MDA-kb2 cells	Luciferase reporter assay with AR using MMTV; cells were co-treated with 1 nM testosterone and tea tree oil for 18 h; DMSO, 1 nM testosterone, and 1 nM testosterone + 1 μ M flutamide were used as controls	Increasing concentrations of tea tree oil, co-treated with testosterone, significantly inhibited AR MMTV-mediated activity at concentrations \geq 0.0005% (v/v); change in AR MMTV-mediated activity, as compared to testosterone, was 36%	⁹⁹
tea tree oil	0.025% (v/v) in DMSO	MDA-kb2 cells (AR-positive)	Determined AR-regulated gene expression using quantitative PCR; cells were co-treated with 1 nM testosterone and tea tree oil for 18 h; DMSO, 1 nM testosterone, and 1 nM testosterone + 1 μ M flutamide were used as controls; mRNA levels of AR target genes (<i>CTP4F8</i> , <i>UGT2B28</i> , and <i>SEC14L2</i>) were measured	Tea tree oil, co-treated with testosterone, significantly inhibited all 3 target genes	⁹⁹

Table 16. Dermal irritation and sensitization studies

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
IRRITATION					
ANIMAL					
Melaleuca Alternifolia (Tea Tree) Leaf Oil	undiluted; 0.5 ml	4 NZW rabbits	single 4-h semi-occlusive patch applied to clipped dorsal skin; the test site was evaluated at 1, 24, 48, and 72 h and 7 d after patch removal	irritant effects; average scores were 2.0 for erythema and 1.7 for edema	112
Melaleuca Alternifolia (Tea Tree) Leaf Oil	undiluted; 5.0 g/kg	10 rabbits	single 24-h occlusive patch on clipped intact and abraded abdominal skin (see acute dermal toxicity study)	irritant effects; skin abnormalities at necropsy (details not provided)	82,113
tea tree oil (conformed to ISO standards)	0.625, 1.25, 2.5, 5, and 10%; 50 µl	5 female Wistar rats	single 4-h application (type of patch not specified) applied to shaved skin; application was rinsed with distilled water; test site was evaluated 24 and 48 h after application	no irritation was observed with ≤ 2.5% 5% produced very slight erythema and edema at 24 and 48 h 10% produced well-define erythema and very slight edema at 24 and 48 h	27
tea tree oil	12.5, 25, 50, and 75% (vehicle not specified)	rabbits; number not provided	semi-occlusive patch test performed according to OECD 404 (acute dermal irritation/corrosion study)	applications of 12.5 and 25% were not irritating; 50% was minimally irritating; 75% was slightly irritating	6
tea tree oil	25% in paraffin oil	rabbits; number not provided	repeated applications for 30 d to shaved skin	initial minor irritations declined with time; microscopic skin changes were observed	6
tea tree oil	undiluted; 0.5 ml	3 female NZW rabbits	OECD TG 404; 4 h semi-occlusive application; 4 cm ² patch	after 60 min: mild; at 24 and 48 h: severe irritant at 72 h: a moderate irritant; 7 and 14 d: mild irritant reversible within 21 d	114
tea tree oil	undiluted; 0.5 ml	6 NZW rabbits	Draize study; test material was applied to intact and abraded skin for 72 h (type of patch not specified)	Draize irritation index = 5.0; severe irritant	6,7
HUMAN					
Melaleuca Alternifolia (Tea Tree) Leaf Oil	1% in pet	22 subjects	48-h occlusive patch (conducted as a pre-test for a maximization test)	no irritation	113,115
tea tree oil	0, 1, 2.5, 5, and 10% in a 0.05 ml sorbolene cream	28 subjects	occlusive patches applied to the back, 5x/wk for 3 wk, for a total of 15 applications; duration of dosing not stated	5 subjects reported slight irritation: 1 to 1%; 1 to 2.5%; 2 with 5%; 2 with 10% slight irritation was observed for 1 subject on 11 of the 15 d with 10% tea tree oil; for the others, irritation was reported only for 1 or 2 d	16
tea tree oil	25% in soft white paraffin (8 samples; contained 1.5-28.8% 1,8-cineole and 22.6-40.3% terpinen-4-ol)	28 initial subjects; 25 subjects completed the study	24-h occlusive patches were applied to the upper arm or back, 5x/wk for 3 wk - 1,8-cineole (3.8-21%) was tested for comparison	no irritation to the oil or 1,8-cineole was observed - an allergic, but not irritant response (erythema with marked edema and itching), was observed in 3 subjects to all 8 samples: 1 subject had a +3 response at day 3; 1 had a +3 reaction to on day 8; and 1 subject had a +2 reaction on day 14. These subjects were withdrawn from the trial and tested for sensitization (described under 'Sensitization')	116-118
tea tree oil	undiluted; 10 samples	219 subjects	48-h occlusive application	prevalence of marked irritancy was 2.4-4.3% prevalence of any irritancy (mild to marked) was 7.2-10.1%	6,12

Table 16. Dermal irritation and sensitization studies

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
SENSITIZATION					
ANIMAL					
tea tree oil (purity, ISO Standard 4730-2004; GLP-compliant)	0, 5, 25, and 50% in PEG 400	female CBA mice, 5/group	LLNA Ear thickness was measured prior to application on day 1, after 48 h and prior to 3 rd (and last) application on day 3, and on day 6; mice were injected with 5-bromo-2'-deoxy-uridine 5 d after initial application, and lymph nodes were isolated at necropsy B:T cell ratio was measured in lymph node preparations by immunotyping 25% α -hexylcinnamaldehyde was used as the positive control	estimated concentration of a substance expected to produce a stimulation index of 3 (EC3) value of 8.3% (categorized as weak ⁷ or moderate ⁶ sensitization potential) Sensitizing response at 25 and 50% (stimulation index (SI) of 2.1, 7.7, and 7.9 at 5, 25, and 50%, respectively); the sensitizing effect was supported by immunotyping (B cells and B:T cell ratio increased by >25% compared to controls ³) No dermal irritating response (as determined by change in ear thickness)	3,6,7
tea tree oil (purity, ISO Standard 4730-2004; GLP-compliant)	0, 2, 20, and 100% in PEG 300	female CBA mice, 5/group	LLNA; no positive control	EC3 value of 4.4% (moderate skin sensitizer) SI were 2.4, 6.9, and 16 at 2, 20, and 100%, respectively	6,7
tea tree oil (non-oxidized, undegraded; purity, ISO Standard 4730; GLP-compliant)	0, 2, 20, and 100% in PEG 300	female CBA mice, 5/group	LLNA; no positive control	EC3 value of 24.3% (moderate sensitization potential) SI were 1.8, 2.8, and 6.5 at 2, 20, and 100%, respectively	6,7
tea tree oil (non-oxidized, undegraded; purity, ISO Standard 4730; GLP-compliant)	0, 2, 20, and 100% in PEG 300	female CBA mice, 5/group	LLNA; no positive control	EC3 value of 25.5% classified as weak ⁷ or moderate ⁶ sensitization potential) SI were 1.6, 2.8, and 5.7 at 2, 20, and 100%, respectively (a comment was made that PEG is not a recommended vehicle for the LLNA ⁹)	6,7
tea tree oil	<u>induction</u> , intradermal: 5% in paraffin oil B.P. and 1:1:1 mixture of the oil, saline, and Freund's complete adjuvant (FCA); <u>epidermal</u> : 100% <u>challenge</u> : 30% in pet	albino guinea pigs, 20/group	guinea pig maximization test; induction consisted of 2 intradermal injections, followed 1 wk later by a 48-h occlusive patch; the challenge was conducted 2 wk later with a 24-h occlusive patch	not sensitizing	3,7
tea tree oil	<u>induction</u> : not stated <u>challenge</u> : 10% and 30%	10 Pirbright white guinea pigs	Adjuvant maximization protocol (FCA method; details not provided) reacting animals were cross-challenged with terpinen-4-ol	<u>10% challenge</u> : no reactions <u>30% challenge</u> : positive reactions in 3/10 animals at 48 h no response to cross-challenge with terpinen-4-ol	3,120
tea tree oil (freshly distilled)	"pure" 30 mg for induction 0.05 ml for challenge	10 female Pirbright white guinea pig	modified FDA technique; the material was dissolved in 4 ml FDA, and emulsified with 4 ml physiological saline (30 mg); challenge was performed 11 d after induction, with an open epicutaneous application of pure test material; test site scores were recorded at 24 and 48 h, according to the International Contact Dermatitis Research Group (ICDRG)	mean response: 0.4 (24 h); 0.5 (48 h) low sensitizing capacity	119
oxidized tea tree oil (exposed to light, warmth, moisture, and oxygen)	"pure"	10 guinea pigs 10 guinea pigs 10 guinea pigs	challenge material; oxidized tea tree oil challenge material: oil stored for 2 mo in a transparent flask challenge material: oil stored for 2 mo in a brown flask challenge material: oil stored for 2 mo in a closed flask challenge material: oil stored for 2 mo in an open flask challenge material: monoterpene fraction	mean response: 0.45 (24 h); 1.78 (48 h) mean response: 0.8 (24 h); 1.0 (48 h) mean response: 0.55 (24 h); 1.1 (48 h) mean response: 0.62 (24 h); 0.65 (48 h) mean response: 1.0 (24 h); 1.58 (48 h) mean response: 0.85 (24 h); 0.9 (48 h)	

Table 16. Dermal irritation and sensitization studies

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
		10 guinea pigs	challenge material: sesquiterpene fraction challenge material: thujene/pinene-free fraction challenge materials (in acetone) – at 5%: <i>p</i> -cymene; 1,8-cineole; myrcene; sabinene; α -terpinene at 10%: viridiflorene; aromadendrene; α -terpinene; ascaridole; terpinen-4-ol; α -pinene; β -pinene; α -terpineol; terpinolene	mean response: 0.2 (24 h); 0.18 (48 h) mean response: 1.3 (24 h); 1.7 (48 h) mean response with <i>p</i> -cymene: 1.25 (24 h); 1.13 (48 h) for all others mean response varied from 0.0 – 0.3 (24 h) to 0.0 0 0.53 (48 h)	
HUMAN					
formulation containing 0.001% Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Extract	neat; 0.05 ml	25 subjects	Maximization test 5 induction exposures to either the upper outer arm, volar forearm, or back of each subject consisted of pretreatment with an occlusive patch (15 mm disc of Webril cotton) containing 0.05 ml 0.25% aq. sodium lauryl sulfate (SLS) for 24 h, followed by application of an occlusive patch containing 0.05 ml of the test material (to the same site) for 24 or 72 h. Because the test formulation contained volatile ingredients, it was allowed to air-dry for ~30 min prior to application. After a 10-d non-treatment period, challenge was performed at a previously untreated site by first applying an occlusive patch containing 0.05 ml 5.0% aq. SLS for 1 h, followed by a 48-h occlusive patch containing the test material.	not a sensitizer no reactions were observed 48 or 72 h after application of the challenge patch	121
bubbling face mask containing 0.0078% Melaleuca Alternifolia (Tea Tree) Leaf Extract	neat	105 subjects	modified Draize HRIPT during induction, a total of nine 47- or 71-h occlusive patches were applied 3x/wk for 3 wk; after a 14-d non-treatment period, a 48-h challenge application was made, and challenge sites were scored 1 and 48	low potential for irritation and sensitization faint, mild erythematous reactions were observed during induction; no reactions were observed upon challenge	122
Melaleuca Alternifolia (Tea Tree) Leaf Oil	1% in pet	22 subjects	Kligman maximization test occlusive patch applied to the volar forearm for 5 alternate-day 48-h periods; patch site was pretreated for 24 h with 5% aq. SLS; for challenge, after a 10 – 14-d non-treatment period, an occlusive patch was applied to a previously untreated site; 5% SLS was applied to the test site for 30 min under occlusion on the left side of the back, and the test materials were applied without SLS treatment on the right side	not a sensitizer	113,115
Melaleuca Alternifolia (Tea Tree) Leaf Oil	10% in caprylic/capric triglycerides; 200 μ L, volatilized for 30 min	102 subjects	modified HRIPT 24-h semi-occlusive induction patches (2 cm ² absorbent pad) were applied 3x/wk for 3 wk; after a 10-d non-treatment period, 24-h challenge applications were made to the test site and a previously untreated site induction sites were scored 24- or 48-h after application, challenge sites were scored upon patch removal and at 24 h	not an irritant or sensitizer	123

Table 16. Dermal irritation and sensitization studies

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
tea tree oil (conformed to ISO standards; peroxide content was 9.5 mEq O ₂ /kg)	5% in a cream base; 25% in a cream, ointment, and gel base; 100% negative control; cream base	309 subjects	Draize sensitization study <u>induction:</u> 48-h occlusive applications were made with Finn chambers (11 mm) containing 100 µl of the liquid formulation or 100 µg of the solid-phase preparation to the upper arm or the back, 3x/wk for 3 wk <u>challenge:</u> after a 2-wk non-treatment period, a 48-h patch was applied to a previously untreated site	Scoring for irritation was based on 306 subjects because 3 subjects were not included because they developed grade 3 vesicular reactions during induction); allergenicity was evaluated with all 309 subjects During induction; the maximum mean irritancy score was 0.2505/4, with undiluted tea tree oil Of the 3 subjects that developed grade 3 vesicular reactions, only one subject (day 8 reaction) returned for challenge, in which a positive grade 3 reaction was confirmed; because different samples were tested simultaneously, it was not possible to determine which specific concentration was responsible for inducing sensitization at challenge; no other subjects had reactions at challenge	124
tea tree oil	“varying concentrations” (not specified)	3 sensitized subjects (from the irritation study described above)	tested 2 wk after initial study	all 3 had positive results at 3 and 7 d	116-118
major component of tea tree oil	25% in soft white paraffin; similar dilutions as above		major components of tea tree oil were also patch-tested (24 - 48 h)	one subject had an allergic response to α-terpinene (tested at 5.9% in soft white paraffin) none of the subjects reacted to α-pinene, β-pinene, limonene, p-cymene, 1.8-cineole, γ-terpinene, terpinolene, terpinen-4-ol, or α-terpineol all 3 sensitized subjects reacted positively to the sesquiterpenoid fractions and sesquiterpene hydrocarbons; 1 subject reacted to the 0.03% sesquiterpene alcohol sample	
crude sesquiterpenoid fractions; sesquiterpene hydrocarbon concentrate; sesquiterpene alcohol concentrate	crude fraction - 10.7%; sesquiterpene hydrocarbon fraction – 1.5%; 98% sesquiterpene alcohol –tested at 0.03% 5.3% sesquiterpene alcohol –tested at 1.4% vehicle – soft white paraffin				

Table 17. Retrospective, multicenter, and cross-sectional patch test studies with tea tree oil

Years/Testing Group	Concentration/Vehicle	# patients	# Positive (%)	Relevance	Comments	Reference
NORTH AMERICA						
2000 – 2007; Mayo Clinic *	oxidized, 5% pet**	869	18 (2.1%)	not stated	macular erythema – 3 (0.3%); weak reaction – 9 (1%); strong reaction – 5 (0.6%); extreme reaction – 1 (0.1%)	128
2003 - 2004; NACDG	oxidized, 5% pet	5137	45 (0.9%)	not stated		126
2003 - 2006; NACDG***	oxidized, 5% pet	9569	all rxn:101 (1.0%) “+ “only: 55 (0.6%)	not stated	positivity ratio (percent of weak (+) reactions among the sum of all positive reactions) – 54.5% reaction index (number of positive reactions minus questionable and irritant reactions/sum of all 3) – 0.73 85 allergic reactions (not irritant; not questionable) 117 allergic reactions (with irritant; with questionable)	134
2003 - 2007; NACDG	oxidized, 5% pet	11,649 (ages 19 – 64)	35 (0.3%)	22 (0.2%)		141

Table 17. Retrospective, multicenter, and cross-sectional patch test studies with tea tree oil

Years/Testing Group	Concentration/Vehicle	# patients	# Positive (%)	Relevance	Comments	Reference
2005 - 2006; NACDG	oxidized, 5% pet	4435	1.4%	definite - 8.2% probable - 27.9% possible - 36.1%		129
2007 - 2008; NACDG	oxidized, 5% pet**	5078	1.4%	definite – 5.7% probable – 31.4% possible – 40.0% past – 5.7%	Significance-Prevalence Index Number (SPIN) - 55	130
2009 - 2010; NACDG	oxidized, 5% pet	4299	1.0%	definite - 14.3% probable - 35.7% possible - 21.4%	SPIN – 45 (rank 36)	131
2011 - 2012; NACDG	oxidized, 5% pet (Melaleuca Alternifolia (Tea Tree) Leaf Oil)	4231	36 (0.9%)	definite - 11.1% probable - 41.7% possible - 22.2%	reaction severity: 17 +++; 8 ++; 10 +; 1 +/- SPIN – 41 (rank 41)	132
2015 - 2016, NACDG	oxidized, 5% pet (tea tree leaf oil)	5593	66 (1.2%)	definite – 7 (10.6%) probable – 20 (30.3%) possible – 19 (28.8%) past – 8 (12.1%)	SPIN – 47 (rank 36)	133
2003; NACDG	oxidized (5% pet)**	1603	5 (0.3%)	definite - 0% probable – 1 (20%) possible – 3 (60%) unknown – 1 (20%)	only 1/5 patients that reacted to tea tree oil also reacted to the fragrance makers fragrance mix and <i>Myroxilon pereirae</i> in the test population, younger patients were more likely to be allergic to tea tree oil	135
2009 – 2014; NACDG	oxidized, 5% pet	13,398	123 (0.92%)	not stated	63 of the patients that reacted to oxidized tea tree oil did not react to any of the fragrance mixes that were tested; half of the reactions to tea tree oil were strong (13 ++ and 19 +++ reactions), and of definite (8; 12.7%) or probable (25, 39.7%) clinical relevance	136
2014 - 2017; Northwestern Medicine patch-testing clinic; 48-h patch	oxidized, 5% pet (Melaleuca Alternifolia (Tea Tree) Leaf Oil)	502 (total) <i>current AD?</i> : yes, 108; no, 394 <i>past AD?</i> : yes, 109; no, 209	current AD:0 no current AD: 1 (0.2%) past AD: 0 (both groups)	not stated		137
CROSS-SECTIONAL STUDIES						
formulation type-specific						
2001 - 2004; NACDG	5% (oxidized) associated with a moisturizer	835 529 female/ 306 male with moisturizer- associated positive reactions	1.2% 1.5% (F) 0.7% (M)	not stated	test group comprised a subgroup of patients with moisturizer-associated positive reactions from a parent group of patients (n = 2193; 1582 females and 611 males) with allergic reactions to cosmetics; the percent of male patients with a positive allergic reaction to moisturizers (50.1%) was greater than female patients (33.4%)	138

Table 17. Retrospective, multicenter, and cross-sectional patch test studies with tea tree oil

Years/Testing Group	Concentration/Vehicle	# patients	# Positive (%)	Relevance	Comments	Reference
<i>site-specific</i>						
2003 - 2004; NACDG	oxidized, 5% pet*	1959 hand dermatitis patients	4 (0.2%)	3 (75%)	test group was a subgroup of patients with hand-only reactions and final diagnosis code that included atopic contact dermatitis (ACD); parent group n = 5148	139
		959 hand dermatitis patients	4 (0.4%)	2 (50%)	test group was a subgroup of patients with hand-only reactions and final diagnosis code was only ACD; parent group n = 5148	
2001 - 2004; NACDG	oxidized, 5% pet	60 lip ACC patients	3 (5%)	not stated	of 10,061 patients, 196 had a skin condition limited to the lips that was ACC; the test group consisted of subjects from the "lip" group that had at least one clinically relevant reaction to an NACGD series allergen	140
<i>age specific - children</i>						
2003 - 2007; NACDG***	oxidized, 5% pet	1007 ≤18 yr	4 (0.4%)	4 (0.4%)		141
2003 - 2004, NACDG***	oxidized, 5% pet	age 0 - 5 y (n not specified)	14.3%	14.3%		142
		age 0 - 18 yr (n not specified)	1.1%	1.1%		
2005 - 2012, NACDG	oxidized, 5% pet	n = 40, age 0 - 5 yr	0%	0%		143
		n = 836, age 6 - 18 yr	0.8%	0.4%		
		n = 876, age 0 - 18 yr	0.8%	0.3%		
<i>age-specific - older individuals</i>						
2003 - 2007; NACDG***	oxidized, 5% pet	2409 ≥65 yr old	8 (0.3%)	6 (0.3%)		141
EUROPE						
2001, Sept - 2002, Jan; Denmark	5% in a commercial lotion; 10% in pet also tested with the European standard series	217	5% lotion: 1.4% weak positive; 20.3% weak irritant reactions 10% pet: 0.5% (++ reaction)		Finn chambers were applied to the upper back for 2 d; the test sites were scored on day 3 using ICDRG criteria 3 subjects had weakly positive reactions to the lotion (categorized as non-relevant) 44 subjects had weak irritant reactions to the lotion 1 subject had a "++" reaction to the test substance in pet and the lotion (this subject had previously experienced dermatitis following application of a cosmetic product that contained tea tree oil)	144
2003, June - Aug; Denmark	5% (4 lotions) also tested with the European standard series	160	3.1% had irritant reactions 0 allergic reactions		Finn chambers were applied to the upper back for 2 d; the test sites were scored on day 3 using ICDRG criteria no allergic reactions to the lotions were reported 5 subjects (3.1%) had irritant reactions: 1 subject reacted to all 4 lotions and all substances in the European standard series; 3 had weak irritant reactions to 3 of the lotions; 1 subject had a weak irritant reaction to all 4 lotions	144
pre-2004 (yr not stated; 15 mo study) Sweden (4 clinics)	5% in alcohol	1075	2.7% 3.0 (F)/1.9 (M) 3.1% irritant/doubtful	not stated	509/1075 have/had adverse reactions to cosmetics or skin care products	145

Table 17. Retrospective, multicenter, and cross-sectional patch test studies with tea tree oil

Years/Testing Group	Concentration/Vehicle	# patients	# Positive (%)	Relevance	Comments	Reference
1999-2000; Germany and Austria (11 labs); German Contact Dermatitis Research Group (DKG)	standardized, 5% in diethyl phthalate	3375	36 (1.1%)	56%	readings were taken on days 2 and 3 positive patch test reactions ranged from 0 to 2.3% among the centers 36 patients (1.1%) with reactions; 14 of these patients also had a positive response to oil of turpentine regional differences in frequencies were noted	4,6,146
1998-2003; Germany	oxidized, 5% (contained 16 identified allergens)	6896	70 (1.0%)		38 of the patients with positive results were tested with the 16 single allergens; reactions were observed with the following: terpinolene (23); ascaridole (21); α -terpinene (18); 1,2,4-trihydroxymethane (14); α -phellandrene (10); (+)-limonene (5); myrcene (4); viridiflorene (S) (3); aromadendrene (S) (1) No reactions were observed with (+) or (-)-carvone; sabinene; terpinen-4-ol; <i>p</i> -cymene; 1,8-cineole, or α -pinene	147
1999 – 2003, Germany	oxidized, 5% (contained 16 identified allergens)	2284	21 (0.9%)		20 of the patients with positive results were tested with the 16 single allergens; reactions were observed with the following: terpinolene (17); ascaridole (15); α -terpinene (16); 1,2,4-trihydroxymethane (13); α -phellandrene (7); (+)-limonene (11); myrcene (7); viridiflorene (S) (1); aromadendrene (S) (1); (+)-carvone (4); (-)-carvone (4); sabinene (2); terpinen-4-ol (1) No reactions were observed with <i>p</i> -cymene; 1,8-cineole, or α -pinene	147
2012, Feb – 2013, Mar; Netherlands	5% oxidized tea tree oil	221	2 (0.9%; +)		no irritant reactions reported	148
2012, Nov – 2013, Feb	1, 2, and 5% ascaridole and 5% oxidized tea tree oil	additional 29 re-patch patients from a different ascaridole study (250 total)			co-sensitization was evaluated: in 30 patients that had positive reactions to any concentration of ascaridole, 6 tested positive to tea tree oil in 220 patients that did not react to any concentration of ascaridole, none reacted to tea tree oil	
1990-2016; Belgium	oxidized, 1 and 5%, pet	105, from a total of 15,980 patients tested (125 had tested positive to a botanical)	11(10.5%)		Retrospective analysis of patients who had attended a patch test clinic (tertiary referral center) because of contact dermatitis, and were identified as being allergic to herbal medicines and/or botanical ingredients Patch tests were applied to the back, and readings were performed according to European Society of Contact Dermatitis guidelines	149
2000-2009; Belgium	not stated	301 reactions to a fragrance mix	1/88 (1.1%) reactions to skin care products	not stated	study of “presence confirmed” fragrance allergens in cosmetic products to which patients reacted positively a reaction was only observed in a skin care product, and not the other 14 cosmetic product categories, containing tea tree oil	150
2000-2010; Belgium	not stated	621 reactions to non-fragrance allergens	5/212 (2.4%) reactions to skin care products	not stated	study of non-fragrance allergens in cosmetic products to which patients reacted positively reactions were only observed in skin care products, and not the other 10 cosmetic product categories, containing tea tree oil	151
2011-2012; Italy (multicenter)	5% pet	19 patients that had positive reactions to botanicals	2 (10.5%)	100%	original test group consisted of 1274 patients that used botanicals; 139 had cutaneous reactions; 122/139 were patch tested with the botanical integrative series; 19 had positive reactions, 2 of which were to tea tree oil	152
1997; Swiss clinic	5, 10, 50, and 100% in arachis oil	1216	7 (0.6%)	not stated	14 eczema patients tested used products that contained tea tree oil; the elicitation concentrations were not given the study authors stated that allergic potential to low concentrations is presumed to be low on healthy skin; photoaged tea tree oil is the stronger sensitizer	6,153
pre-2015 (5 yrs ; years not specified); Spain	5% pet	not stated	5 (0.4%)	100%	strong reactions were observed in all patients 3/5 also reacted to limonene	154

Table 17. Retrospective, multicenter, and cross-sectional patch test studies with tea tree oil

Years/Testing Group	Concentration/Vehicle	# patients	# Positive (%)	Relevance	Comments	Reference
1996-1997, UK	neat	29 patients thought to have a cosmetic dermatitis; plant series had been applied	7 (24.1%)	not stated	Patch tests were performed with a standard and plant series as well as the patient's own cosmetic products; in addition, where there was a strong suspicion of fragrance allergy, patients were also tested to an extended fragrance series Site of contact dermatitis was variable, but was primarily involved face, neck, or fingertips; 23 (79%) of the patients had a positive reaction to fragrance mix Reactions were mainly seen in people who had been using tea tree oil, and who gave a history of worsening dermatitis on use of the product; 5 of the 7 patients recalled use of products containing tea tree oil; one additional patient may have been exposed via aromatherapy; reactions were not thought to be irritant The researchers stated that although no controls were formally tested, the same concentration of tea-tree oil was tested routinely in their plant series, and over the same 2-yr period, 9/165 patients tested positively to the oil, including those reported in this study 23/29 patients had a positive reaction to the fragrance mix included in the standard series; 17 patients had a positive reaction to at least 1 component of the plant series	155
2001, UK	neat, oxidized	550	13 (2.4%)	definite: 4 (30%) possibly: 5 (38.5%)	irritant reactions – 38%	4
2008-2014, UK	5% pet	2104	+ / + / + / + / + : 11 (0.5%) ? + : 2 (0.1%) irritant: 3 (0.1%)	not stated	Patients were also tested with a fragrance series; the researchers noted that 4 of the subjects with a positive reaction to tea tree oil did not react to any of the fragrance series ingredients, oxidized linalool, or oxidized limonene	156
2016, UK	5% pet	1019	0.29%	0.29%		157
2016-2017, UK/Ireland	oxidized, 5% pet	4224	0.45%			127
AUSTRALIA						
not stated	10%	219	2.9% - 4.8%	not stated	prevalence increased to 4.6-7.7% using only patients with prior tea tree oil exposure	158
1999	not stated	477	12 (2.5%)	not stated		4
2000-2004; Skin and Cancer Foundation	oxidized, 5% pet; oxidized, 10% in white soft paraffin	2320	41 (1.8%)	41%	17 of 41 patients with positive reactions recalled prior use of tea tree oil; 8 specified prior application of neat tea tree oil	158
2001-2010; Skin and Cancer Foundation	oxidized, 5% pet** 10% pet	794 5087	28 (3.5%) 129 (2.5%)	43% 33%		159

*NACDG procedures (48-h occlusive patches using Finn chambers o Scanpor tape) were followed

** patches obtained from Chemotechnique Diagnostics, which are supplied as oxidized tea tree oil, 5% pet

*** total testing period was 1994 – 2006; however, tea tree oil (pet, oxidized) was added to the NACDG test tray in 2003¹²⁶

Table 18. Cross-reactivity with tea tree oil

Test Substance	Years/Location (if known)	positive reactions /# subjects	Cross Reactivity	Comments (if applicable)	Reference
5, 10, 50, and 100% tea tree oil in arachis oil	1997; Swiss clinic	7/1216 (described previously)	2 of the 7 patients also exhibited a type IV hypersensitivity towards fragrance mix or colophony	study authors stated there was a possibility of an allergic group reaction caused by contamination of the colophony with the volatile fractions of turpentine	6,153
5% tea tree oil in diethyl phthalate	1999-2000; Germany and Austria (11 labs)	36/3375 (described previously)	14/36 patients (38.9%) also had positive patch test reactions to oil of turpentine		146
5% tea tree oil in alcohol	pre-2004 (15 mo study); Sweden	2.7% (1075 subjects) (described previously)	no correlation was reported between positive reactions to tea tree oil and colophony		145
Other Compounds as the Test Substance					
compound tincture of benzoin	1999; Melbourne, Australia	45/477 patients with reaction to the tincture (there were 14 strong and 25 weak positive reactions on days 2 and 4, and 6 weak reactions on day 4 only))	9/45 patients (20%) also had positive reactions to tea tree oil 5/14 patients with strong (++) reactions to the tincture had ++ or +++ reactions to tea tree oil	patch testing with compound tincture of benzoin was occlusive	161
Cross-Reactions Described in Case Reports (see Table 19 for case report details)					
tea tree oil, undiluted		patient with atopic dermatitis	positive reactions to the tea tree oil and eucalyptol (+/+++)		49
tea tree oil, undiluted		patient had a 1-wk history of dermatitis on the forehead and around the mouth	an erythematopapular reaction (++) was reported at the application site of 20% colophony in pet		162
tea tree oil		patient with pruritic erythematous rash	positive reactions to tea tree oil and colophony		163
5% oxidized tea tree oil, pet 1, 2, and 5% ascaridole, pet		patient with periorbital dermatitis	“?” reaction to oxidized tea tree oil (days 3 and 7) + reactions to 1 and 2% ascaridole; irritant reaction to 5% ascaridole (days 3 and 7)	patient had used an herbal remedy containing tea tree oil to treat dermatitis, and a soap that contained tea tree oil	164
5% oxidized tea tree oil, pet 1, 2, and 5% ascaridole, pet		patient with periorbital dermatitis and folliculitis barbae	+ reaction to oxidized tea tree oil (days 3 and 7) + reactions to 1, 2, and 5% ascaridole (days 3 and 7)	patient had used a shaving cream that contained tea tree oil	164

Table 19. Case reports with tea tree oil

Test Substance	Subject(s)/Symptoms	Testing	Results/Comments	Reference
DERMAL EXPOSURE				
<i>used in treatment of dermatitis and/or psoriasis</i>				
tea tree oil, undiluted	a patient with long-standing atopic dermatitis was treated with undiluted tea tree oil; the dermatitis initially improved, but then worsened; the patient was then advised to ingest oil mixed with honey	patch testing was first performed with the European standard series, additional series (not described), and the patient's own products; additional testing was then performed with the main components of the oil all at 5% pet, except linalool was tested at 10% pet)	Initial patch testing produced positive reactions (++/++) to tea tree oil only Subsequent testing resulted in positive reactions to the oil and eucalyptol (+/+++) 20 controls had negative results	49
tea tree oil	subject treated atopic eczema with tea tree oil		became sensitized within 3 mo; also reacted to fragrances, turpentine, and several Compositae plants.	119
melaleuca oil (tea tree oil), undiluted	7 patients in a 3-yr period with eczematous dermatitis consisting of ill-defined plaques of erythema, edema, and scaling after application to compromised skin; vesiculation was present in 3 patients	48-h applications (Finn chambers) were made to the upper back with a standard battery of 20 allergens, and a 1% (v/v) solution of melaleuca oil, 1, 5, or 10% (v/v) solution of 11 primary constituents of <i>Melaleuca alternifolia</i> , and 5% d-carvone in anhydrous ethanol (except myrcene was dissolved in olive oil); patches with ethanol and olive oil and a blank chamber were used as controls 20 control patients with unrelated dermatoses were patch tested with 1% melaleuca oil 10 control patients were patched with 1% of the 11 constituents and 5% d-carvone and 7 control patients were patched with 5 or 10% of the constituent compounds	- All patients reacted to 1% melaleuca oil (1 had a score of +2, 5 with a score of +3, 1 with a score of +4) - All patients reacted to 1% of: d-limonene (6 patients), α-terpinene (5 patients), and aromadendrene (5 patients) - 1% terpinen-4-ol, p-cymene, and α-phellandrene each caused a reaction in 1 patient - 1 subject had a reaction during testing with the routine battery controls: both groups had negative results to the test articles at 1%; most of the 7 controls reacted to 5 or 10% d-limonene, α-terpinene, aromadendrene, α-phellandrene, α-pinene, and aromadendrene	120
tea tree oil, 5% (pet, or own product)	5 patients presented with strong, relevant, reactions (on the eyelids, hands, arms, feet, or legs) after using tea tree oil to treat what was presumed to be dermatitis		All 5 subjects reacted (++ or +++) to tea tree oil; this corresponds to 0.4% of all patients studied over a 5-yr period 3 of the patients also reacted to oxidized d-limonene	154
tea tree oil	the patient presented with periorbital dermatitis; she had used an herbal remedy containing tea tree oil to treat dermatitis, and a soap that contained the oil	patch testing was performed with the local extended European baseline series and a cosmetic series; oxidized tea tree oil, 5% in pet was also tested	the patient did not react to the standard series a "???" reaction was observed on d 3 and 7 with oxidized tea tree oil	164
tea tree oil, undiluted	a patient with history of psoriasis applied the oil to psoriatic lesions on the leg and reported immediate, intense erythema of the legs, throat constriction, changes in phonation, pruritus, flushing and light-headedness. The subject had used tea tree oil shampoos, but had never applied oil to the lesions before.	Skin-prick and intradermal tests were conducted with 0.01, 0.1, and 1% dilutions in phenol saline solution. An enzyme-linked immunosorbent assay for specific immunoglobulin (Ig) G and IgE against tea tree oil was performed. Five control subjects were also tested.	The patient did not react to the skin prick testing, and did not react to the low or mid-dose with intradermal testing, but there was a positive wheal and flare reaction within 20 min with 1% tea tree oil. No specific IgG or IgE was detected. Control results - negative	165
tea tree oil	used to treat psoriasis vulgaris		subject became sensitized within 3 mo; also reacted to fragrance mix, balsam of Peru, and turpentine	119
tea tree oil, 5% pet	five patients had occupational contact dermatitis caused by limonene	these patients were patch-tested with tea tree oil	2 of the patients had a strong reaction (++) and 2 had a very strong reaction (+++) to tea tree oil, results were negative in the fifth subject	166
<i>other direct skin or nail applications</i>				
wart paint containing tea tree oil (concentration not stated)	the patient had a 4-mo history of blistering dermatitis over the right temple that occurred 24 h after treatment of 2 seborrheic warts with a wart paint that contained tea tree oil	patch testing was performed using Finn chambers with the European standard series, 1% aqueous (aq). tea tree oil, and other compounds	at d 3, a papulovesicular reaction (+++) was observed at the site of an open patch to the tea tree oil and an erythematopapular reaction (++) to 1% tea tree oil reported 50 controls were negative with 1 and 5%	167
tea tree oil	patient treated warts on his hands		became sensitized in 3 mo	119

Table 19. Case reports with tea tree oil

Test Substance	Subject(s)/Symptoms	Testing	Results/Comments	Reference
pure tea tree oil	patient developed an acute erythematoidematous perioral reaction 9 d after topical use of to treat angular cheilitis	patient was patch-tested with the Italian standard SIDAPA (Italian Society of Allergological, Occupational and Environmental Dermatology), an integrative cheilitis series, a 5% patch of oxidized tea tree oil, and the diluted used product (50% pet), on Van der Bend chambers. Patch tests were applied under occlusion on the back for 2 d; readings were performed on d 2 and d 4.	The patient showed positive reactions to the test product (50% pet; ++ on d 2 and d 4) and to the patch with 5% oxidized tea tree oil (+d 2/++d 4), as well as nickel (++ d 2 and d 4)	¹⁶⁸
tea tree oil	the patient had a 9-yr history of large, painful, red lesions occurring on the face and neck; she had been using the oil for several skin conditions, including acne and tinea pedis	patient was instructed to discontinue using the oil on her face; a usage test was conducted with application of a small amount of the oil to the back of her neck 2x/d for 2 d	a large, ill-defined, erythematous eruption with severe pain and pruritus occurred at the site of the usage test patient was instructed to discontinue using products with the oil; incidental use of a tea-tree oil toothpaste cause lesions in the mouth; otherwise, no lesions were observed	¹⁶⁹
tea tree oil, undiluted	the patient had a 1-wk history of dermatitis on the forehead and around the mouth; she had used the oil for years without any similar reactions; the symptoms worsened with topical treatment with corticosteroids and erythromycin	patch testing was performed with the European standard series and the oil using Finn chambers	at d 3, a papulovesicular reaction (+++) was observed with the tea tree oil, and an erythematopapular reaction (++) was reported at the application site of 20% colophony in pet	¹⁶²
tea tree oil	6-wk history of papulo-vesicular eruption affecting the left forearm; condition had worsened with application of tea tree oil	patch testing was performed with the oil	strongly positive reaction after 48 h of patch testing The condition cleared with discontinuation of oil and application of topical corticosteroids	¹⁷⁰
tea tree oil, 5%	bullous eruption resulting from allergic contact dermatitis caused by application of Burnshield®, a tea tree oil-containing hydrogel, and a Burnshield® dressing	occlusive 48-h patch testing was conducted on the upper back using the British Contact Dermatitis Society baseline series, a cosmetic/facial series, a fragrances/essential oils series, and the patient's own products, including the Burnshield® products	Positive reactions to tea tree oil were recorded on d 2 (+) and d 4 (++) . Positive reactions (+++) also were observed at both time periods with both Burnshield® products. (Positive results were also reported with a number of other test substances.)	¹⁷¹
tea tree oil, 5%	applied to treat chronic, recurrent tinea versicolor	testing was not done; the patient was instructed to apply hydrocortisone	patient suddenly developed a pruritic confluent erythematous rash on the anterior neck and upper back; the rash completely resolved within 1 wk of discontinuing application of the oil	¹⁷²
tea tree oil	plaster applied to breast skin after an operation, and treated with tea tree oil; the oil was also applied due to insect bites		irritant reaction to tea tree oil; also reacted to turpentine	¹¹⁹
tea tree oil (concentration not stated; assumed undiluted)	The patient applied the oil to the umbilicus area following piercing, and after 2 wk of exposure developed a pruritic erythematous rash over the umbilical region, which gradually spread, with the development of blisters; the patient was prescribed erythromycin and was advised to continue applying the oil, which resulted in an increase in the size and number of the blisters and a separate vesicular eruption on the left flank at the site of contact with medical tape	patch testing was performed with the European standard series, tea tree oil, and "Ster-Zac" powder, which she also used a histological exam was also performed	patch testing reported positive reactions to tea tree oil and colophony The histological examination showed subepidermal blistering with edematous dermal papillae containing numerous neutrophils; direct immunofluorescence showed a bright linear band of IgA at the basement membrane zone in peri-lesional skin; these results were reported to be characteristic of linear IgA disease	¹⁶⁵
tea tree oil	used to treat sunburn		no reactions at site of application, but reacted to tea tree oil at patch testing	¹¹⁹

Table 19. Case reports with tea tree oil

Test Substance	Subject(s)/Symptoms	Testing	Results/Comments	Reference
tea tree oil	10-yr old male with irritating eruption on the left knee and an itch on the sole of the right foot; the oil had been applied 3x/d. Upon examination, the patient had an acute vesiculo-bullous eruption affecting the lower thigh and upper lower leg in the region of the left knee, and a bulla was also present on the sole of the right foot near the metatarso-phalangeal joint	Patch testing was performed with the oil	A bullous reaction appeared after 24 h, necessitating removal of the patch. The lesions cleared with application of cold compresses and topical corticosteroids.	170
tea tree oil (and other herbal extracts)	patient solely used herbal extracts for hygiene and cosmetic purposes, including at least 500 ml of tea tree oil		became sensitized and had to be admitted to the hospital for treatment of skin lesions reacted to colophony, Compositae plants, fragrances, turpentine, and 10 different plant oils	119
tea tree oil	The patient presented with a severe and widely scattered dermatitis of 1 wk duration; the left shin displayed an 8 x 20 cm, scarlet, annular plaque with a purpuric margin; numerous other erythematous papules and plaques, ranging in size from 0.5 - 3 cm, were scattered on the trunk and the extensor aspect of the extremities; no involvement of the palms, soles, or mucous membranes. 3 wk prior, the patient treated a superficial abrasion of the left shin with tea tree oil under an occlusive dressing; after 2 wk, the treated area became red and itchy. Applications were discontinued, but lesions on the left leg enlarged in an annular pattern and spread to distant sites on the trunk and extremities.	Patient was treated medically, and lesions cleared within 2 wk. After 5 mo, patch testing was performed with the North American standard series, tea tree oil, abitol, abietic acid, and turpentine peroxides, as well as with the patient's aged (oxidized) sample of tea tree oil.	at 96 h, the patient reacted to both tea tree oil samples, with a stronger reaction the aged preparation. (He also had positive reactions to colophony, balsam of Peru, and abitol.) The researchers stated that although, clinically, the case mimicked erythema multiforme, that diagnosis was not supported by the histological findings, which were those of a spongiotic dermatitis. The researchers stated that erythema multiforme-like id-reaction described the eruption.	173
tea tree oil products (and creams containing lavender oil)	marked erythema and lichenification of the groin, suprapubic area, and perianal and vulval mucosa; eczema of the right (dominant), but not left, hand; eczema of the periorbital area and axillae4 6-mo history of these symptoms; had used tea tree oil products extensively (and had also used creams containing lavender oil).	Patch testing was performed with the European standard series, tea tree oil, and aromatherapy lavender gel.	positive reactions at d 2 and 4 (++) with tea tree oil; also with lavender gel (++) and quaternium-15 (+)	174
5% tea tree oil, oxidized, in pet	patient had periorbital dermatitis and persistent follicular barbae		+ reaction to 5% oxidized tea tree oil patient used a shaving oil that contained tea tree oil; skin problem resolved with discontinued use	164
1 and 5% tea tree oil, in pet	patient was an aromatherapist with eczema on arms and upper trunk, which later spread to the legs, face, and hands; hand eczema became chronic and was associated with handling several different substances, including essential oils, which she diluted herself	Patch testing was performed with the European standard, a perfume series, and several essential oils	+ reaction with 1%, and ++ reaction to 5%, tea tree oil, on d 3 Also had positive reaction to the fragrance mix, some oils from the perfume series, and 17 of 20 essential oils that were tested	175
pure tea tree oil	3 wk after application of the oil for suspected onychomycosis, the patient presented with acute periungual eczema on the first toe and on the medial surface of the second toe	Testing was performed using the Italian standard SIDAPA series, the product as used, and diluted to 2% and 5%.	Positive results were obtained with the pure test article (tea tree oil; ++ d 2/+++ d 4), was well as when tested at 2% (++ d 2/+++ d 4) and 5% (++ d 2/+++ d 4), as well as for fragrance mix 1 (++ d 2/+++ d 4).	168
from hand wash or shampoos				
hand wash containing 3% tea tree oil	patient developed raised red lesions at the sites of contact within 5 min of application; the reaction occurred on 3 separate occasions; she had regularly used a tea tree oil shampoo without adverse effects	Patch testing was performed using IQ chambers with 3% (same oil as in the wash), 10 different samples of 10%, and the same 10 samples of 100% tea tree oil.	no reactions occurred with 3 or 10% tea tree oil; mild erythema and pruritus occurred with 6 of the oils in 1 test, and in 4of the oils in a second test testing with the individual component of the wash produced inconsistent results	176

Table 19. Case reports with tea tree oil

Test Substance	Subject(s)/Symptoms	Testing	Results/Comments	Reference
shampoo containing tea tree oil	patient used the shampoo, and tea tree oil for blisters on his face	epicutaneous testing	patient became sensitized use of the products reacted to tea tree oil only (other test substances were not identified)	¹¹⁹
shampoo, to which tea tree oil was added			also reacted to fragrances, turpentine, and tiger balsam, which he had used against the side effects of the oil	¹¹⁹
tea tree oil transfer to sunglasses	the patient presented with a 12-mo history of intermittent eye-lid dermatitis; she had a history of scalp psoriasis and no history of atopy; the patient was using a shampoo containing tea tree oil; the patient had previously applied pure tea tree oil to acne papules	48-h patches were applied using an extended European standard series, cosmetic series, ingredients of creams and a variety of her own samples (appropriately diluted); readings were taken on day 2 and day 4	On day 4, there were positive results to nickel (++), tea tree oil (+), and scrapings from the frame of her sunglasses (+) (the sunglasses did not contain nickel) the rash resolved with avoidance of the shampoo and the sunglasses, but flared within 48 h of wearing the glasses. The glasses were thoroughly cleaned, and the rash did not reappear; the patient frequently placed her glasses on her wet hair, and it was assumed that sufficient residue of the tea tree oil shampoo was transferred to the sunglasses, precipitating the recurrent flares of eyelid dermatitis, even after the shampoo was no longer used	¹⁷⁷
CASE REPORTS WITH OXIDIZATION COMPONENTS				
7 typical constituents (5 or 10%) and 2 degradation products (5%) of tea tree oil	15 patients sensitive to tea tree oil from both dermal and oral routes of exposure	Readings were taken at 72 h.	# of patients with reactions to constituents: 5% α -terpinene (10); 5% α -phellandrene (6); 10% terpinolene (15); 5% myrcene (2); d/l-carvone (1); 5% aromadendrene (1); 5% viridiflorene (2) # of patients with reactions to degradation products: 5 5% 1,2,4-trihydroxymenthane (11); 5% ascaridole (10)	¹⁷⁸
EXPOSURE TO VAPORS				
tea tree oil, aq. solution	a patient with hand eczema and a known allergy to turpentine inhaled vapors from a hot aq. solution of the oil (concentration and duration of exposure not stated); after 2 successive days, he developed an acute exudative edematous dermatitis of the face and eyelids, which spread to his trunk and arms	Patch testing (Finn chambers) was first performed with the European standard series, a cosmetic series, several essential oils, and the patient's own products.	positive reactions were observed with tea tree oil, as well as colophony, fragrance mix, several oils, and methylchloroisothiazolinone	¹⁷⁹

Table 20. SED of tea tree oil, assuming 3% absorption ⁶

Product Type	Concentration of tea tree oil (%)	Amount applied (mg)	Retention Factor	SED (mg/kg/d)
tea tree oil (undiluted)	100	200	1	3.33
bath additive	15	10,000	0.01	0.25
cleansing face wash	0.7	5000	0.01	0.006
anti-dandruff shampoo	2.0	8000	0.01	0.027
deodorant stick/roller	2.5	500	1	0.21
foot powder	1.0	2000	1	0.33
foot spray	2.0	2000	1	0.67
body lotion	1.25	8000	1	1.67
hand wash	0.7	3000	0.01	0.0035
mouthwash	0.2	10,000	0.1	0.033
hand wash /solid soap	2.0	500	0.01	0.0017

Table 21. SED and MOS of tea tree oil, assuming 100% absorption ⁴⁰

Product Type	Concentration of tea tree oil (%)	Calc relative daily exposure (mg/kg bw/d)	SED (mg/kg bw/d)	MOS (NOAEL/SED)*
mouthwash	0.2	32.54	0.065	1798
shampoo	2.0	1.51	0.030	3900
deodorant stick/roller	2.5	22.03	0.55	213
foot powder**	1.0	1.67	0.033	3545
body lotion (total body)	1.25	123.20	1.54	76
hand wash /solid soap	2.0	3.33	0.067	1757
neat (nails)	not stated	not stated	1.67	
overall***			2.22	53

* NOAEL = 117 mg/kg bw/d (for renal effects, derived based on repeated dose systemic toxicity of tea tree oil constituents)

**2 applications/d

***shampoo + deodorant stick + foot powder + body lotion + hand wash soap + neat tea tree oil (nails)

REFERENCES

1. Nikitakis J, Kowcz A, (eds). Web-Based *International Cosmetic Ingredient Dictionary and Handbook*. <http://webdictionary.personalcarecouncil.org/jsp/Home.jsp>. Washington, DC: Personal Care Products Council. Last Updated 2020. Accessed 4/20/2020.
2. Carson CF, Riley TV. Safety, efficacy and provenance of tea tree (*Melaleuca alternifolia*) oil. *Contact Dermatitis*. 2001;45(2):65-67.
3. European Medicines Agency. Assessment report on *Melaleuca alternifolia* (Maiden and Betch) Cheel, *M. linariifolia* Smith, *M. dissitiflora* F. Mueller and/or other species of *Melaleuca*, aetheroleum. https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-melaleuca-alternifolia-maiden-betch-cheel-m-linariifolia-smith-m/other-species-melaleuca-aetheroleum_en.pdf. Last Updated 2015. Accessed 3/16/2016. EMA/HMPC/320932/2012. Committee on Herbal Medicine Products (HMPC).
4. de Groot AC, Schmidt E. Tea tree oil: Contact allergy and chemical composition. *Contact Dermatitis*. 2016;75(3):129-143.
5. de Groot AC, Schmidt E. Eucalyptus oil and tea tree oil. *Contact Dermatitis*. 2015;73(6):381-386.
6. Scientific Committee on Consumer Products (SCCP). SCCP, Opinion on tea tree oil, 16 December 2008. http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_160.pdf. Last Updated 2008. Accessed 11/28/2016.
7. European Chemicals Agency (ECHA). *Melaleuca alternifolia*, ext (tea tree oil; CAS No. 85085-48-9). <https://echa.europa.eu/en/registration-dossier/-/registered-dossier/20921>. Last Updated 1/21/2021. Accessed 2/22/2021.
8. European Medicines Agency. European Union herbal monograph on *Melaleuca alternifolia* (Maiden and Betch) Cheel, *Melaleuca linariifolia* Smith, *Melaleuca dissitiflora* F. Mueller and/or other species of *Melaleuca*, aetheroleum. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2015/04/WC500185282.pdf. Last Updated 2015. Accessed 3/8/2016. EMA/HMPC/320930/2012. Committee on Herbal Medicinal Products (HMPC).
9. European Medicines Agency. Herbal medicine: Summary for the public. Tea tree oil. https://www.ema.europa.eu/documents/herbal-summary/tea-tree-oil-summary-public_en.pdf. Last Updated 2017. Accessed 2/8/2019. EMA/814441/2016.
10. Barbosa LCA, Silva CJ, Teixeira RR, Meira RMSA, Pinheiro AL. Chemistry and biological activities of essential oils from *Melaleuca* L. species. *Agric Conspec Sci*. 2013;78(1):11-23.
11. World Health Organization. WHO Monographs on Selected Medicinal Plants - Volume 2. <http://digicollection.org/hss/en/d/Js4927e/17.html#Js4927e.17>. Last Updated 5/12/2012. Accessed 10/22/2020. Aetheroleum *Melaleuca* Alternifoliae; pages 172-179.
12. Rural Industry Research and Development Corporation (RIRDC). The effectiveness and safety of Australian tea tree oil. <http://www.teatreeonders.com/support-files/teatreeeffectiveness-andsafetyreport-sbiupload.pdf>. Last Updated 2007. Accessed 1/26/2016.
13. Gafner S, Dowell A. Tea tree oil laboratory guidance document. Austin, TX: ABC-AHP-NCNPR Botanical Adulterants Prevention Program. 2018. https://www.researchgate.net/publication/328175728_Tea_Tree_Oil_Laboratory_Guidance_Document Accessed 07/09/2019.
14. Bejar E. Adulteration of tea tree oil (*Melaleuca alternifolia* and *M. linariifolia*). *Botanical Adulterants Program, American Botanical Council*. 2017:1-5.
15. Royal Botanical Gardens Kew. *Melaleuca alternifolia* (tea tree). <http://www.kew.org/science-conservation/plants-fungi/melaleuca-alternifolia-tea-tree>. Last Updated 2017. Accessed 2/2/2017.
16. Southwell I, Lowe R, (eds). *Tea Tree. The Genus Melaleuca*. Harwood Academic Publishers; 1999.

17. Carson CF, Hammer KA, Riley TV. *Melaleuca alternifolia* (tea tree) oil: A review of antimicrobial and other medicinal properties. *Clinical Microbial Reviews*. 2006;19(1):50-62.
18. Native Extracts. 2020. Safety data sheet: Melaleuca Alternifolia (Tea Tree) Leaf Extract. Unpublished data submitted by the Personal Care Products Council on January 13, 2021.
19. Anonymous. 2020. Safety data sheet: Tea Tree (*Melaleuca alternifolia*) leaf oil. Submitted by the Australian Tea Tree Industry Association, Ltd on September 28, 2020.
20. Australian Tea Tree Industry Association (ATTIA). Stability of pure Australian tea tree oil. Version 1.1. https://teatree.org.au/teatree_about_packaging.php#:~:text=Stability%20of%20pure%20Australian%20TTO,or%20below%2025%C2%B0C. Last Updated Accessed 12/9/2020.
21. Australian Tea Tree Industry Association (ATTIA). Stability of pure Australian tea tree oil. Casino, New South Wales, Australia: ATTIA; 2012. https://webcache.googleusercontent.com/search?q=cache:0FQ_mZZW-RwJ:https://attia.org.au/mce_doc.php%3Fid%3D18+&cd=3&hl=en&ct=clnk&gl=us
22. Southwell I. Tea tree oil stability and evaporation rate. An addendum to RIRDC project: “*p*-Cymene and organic peroxides as indicators of oxidation in tea tree oil” by Ian Southwell, September 2006, RIRDC Publication No 06/112, RIRDC Project No ISO-2A. 2007. https://agrifutures.com.au/wp-content/uploads/2020/03/06-112_addendum.pdf. Accessed 10/26/2020.
23. Native Extracts. 2020. Manufacturing concentrate flowchart. Unpublished data submitted by the Personal Care Products Council on January 13, 2021.
24. Australian Tea Tree Industry Association (ATTIA). Australian Tea Tree Oil, *Melaleuca alternifolia*. ISO 4730: 2017 and AS 2782: 2017 Standards. <http://www.teatree.org.au/standards.php>. Last Updated 8/31/2020. Accessed 10/22/2020.
25. Homer LE, Leach DN, Lea D, Lee LS, Henry RJ, Baverstock PR. Natural variation in the essential oil content of *Melaleuca alternifolia* (Cheel) (Myrtaceae). *Biochem Syst Ecol*. 2000;28(4):367-382.
26. T.G. Cassegrain & Co Pty Ltd. How Tea tree Oil is Made - Cassegrain Kalara Tea Tree Oil. <https://www.kalaraoil.com/about-tea-tree-oil>. Last Updated 2020. Accessed 12/10/2020.
27. Lee C-J, Chen L-W, Chen L-G, et al. Correlations of the components of tea tree oil with its antibacterial effects and skin irritation. *J Food Drug Anal*. 2013;21(2):169-176.
28. Rodney J, Sahari J, Shah MKM. Review: Tea tree (*Melaleuca alternifolia*) as a new material for biocomposites. *J Appl Sci & Agric*. 2015;10(3):21-39.
29. Baker GR, Lowe RF, Southwell IA. Comparison of oil recovered from tea tree leaf by ethanol extraction and steam distillation. *J Agric Food Chem*. 2000;48(9):4041-4043.
30. Southern Cross University. 2020. Certificate of analysis - cosmetic (fragrance) allergens: Melaleuca Alternifolia (Tea Tree) Leaf Extract. Unpublished data submitted by the Personal Care Products Council on January 13, 2021.
31. Southern Cross University. 2018. Certificate of analysis - LCMS compositional analysis: Melaleuca Alternifolia (Tea Tree) Leaf Extract. Unpublished data submitted by the Personal Care Products Council on January 13, 2021.
32. Native Extracts. 2018. Safety data sheet: Vitis Vinifera (Grape) Seed Oil and Melaleuca Alternifolia (Tea Tree) Leaf Extract. Unpublished data submitted by the Personal Care Products Council on January 13, 2021.
33. Southern Cross University. 2020. Certificate of analysis - cosmetic (fragrance) allergens: Vitis Vinifera (Grape) Seed Oil and Melaleuca Alternifolia (Tea Tree) Leaf Extract. Unpublished data submitted by the Personal Care Products Council on January 13, 2021.
34. Southern Cross University. 2018. Certificate of analysis - fatty acids: Vitis Vinifera (Grape) Seed Oil and Melaleuca Alternifolia (tea Tree) Leaf Extract. Unpublished data submitted by the Personal Care Products Council on January 13, 2021.

35. Southwell I, Russell M, Davies N. Detecting traces of methyl eugenol in essential oils: Tea tree oil, a case study. *Flavour and Fragrance Journal*. 2011;26:336-340.
36. European Commission. Opinion concerning methyleugenol adopted by the Scientific Committee on Cosmetic Products and Non-Food Products (SCCNFP) during the 14th plenary meeting of 24 October 2000. https://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/sccnfp_opinions_97_04/sccp_out126_en.htm Last Updated 2000. Accessed 6/4/2020.
37. Carson CF, Hammer KA, Riley TV. Compilation and review of published and unpublished tea tree oil literature. A report for the Rural Industries Research and Development Corporation (RIRDC). www.attia.org.au/mce_doc.php?id=7. Last Updated 2005. Accessed 2/1/2016. RIRDC Publication No 05/151; RIRDC Project No UWA-75A.
38. Sadgrove N, Jones G. A contemporary introduction to essential oil: Chemistry, bioactivity and prospects for Australian agriculture. *Agriculture*. 2015;5:48-102.
39. Brophy JJ, Davies NW, Southwell IA, Stiff IA, Williams LR. Gas chromatographic quality control for oil of *Melaleuca terpinen-4-ol* type (Australian tea tree). *J Agric Food Chem*. 1989;37(5):1330-1335.
40. Mattilsynet (Norwegian Food Safety Authority). Risk profile: Tea tree oil - TTO; CAS No. 85085-48-9, 68647-73-4, and 8022-72-8. http://www.mattilsynet.no/kosmetikk/stoffer_i_kosmetikk/risk_profile_template_tto.11320/binary/Risk%20Profile%20Template%20TTO. Last Updated 2012. Accessed 9/14/2016.
41. Cross SE, Russell M, Southwell I, Roberts MS. Human skin penetration of the major components of Australian tea tree oil applied in its pure form and as a 20% solution in vitro. *Eur J Pharm Biopharm*. 2008;69(1):214-222.
42. Labib RM, Ayoub IM, Michel HE, et al. Appraisal on the wound healing potential of *Melaleuca alternifolia* and *Rosmarinus officinalis* L. essential oil-loaded chitosan topical preparations. *PLoS One*. 2019;14(9):e0219561.
43. Keszei A, Hassan Y, Foley WJ. A biochemical interpretation of terpene chemotypes in *Melaleuca alternifolia*. *J Chem Ecol*. 2010;36(6):652-661.
44. Southwell I, Dowell A, Morrow S, Allen G, Savins D, Shepherd M. Monoterpene chiral ratios: Chemotype diversity and interspecific commonality in *Melaleuca alternifolia* and *M. linariifolia*. *Industrial Crops and Products*. 2017;109(Dec 15):850-856.
45. European Commission. Commission Regulation (EU) No. 344/2013 of 4 April 2013 amending Annexes II, III, V, and VI to Regulations (EC) No, 1223/2009 of the European Parliament and of the Council on cosmetic products. <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32013R0344&from=EN>. Last Updated 2013. Accessed 3/16/2016.
46. Essential Oils Direct Ltd. Material Safety Data Sheet: Tea tree oil (*Melaleuca Alternifolia* (Tea Tree) Leaf Oil). http://www.essentialoilsdirect.co.uk/tea_tree-melaleuca_alternifolia-essential_oil.html. Last Updated 2011. Accessed 2/1/2016.
47. Hammer KA, Carson CF, Riley TV. Antifungal activity of tea tree oil *in vitro*. A report for the Rural Industries Research and Development Corporation (RIRDC). <https://rirdc.infoservices.com.au/downloads/01-011>. Last Updated 2001. Accessed 2/1/2016. RIRDC Publication No 01/11; RIRDC Project No UWA-50A.
48. Tisserand R, Young R. *Essential Oil Safety. A Guide of Health Care Professionals*. 2nd ed: Churchill Livingstone Elsevier; 2014.
49. de Groot AC, Weyland JW. Systemic contact dermatitis from tea tree oil. *Contact Dermatitis*. 1992;27(4):279-280.
50. Rudbäck J, Bergström MA, Börje A, Nilsson U, Karlberg AT. α -Terpinene, an antioxidant in tea tree oil, autoxidizes rapidly to skin allergens on air exposure. *Chem Res Toxicol*. 2012;25(3):713-721.

51. Southwell I. p-Cymene and organic peroxides as indicators of oxidation in tea tree oil. A report for the Rural Industries Research and Development Corporation. 2006. <https://rirdc.infoservices.com.au/downloads/06-112>. Accessed 11/30/2016. RIRDC Publication No 06/112; RIRDC Project No ISO-2A.
52. Sigma-Aldrich. Product Specifications: Tea Tree Oil - FG (CAS No. 68647-73-4). [http://www.sigmaaldrich.com/Graphics/COFAInfo/SigmaSAPQM/SPEC/W3/W390208/W390208-BULK-K_ALDRICH .pdf](http://www.sigmaaldrich.com/Graphics/COFAInfo/SigmaSAPQM/SPEC/W3/W390208/W390208-BULK-K_ALDRICH.pdf). Last Updated 2016. Accessed 1/29/2016.
53. Sigma-Aldrich. Certificate of Analysis: Tea tree oil - Certified organic (NOP). Product number W390215; batch number MKBB4099V. [https://www.sigmaaldrich.com/Graphics/COFAInfo/SigmaSAPQM/COFA/W3/W390215/W390215-1KG-K_MKBB4099V .pdf](https://www.sigmaaldrich.com/Graphics/COFAInfo/SigmaSAPQM/COFA/W3/W390215/W390215-1KG-K_MKBB4099V.pdf). Last Updated 7/16/2009. Accessed 3/4/2020.
54. US Food and Drug Administration (FDA). Tea Tree Oil. Pharmacy Compounding Advisory Committee Meeting. <http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm509958.pdf>. Last Updated 2016. Accessed 9/20/2016.
55. Aston Chemicals. Melafresh Exfol 300. <http://www.aston-chemicals.com/single-product?id=315>. Last Updated 2015. Accessed 1/29/2016.
56. US Food and Drug Administration (FDA) Center for Food Safety & Applied Nutrition (CFSAN). 2021. Voluntary Cosmetic Registration Program (VCRP) - Frequency of Use of Cosmetic Ingredients. College Park, MD. Obtained under the Freedom of Information Act from CFSAN; requested as "Frequency of Use Data" January 4, 2021; received January 21, 2021.
57. Personal Care Products Council. 2019. Concentration of use by FDA product category: *Melaleuca alternifolia* (tea tree)-derived ingredients. Unpublished data submitted by the Personal Care Products Council on April 11, 2019.
58. Johnsen MA. The influence of particle size. *Spray Technol Marketing*. 2004;14(11):24-27.
59. Rothe H. Special Aspects of Cosmetic Spray Evaluation. 2011. Unpublished data presented at the 26 September meeting of the Expert Panel for Cosmetic Ingredient Safety. Washington, D.C.
60. Bremmer HJ, Prud'homme de Lodder LCH, Engelen JGM. Cosmetics Fact Sheet: To assess the risks for the consumer. Updated version for ConsExpo 4. Bilthoven, Netherlands 2006. RIVM 320104001/2006. Pages 1-77. <https://www.rivm.nl/bibliotheek/rapporten/320104001.pdf>
61. Rothe H, Fautz R, Gerber E, et al. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. *Toxicol Lett*. 2011;205(2):97-104.
62. CIR Science and Support Committee of the Personal Care Products Council (CIR SSC). 2015. Cosmetic Powder Exposure. Unpublished data submitted by the Personal Care Products Council on November 3, 2015.
63. Aylott RI, Byrne GA, Middleton J, Roberts ME. Normal use levels of respirable cosmetic talc: preliminary study. *Int J Cosmet Sci*. 1979;1(3):177-186.
64. Russell RS, Merz RD, Sherman WT, Siverston JN. The determination of respirable particles in talcum powder. *Food Cosmet Toxicol*. 1979;17(2):117-122.
65. Federal Institute for Risk Assessment (BfR). Use of undiluted tea tree oil as a cosmetic. Opinion of the Federal Institute for Risk Assessment (BfR). http://www.bfr.bund.de/cm/349/use_of_undiluted_tea_tree_oil_as_a_cosmetic.pdf. Last Updated 9/1/2003. Accessed 1/26/2016.
66. Newberne P, Smith RL, Doull J, et al. GRAS Flavoring Substances 18. *Food Technology*. 1998;52(9):65-92.
67. Fukushima S, Cohen SM, Eisenbrand G, et al. FEMA GRAS assessment of natural flavor complexes: Lavender, Guaiac Coriander-derived and related flavoring ingredients. *Food Chem Toxicol*. 2020;145:111584.
68. National Institute of Health (NIH) National Center for Complementary and Integrative Health (NCCIH). Tea Tree Oil. <https://nccih.nih.gov/health/tea/treeoil.htm>. Last Updated 2016. Accessed 1/19/2017.

69. US Food and Drug Administration (FDA). Safety and effectiveness of consumer antiseptic rubs; topical antimicrobial drug products for over-the-counter human use. (April 12, 2019; <https://www.govinfo.gov/content/pkg/FR-2019-04-12/pdf/2019-06791.pdf>). *Federal Register*. 2019;84(71):14847-14864.
70. Zhang X, Guo Y, Guo L, Jiang H, Ji Q. In vitro evaluation of antioxidant and antimicrobial activities of *Melaleuca alternifolia* essential oil. *Biomed Res Int*. 2018;2018:1-8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960548/pdf/BMRI2018-2396109.pdf>. Accessed 11/29/2018.
71. Capetti F, Sgorbini B, Cagliero C, et al. *Melaleuca alternifolia* essential oil: Evaluation of skin permeation and distribution from topical formulations with a solvent-free analytical method. *Planta Med*. 2020;86(6):442-450.
72. Sgorbini B, Cagliero C, Argenziano M, Cavalli R, Bicchi C, Rubiolo P. In vitro release and permeation kinetics of *Melaleuca alternifolia* (tea tree) essential oil bioactive compounds from topical formulations. *Flavour and Fragrance Journal*. 2017;35(5):354-361.
73. Minghetti P, Casiraghi A, Cilurzo F, Gambaro V, Montanari L. Formulation study of tea tree oil patches. *Nat Prod Commun*. 2009;4(1):133-137.
74. Reichling J, Landvatter U, Wagner H, Kostka KH, Schaefer UF. In vitro studies on release and human skin permeation of Australian tea tree oil (TTO) from topical formulations. *Eur J Pharm Biopharm*. 2006;64(2):222-228.
75. Cal K. Skin penetration of terpenes from essential oils and topical vehicles. *Planta Med*. 2006;72(4):311-316.
76. Casiraghi A, Minghetti P, Cilurzo F, Selmin F, Gambaro V, Montanari L. The effects of excipients for topical preparations on the human skin permeability of terpinen-4-ol contained in tea tree oil: Infrared spectroscopic investigations. *Pharm Dev Technol*. 2010;15(5):545-552.
77. Hammer KA, Carson CF, Riley TV, Nielsen JB. A review of the toxicity of *Melaleuca alternifolia* (tea tree) oil. *Food Chem Toxicol*. 2006;44(5):616-625.
78. Nielsen JB. What you see may not always be what you get - Bioavailability and extrapolation from in vitro tests. *Toxicol In Vitro*. 2008;22(4):1038-1042.
79. Nielsen JB. Natural oils affect the human skin integrity and the percutaneous penetration of benzoic acid dose-dependently. *Basic Clin Pharmacol Toxicol*. 2006;98(6):575-581.
80. Nielsen JB, Nielsen F. Topical use of tea tree oil reduces the dermal absorption of benzoic acid and methiocarb. *Arch Dermatol Res*. 2006;297(9):395-402.
81. Ballam L, Heard CM. Pre-treatment with *Aloe vera* juice does not enhance the in vitro permeation of ketoprofen across skin. *Skin Pharmacol Physiol*. 2010;23(2):113-116.
82. Research Institute for Fragrance Materials Inc. (RIFM). 1982. Acute toxicity studies; RIFM report #1689. Data provided to CIR on February 4, 2016 by RIFM, Woodcliff Lake, NJ, USA.
83. Villar D, Knight MJ, Hansen SR, Buck WB. Toxicity of melaleuca oil and related essential oils applied topically on dogs and cats. *Vet Hum Toxicol*. 1994;36(2):139-142.
84. Bischoff K, Guale F. Australian tea tree (*Melaleuca alternifolia*) oil poisoning in three purebred cats. *J Vet Diagn Invest*. 1998;10:208-210.
85. Elmi A, Venrella D, Varone F, et al. In vitro effects of tea tree oil (*Melaleuca alternifolia* essential oil) and its principal component terpinen-4-ol on swine spermatozoa. *Molecules*. 2019;24(6):E1071.
86. Evandri MG, Battinelli L, Daniele C, Mastrangelo S, Bolle P, Mazzanti G. The antimutagenic activity of *Lavandula angustifolia* (lavender) essential oil in the bacterial reverse mutation assay. *Food Chem Toxicol*. 2005;43(9):1381-1387.
87. Fletcher JP, Cassella JP, Hughes D, Cassella S. An evaluation of the mutagenic potential of commercially available tea tree oil in the United Kingdom. *International Journal of Aromatherapy*. 2005;15(2):81-86.

88. Pereira TS, de Sant'anna JR, Silva EL, Pinheiro AL, de Castro-Prado MA. In vitro genotoxicity of *Melaleuca alternifolia* essential oil in human lymphocytes. *J Ethnopharmacol.* 2014;151(2):852-857.
89. Kozics K, Buckova M, Puskarova A, Kalaszova V, Cabicarova T, Pangallo D. The effect of ten essential oils on several cutaneous drug-resistant microorganisms and their cyto/genotoxic and antioxidant properties. *Molecules.* 2019;24(24):4570.
90. Greay SJ, Ireland DJ, Kissick HT, et al. Induction of necrosis and cell cycle arrest in murine cancer cell lines by *Melaleuca alternifolia* (tea tree) oil and terpinen-4-ol. *Cancer Chemother Pharmacol.* 2010;65(5):877-888.
91. Calcabrini A, Stringaro A, Toccaceli L, et al. Terpinen-4-ol, the main component of *Melaleuca alternifolia* (tea tree) oil inhibits the *in vitro* growth of human melanoma cells. *J Invest Dermatol.* 2004;122(2):349-360.
92. Ramadan MA, Shawkey AE, Rabeh MA, Abdellatif AO. Expression of *P53*, *BAX*, and *BCL-2* in human malignant melanoma and squamous cell carcinoma cells after tea tree oil treatment in vitro. *Cytotechnology.* 2019;71(1):461-473.
93. Assmann CE, Cadona FC, da Silva Rosa Bonadiman B, Dornelles EB, Trevisan G, da Cruz IBM. Tea tree oil presents in vitro antitumor activity on breast cancer cells without cytotoxic effects on fibroblasts and on peripheral blood mononuclear cells. *Biomed Pharmacother.* 2018;103:1253-1261. doi: 10.1016/j.biopha.2018.04.096. Epub;2018 May 7.:1253-1261.
94. Arcella A, Maria A, Sabrina S, et al. Tea tree oil a new natural adjuvant for inhibiting glioblastoma growth. *Journal of Pharmacognosy and Phytotherapy.* 2019;11(3):61-73.
95. Byahatti S, Bogar C, Bhat K, Dandagi G. Evaluation of anticancer activity of *Melaleuca Alternifolia*. (i. e. tea tree oil) on breast cancer cell line (MDA MB)- An in-vitro study. *IP Int J Med Microbiol Trop Dis.* 2018;4(3):176-180.
96. Byahatti S, Bogar C, Bhat K, Dandagi G. Evaluation of anticancer activity of *Melaleuca alternifolia* (i.e., tea tree oil) on colon cancer cell line (HT29) - An in vitro study. *Journal of Advanced Clinical & Research Insights.* 2018;5(4):99-103.
97. Hayes AJ, Leach DN, Markham JL, Markovic B. In vitro cytotoxicity of Australian tea tree oil using human cell lines. *Journal of Essential Oil Research.* 1997;9(5):575-582.
98. Greay SJ, Ireland DJ, Kissick HT, Beilharz MW. Inhibition of established subcutaneous murine tumour growth with topical *Melaleuca alternifolia* (tea tree) oil. *Cancer Chemother Pharmacol.* 2010;66(6):1095-1102.
99. Ramsey JT, Li Y, Arao Y, et al. Lavender products associated with premature thelarche and prepubertal gynecomastia: Case reports and endocrine-disrupting chemical activities. *J Clin Endocrinol Metab.* 2019;104(11):5393-5405.
100. Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. *N Engl J Med.* 2007;356(5):479-485.
101. Myers SL, Yang CZ, Bittner GD, Witt KL, Tice RR, Baird DD. Estrogenic and anti-estrogenic activity of off-the-shelf hair and skin care products. *J Expo Sci Environ Epidemiol.* 2015;25(3):271-277.
102. Bertocchi M, Rigillo A, Elmi A, et al. Preliminary assessment of the mucosal toxicity of tea tree (*Melaleuca alternifolia*) and rosemary (*Rosmarinus officinalis*) essential oils on novel porcine uterus models. *Int J Mol Sci.* 2020;21(9):E3350.
103. Zhang SY, Robertson D. A study of tea tree oil ototoxicity. *Audiol Neurootol.* 2000;5(2):64-68.
104. Abe S, Maruyama N, Hayama K, et al. Suppression of tumor necrosis factor-alpha-induced neutrophil adherence responses by essential oils. *Mediators Inflamm.* 2003;12(6):323-328.
105. Brand C, Grimaldeston MA, Gamble JR, Drew J, Finaly-Jones JJ, Hart PH. Tea tree oil reduces the swelling associated with the efferent phase of a contact hypersensitivity response. *Inflamm Res.* 2002;51(5):236-244.

106. Maruyama N, Sekimoto Y, Ishibashi H, et al. Suppression of neutrophil accumulation in mice by cutaneous application of geranium essential oil. *J Inflamm (Lond)*. 2005;2(1):1-11.
107. Golab M, Burdzenia O, Majewski P, Skwarlo-Sonta K. Tea tree oil inhalations modify immunity in mice. *J Appl Biomed*. 2005;3(2):101-108.
108. Golab M, Skwarlo-Sonta K. Mechanisms involved in the anti-inflammatory action of inhaled tea tree oil in mice. *Exp Biol Med (Maywood)*. 2007;232(3):420-426.
109. Koh KJ, Pearce AL, Marshman G, Finaly-Jones JJ, Hart PH. Tea tree oil reduces histamine-induced skin inflammation. *Br J Dermatol*. 2002;147(6):1212-1217.
110. Khalil Z, Pearce AL, Satkunanathan N, Storer E, Finlay-Jones JJ, Hart PH. Regulation of wheal and flare by tea tree oil: Complementary human and rodent studies. *J Invest Dermatol*. 2004;123(4):683-690.
111. Hart PH, Brand C, Carson CF, Riley TV, Prager RH, Finlay-Jones JJ. Terpinen-4-ol, the main component of the essential oil of *Melaleuca alternifolia* (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. *Inflamm Res*. 2000;49(11):619-626.
112. Research Institute for Fragrance Materials Inc. (RIFM). 1987. Acute dermal irritation study in rabbits; RIFM report #5668. Data provided to CIR on February 4, 2016 by RIFM, Woodcliff Lake, NJ, USA.
113. Ford RA, Letizia C, Api AM. Monographs on fragrance raw materials. *Food Chem Toxicol*. 1988;26(4):273-415.
114. Nielsen JB. Literature review on tea tree oil. Toxicity profiles for tea tree oil, constituents of tea tree oil and known oxidation products. 2005. Submitted by the Australian Tea Tree Industry Association, Ltd on December 8, 2020.
115. Research Institute for Fragrance Materials Inc. (RIFM). 1981. Report on human maximization studies; RIFM report #1792. Data provided to CIR on February 4, 2016 by RIFM, Woodcliff Lake, NJ, USA.
116. Southwell I, Freeman S, Rubel D. Skin irritancy of tea tree oil. *J Essent Oil Res*. 1997;9(1):47-52.
117. Rubel DM, Freeman S, Southwell IA. Tea tree oil allergy: What is the offending agent? Report of three cases of tea tree oil allergy and review of the literature. *Australas J Dermatol*. 1998;39(4):244-247.
118. Southwell I, Markham J, Mann C, Rural Industries Research and Development Corporation (RIRDC). Why cineole is not detrimental to tea tree oil: Report for the Rural Industries Research and Development Corporation. 1997. <http://nla.gov.au/nla.cat-vn1650711>. Accessed 9/27/2016.
119. Hausen BM, Reichling J, Harkenthal M. Degradation products of monoterpenes are the sensitizing agents in tea tree oil. *Am J Contact Dermat*. 1999;10(2):68-77.
120. Knight TE, Hausen BM. Melaleuca oil (tea tree oil) dermatitis. *J Am Acad Dermatol*. 1994;30(3):423-427.
121. Anonymous. 2005. An evaluation of the contact-sensitization potential of a topical coded product containing 0.001% Melaleuca Alternifolia (Tea Tree) Flower/Leaf/Stem Extract in human skin by means of the maximization assay. Unpublished data submitted by the Personal Care Products Council on February 24, 2021.
122. Anonymous. 2020. A modified Draize repeat insult patch test in a shared panel of 100 healthy volunteers, to investigate the irritation and sensitisation potential of 2 test articles, one containing 0.0078% Melaleuca Alternifolia (Tea Tree) Leaf Extract, following repeated cutaneous patch applications. Unpublished data submitted by the Personal Care Products Council on February 24, 2021.
123. Product Investigations Inc. 2016. Report: PII No. 35747: Determination of the irritating and sensitizing propensities of MT#2700253 (10% Melaleuca Alternifolia (Tea Tree) Leaf Oil in Caprylic/Capric Triglyceride) on human skin. Unpublished data submitted by Personal Care Products Council on March 2, 2016.
124. Aspres N, Freeman S. Predictive testing for irritancy and allergenicity of tea tree oil in normal human subjects. *Exog Dermatol*. 2003;2(5):258-261.

125. Research Institute for Fragrance Materials Inc. (RIFM). 1982. Phototoxicity study of fragrance materials in hairless mice. Report to RIFM. Data provided to CIR on February 4, 2016 by RIFM, Woodcliff Lake, NJ, USA.
126. Warshaw EM, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch-test results, 2003-2004 study period. *Dermatitis*. 2008;19(3):129-136.
127. Rolls S, Owen E, Bertram CG, et al. What is in? What is out? Updating the British Society for Cutaneous Allergy facial series. *Br J Dermatol*. 2020.
128. Wetter DA, Yiannias JA, Prakash AV, Davis MD, Farmer SA, el-Azhary RA. Results of patch testing to personal care product allergens in a standard series and a supplemental cosmetic series: An analysis of 945 patients from the Mayo Clinic Contact Dermatitis Group, 2000-2007. *J Am Acad Dermatol*. 2010;63(5):789-798.
129. Zug KA, Warshaw EM, Fowler JF, Jr., et al. Patch-test results of the North American Contact Dermatitis Group 2005-2006. *Dermatitis*. 2009;20(3):149-160.
130. Fransway AF, Zug KA, Belsito DV, et al. North American Contact Dermatitis Group patch test results for 2007-2008. *Dermatitis*. 2013;24(1):10-21.
131. Warshaw EM, Belsito DV, Taylor JS, et al. North American Contact Dermatitis Group patch test results: 2009 to 2010. *Dermatitis*. 2013;24(2):50-59.
132. Warshaw EM, Maibach HI, Taylor JS, et al. North American Contact Dermatitis Group patch test results: 2011-2012. *Dermatitis*. 2015;26(1):49-59.
133. DeKoven JG, Warshaw EM, Zug KA, et al. North American Contact Dermatitis Group patch test results: 2015-2016. *Dermatitis*. 2018;29(6):297-309.
134. Warshaw EM, Nelsen DD, Sasseville D, et al. Positivity ratio and reaction index: Patch-test quality-control metrics applied to the North American Contact Dermatitis Group database. *Dermatitis*. 2010;21(2):91-97.
135. Belsito DV, Fowler JF, Jr., Sasseville D, Marks JGJ, De Leo VA, Storrs FJ. Delayed-type hypersensitivity to fragrance materials in a select North American population. *Dermatitis*. 2006;17(1):23-28.
136. Warshaw EM, Zug KA, Belsito DV, et al. Positive patch-test reactions to essential oils in consecutive patients from North America and Central Europe. *Dermatitis*. 2017;28(4):246-252.
137. Rastogi S, Patel KR, Singam V, Silverberg JI. Allergic contact dermatitis to personal care products and topical medications in adults with atopic dermatitis. *J Am Acad Dermatol*. 2018;79(6):1028-1033.e1026.
138. Warshaw EM, Buchholz HJ, Belsito DV, et al. Allergic patch test reactions associated with cosmetics: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2004. *J Am Acad Dermatol*. 2008;60(1):23-38.
139. Warshaw EM, Ahmed RL, Belsito DV, et al. Contact dermatitis of the hands: Cross-sectional analyses of North American Contact Dermatitis Group data, 1994-2004. *J Am Acad Dermatol*. 2007;57(2):301-314.
140. Zug KA, Kornik R, Belsito DV, et al. Patch-testing North American lip dermatitis patients: Data from the North American Contact Dermatitis Group, 2001 to 2004. *Dermatitis*. 2008;19(4):202-208.
141. Warshaw EM, Raju SI, Fowler JF, Jr., et al. Positive patch test reactions in older individuals: Retrospective analysis from the North American Contact Dermatitis Group, 1994-2008. *J Am Acad Dermatol*. 2012;66(2):229-240.
142. Zug KA, McGinley-Smith D, Warshaw EM, et al. Contact allergy in children referred for patch testing: North American Contact Dermatitis Group data, 2001-2004. *Arch Dermatol*. 2008;144(10):1329-1336.
143. Zug KA, Pham AK, Belsito DV, et al. Patch testing in children from 2005 to 2012: Results from the North American Contact Dermatitis Group. *Dermatitis*. 2014;25(6):345-355.
144. Veien NK, Rosner K, Skovgaard GL. Is tea tree oil an important contact allergen? *Contact Dermatitis*. 2004;50:378-379.

145. Lindberg M, Tammela M, Bostrom A, et al. Are adverse skin reactions to cosmetics underestimated in the clinical assessment of contact dermatitis? A prospective study among 1075 patients attending Swedish patch test clinics. *Acta Derm Venereol.* 2004;84(4):291-295.
146. Pirker C, Hausen BM, Uter W, et al. Sensitization to tea tree oil in Germany and Austria. A multicenter study of the German Contact Dermatitis Group. (Abstract only). *J Dtsch Dermatol Ges.* 2003;1(8):629-634.
147. Hausen BM. Evaluation of the main contact allergens in oxidized tea tree oil. *Dermatitis.* 2004;15(4):213-214.
148. Christoffers WA, Blomeke B, Coenraads PJ, Schuttelaar ML. The optimal patch test concentration for ascaridole as a sensitizing component of tea tree oil. *Contact Dermatitis.* 2014;71(3):129-137.
149. Gilissen L, Huygens S, Goossens A. Allergic contact dermatitis caused by topical herbal remedies: Importance of patch testing with the patients' own products. *Contact Dermatitis.* 2018;78(3):177-184.
150. Nardelli A, Drieghe J, Claes L, Boey L, Goossens A. Fragrance allergens in 'specific' cosmetic products. *Contact Dermatitis.* 2011;64(4):212-219.
151. Travassos AR, Claes L, Boey L, Drieghe J, Goossens A. Non-fragrance allergens in specific cosmetic products. *Contact Dermatitis.* 2011;65(5):276-285.
152. Corazza M, Borghi A, Gallo R, et al. Topical botanically derived products: use, skin reactions, and usefulness of patch tests. A multicentre Italian study. *Contact Dermatitis.* 2014;70(2):90-97.
153. Fritz TM, Burg G, Krasovec M. Allergic contact dermatitis to cosmetics containing *Melaleuca alternifolia* (tea tree oil). (Abstract only). *Ann Dermatol Venereol.* 2001;128(2):123-126.
154. Muruzábal RS, Garcés MH, García ML, Pascual LL, Pérez AA, Bayona IY. Secondary effects of topical application of an essential oil. Allergic contact dermatitis due to tea tree oil. [English abstract; Spanish paper]. *An Sist Sanit Navar.* 2015;38(1):163.
155. Thomson KF, Wilkinson SM. Allergic contact dermatitis to plant extracts in patients with cosmetic dermatitis. *Br J Dermatol.* 2000;142(1):84-88.
156. Sabroe RA, Holden CR, Gawkrödger DJ. Contact allergy to essential oils cannot always be predicted from allergy to fragrance markers in the baseline series. *Contact Dermatitis.* 2016;74(4):236-241.
157. Wilkinson M, Gallo R, Goossens A, et al. A proposal to create an extension to the European baseline series. *Contact Dermatitis.* 2017;78(2):101-108.
158. Rutherford T, Nixon R, Tam M, Tate B. Allergy to tea tree oil: Retrospective review of 41 cases with positive patch tests over 4.5 years. *Australas J Dermatol.* 2007;48(2):83-87.
159. Toholka R, Wang YS, Tate B, et al. The first Australian baseline series: Recommendations for patch testing in suspected contact dermatitis. *Australas J Dermatol.* 2015;56(2):107-115.
160. Haverhoek E, Reid C, Gordon L, Marshman G, Wood J, Selva-Nayagam P. Prospective study of patch testing in patients with vulval pruritus. *Australas J Dermatol.* 2008;49(2):80-85.
161. Scardamaglia L, Nixon R, Fewings J. Compound tincture of benzoin: A common contact allergen? *Australas J Dermatol.* 2003;44(3):180-184.
162. Selvaag E, Eriksen B, Thune P. Contact allergy due to tea tree oil and cross-sensitization to colophony. *Contact Dermatitis.* 1994;31(2):124-125.
163. Perrett CM, Evans AV, Russell-Jones R. Tea tree oil dermatitis associated with linear IgA disease. *Clin Exp Dermatol.* 2003;28(2):167-170.
164. Christoffers WA, Blömeke B, Coenraads PJ, Schuttelaar ML. Co-sensitization to ascaridole and tea tree oil. *Contact Dermatitis.* 2013;69(3):187-189.

165. Mozelsio NB, Harris KE, McGrath KG, Grammer LC. Immediate systemic hypersensitivity reaction associated with topical application of Australian tea tree oil. *Allergy Asthma Proc.* 2003;24(1):73-75.
166. Pesonen M, Suomela S, Kuuliala O, Henriks-Eckerman ML, Aalto-Korte K. Occupational contact dermatitis caused by D-limonene. *Contact Dermatitis.* 2014;71(5):273-279.
167. Bhushan M, Beck MH. Allergic contact dermatitis from tea tree oil in a wart paint. *Contact Dermatitis.* 1997;36(2):117-118.
168. Lauriola MM, Sena P, De Bitonto A, Corazza M. Allergic contact dermatitis due to "therapeutic uses" of tea tree oil on the lips and toenails. *Dermatitis.* 2020;Publish Ahead of Print.
169. Monthrope YM, Shaw JC. A "natural" dermatitis: Contact allergy to tea tree oil. *Univ Toronto Med J.* 2004;82(1):59-60.
170. Apted JH. Contact dermatitis associated with the use of tea-tree oil. *Australas J Dermatol.* 1991;32(3):177.
171. Storan ER, Nolan U, Kirby B. Allergic contact dermatitis caused by the tea tree oil-containing hydrogel Burnshield®. *Contact Dermatitis.* 2016;74(5):309-310.
172. Stonehouse A, Studdiford J. Allergic contact dermatitis from tea tree oil. *The Consultant.* 2007;47(8):781-782.
173. Khanna M, Qasem K, Sasseville D. Allergic contact dermatitis to tea tree oil with erythema multiforme-like id reaction. *Am J Contact Dermat.* 2000;11(4):238-242.
174. Varma S, Blackford S, Statham BN, Blackwell A. Combined contact allergy to tea tree oil and lavender oil complicating chronic vulvovaginitis. *Contact Dermatitis.* 2000;42(5):309-310.
175. Selvaag E, Holm JO, Thune P. Allergic contact dermatitis in an aroma therapist with multiple sensitizations to essential oils. *Contact Dermatitis.* 1995;33(5):354-355.
176. Greig JE, Thoo S-L, Carson CF, Riley TV. Allergic contact dermatitis following use of a tea tree oil hand-wash not due to tea tree oil. *Contact Dermatitis.* 1999;41(6):354-355.
177. Williams JD, Nixon RL, Lee A. Recurrent allergic contact dermatitis due to allergen transfer by sunglasses. *Contact Dermatitis.* 2007;57(2):120-121.
178. Harkenthal M, Hausen BM, Reichling J. 1,2,4-Trihydroxy menthane, a contact allergen from oxidized Australian tea tree oil. *Pharmazie.* 2000;55(2):153-154.
179. de Groot AC. Airborne allergic contact dermatitis from tea tree oil. *Contact Dermatitis.* 1996;35(5):304-305.
180. National Capital Poison Center. Tea Tree Oil. <http://www.poisson.org/articles/2010-dec/tea-tree-oil>. Last Updated 2017. Accessed 2/6/2017.
181. Lee Ka, Harnett JE, Cairns R. Essential oil exposures in Australia: Analysis of cases reported to the NSW Poisons Information Centre. *Med J Aust.* 2020;212(3):132-133.
182. The Good Scents Company. Tea tree oil. <http://www.thegoodscentscompany.com/data/es1018091.html>. Last Updated 2015. Accessed 8/4/2020.